0001553350-22-000231.txt : 20220322 0001553350-22-000231.hdr.sgml : 20220322 20220321185926 ACCESSION NUMBER: 0001553350-22-000231 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220322 DATE AS OF CHANGE: 20220321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EVOLUTIONARY GENOMICS, INC. CENTRAL INDEX KEY: 0000884363 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 264369698 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54129 FILM NUMBER: 22756804 BUSINESS ADDRESS: STREET 1: 4220 MORNINGSTAR DRIVE CITY: CASTLE ROCK STATE: CO ZIP: 80108 BUSINESS PHONE: (720) 900-8666 MAIL ADDRESS: STREET 1: 4220 MORNINGSTAR DRIVE CITY: CASTLE ROCK STATE: CO ZIP: 80108 FORMER COMPANY: FORMER CONFORMED NAME: Fona, Inc. DATE OF NAME CHANGE: 20100907 FORMER COMPANY: FORMER CONFORMED NAME: PHONE A HOME CORP DATE OF NAME CHANGE: 19930708 FORMER COMPANY: FORMER CONFORMED NAME: FONAHOME CORP DATE OF NAME CHANGE: 19930328 10-K 1 fnam_10k.htm ANNUAL REPORT
0000884363 false FY 2021 0000884363 2021-01-01 2021-12-31 0000884363 2021-06-30 0000884363 2022-02-17 0000884363 2021-12-31 0000884363 2020-12-31 0000884363 fnam:SeriesA1PreferredStockMember 2021-12-31 0000884363 fnam:SeriesA1PreferredStockMember 2020-12-31 0000884363 fnam:SeriesA2PreferredStockMember 2021-12-31 0000884363 fnam:SeriesA2PreferredStockMember 2020-12-31 0000884363 us-gaap:SeriesAPreferredStockMember 2021-12-31 0000884363 us-gaap:SeriesAPreferredStockMember 2020-12-31 0000884363 2020-01-01 2020-12-31 0000884363 us-gaap:CommonStockMember 2020-12-31 0000884363 fnam:PreferredDividendMember 2020-12-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000884363 us-gaap:RetainedEarningsMember 2020-12-31 0000884363 us-gaap:CommonStockMember 2021-03-31 0000884363 fnam:PreferredDividendMember 2021-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000884363 us-gaap:RetainedEarningsMember 2021-03-31 0000884363 2021-03-31 0000884363 us-gaap:CommonStockMember 2021-06-30 0000884363 fnam:PreferredDividendMember 2021-06-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000884363 us-gaap:RetainedEarningsMember 2021-06-30 0000884363 us-gaap:CommonStockMember 2021-09-30 0000884363 fnam:PreferredDividendMember 2021-09-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000884363 us-gaap:RetainedEarningsMember 2021-09-30 0000884363 2021-09-30 0000884363 us-gaap:CommonStockMember 2019-12-31 0000884363 fnam:PreferredDividendMember 2019-12-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000884363 us-gaap:RetainedEarningsMember 2019-12-31 0000884363 2019-12-31 0000884363 us-gaap:CommonStockMember 2020-03-31 0000884363 fnam:PreferredDividendMember 2020-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000884363 us-gaap:RetainedEarningsMember 2020-03-31 0000884363 2020-03-31 0000884363 us-gaap:CommonStockMember 2020-06-30 0000884363 fnam:PreferredDividendMember 2020-06-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000884363 us-gaap:RetainedEarningsMember 2020-06-30 0000884363 2020-06-30 0000884363 us-gaap:CommonStockMember 2020-09-30 0000884363 fnam:PreferredDividendMember 2020-09-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000884363 us-gaap:RetainedEarningsMember 2020-09-30 0000884363 2020-09-30 0000884363 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000884363 fnam:PreferredDividendMember 2021-01-01 2021-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000884363 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000884363 2021-01-01 2021-03-31 0000884363 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000884363 fnam:PreferredDividendMember 2021-04-01 2021-06-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000884363 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000884363 2021-04-01 2021-06-30 0000884363 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000884363 fnam:PreferredDividendMember 2021-07-01 2021-09-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000884363 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000884363 2021-07-01 2021-09-30 0000884363 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0000884363 fnam:PreferredDividendMember 2021-10-01 2021-12-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0000884363 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0000884363 2021-10-01 2021-12-31 0000884363 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000884363 fnam:PreferredDividendMember 2020-01-01 2020-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000884363 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000884363 2020-01-01 2020-03-31 0000884363 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000884363 fnam:PreferredDividendMember 2020-04-01 2020-06-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000884363 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000884363 2020-04-01 2020-06-30 0000884363 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000884363 fnam:PreferredDividendMember 2020-07-01 2020-09-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000884363 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000884363 2020-07-01 2020-09-30 0000884363 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0000884363 fnam:PreferredDividendMember 2020-10-01 2020-12-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0000884363 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0000884363 2020-10-01 2020-12-31 0000884363 us-gaap:CommonStockMember 2021-12-31 0000884363 fnam:PreferredDividendMember 2021-12-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000884363 us-gaap:RetainedEarningsMember 2021-12-31 0000884363 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-12-31 0000884363 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000884363 us-gaap:EquipmentMember 2021-12-31 0000884363 us-gaap:EquipmentMember 2020-12-31 0000884363 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-12-31 0000884363 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0000884363 us-gaap:FurnitureAndFixturesMember 2021-12-31 0000884363 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000884363 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0000884363 us-gaap:InProcessResearchAndDevelopmentMember 2020-12-31 0000884363 us-gaap:PatentsMember 2021-12-31 0000884363 us-gaap:PatentsMember 2020-12-31 0000884363 us-gaap:PatentsMember 2021-01-01 2021-12-31 0000884363 us-gaap:PatentsMember 2020-01-01 2020-12-31 0000884363 us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0000884363 fnam:SBAPaycheckProtectionProgramMember 2020-01-01 2020-04-17 0000884363 fnam:SBAPaycheckProtectionProgramMember 2021-02-01 2021-02-22 0000884363 fnam:SBAPaycheckProtectionProgramMember 2021-01-01 2021-12-31 0000884363 fnam:EconomicInjuryDisasterLoanMember 2020-06-04 2020-06-05 0000884363 fnam:EIDLProgramMember 2020-06-04 2020-06-05 0000884363 fnam:EconomicInjuryDisasterLoanMember 2021-01-01 2021-12-31 0000884363 fnam:EIDLProgramMember 2021-01-01 2021-12-31 0000884363 fnam:EIDLProgramMember 2020-06-05 0000884363 fnam:EIDLProgramMember 2021-12-31 0000884363 fnam:DCADoleMember 2020-08-19 0000884363 fnam:ResearchAgreementUniversityOfWisconsinMadisonMember 2020-09-18 0000884363 fnam:DCADoleMember 2020-08-26 0000884363 fnam:DCADoleMember 2021-07-28 0000884363 fnam:DCADoleMember 2020-12-29 0000884363 fnam:DCADoleMember 2021-09-29 0000884363 2015-10-19 0000884363 us-gaap:ConvertiblePreferredStockMember 2015-10-19 0000884363 fnam:ConvertiblePreferredStockSeriesA2Member 2015-10-19 0000884363 fnam:ConvertiblePreferredStockSeriesA2Member 2021-12-31 0000884363 fnam:ConvertiblePreferredStockSeriesA2Member 2021-01-01 2021-12-31 0000884363 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0000884363 fnam:StandardResearchAgreementMember 2020-09-01 2020-09-18 0000884363 srt:ChiefExecutiveOfficerMember 2021-12-31 0000884363 fnam:SeriesA2PreferredStockMember us-gaap:SubsequentEventMember 2022-01-01 2022-03-21 0000884363 fnam:SeriesA2PreferredStockMember us-gaap:SubsequentEventMember 2022-03-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

———————

FORM 10-K

———————

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended: December 31, 2021

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from: _____________ to _____________

 

Evolutionary Genomics, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   000-54129   26-4369698

(State or other jurisdiction of

incorporation or organization)

   (Commission File Number)  

(I.R.S. Employer

Identification Number)

 

4220 Morning Star Drive, Castle Rock, Colorado 80108
(Address of Principal Executive Offices)
   

Registrant’s telephone number, including area code: (720) 900-8666

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
     

 

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $.001 par value

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐   No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐   No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒   No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒   No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ☐   Accelerated filer   ☐
Non-accelerated filer     ☒   Smaller reporting company  ☒
    Emerging growth company  ☐

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).   ☐ Yes   ☒ No

 

The aggregate market value of common stock held by non-affiliates of the Registrant as of June 30, 2021 was $4,636,289 based on the closing price on the last day of trading prior to June 30, 2021.

 

Shares outstanding as of February 17, 2022 were 5,881,898 shares of common stock, $.001 par value and 577,063 shares of Series A-1 preferred stock, par value $.001 and 102,860 shares of Series A-2 preferred stock, par value $.001. The Registrant’s common stock trades on the OTC Markets under the trading symbol “FNAM”.

 

DOCUMENTS INCORPORATED BY REFERENCE: None

 
 
 
 

Evolutionary Genomics, Inc.

 

TABLE OF CONTENTS

 

 

    PAGE
  PART I  
ITEM 1. Business 1
ITEM 1A. Risk Factors 9
ITEM 1B. Unresolved Staff Comments 15
ITEM 2. Properties 15
ITEM 3. Legal Proceedings 15
ITEM 4. Mine Safety Disclosures 15
     
  PART II  
ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 16
ITEM 6. [Reserved] 16
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 16
ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk 19
ITEM 8. Financial Statements and Supplemental Data 19
ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 19
ITEM 9A. Controls and Procedures 19
ITEM 9B. Other Information 20
ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 20
     
  PART III  
ITEM 10. Directors, Executive Officers and Corporate Governance 21
ITEM 11. Executive Compensation 23
ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 24
ITEM 13. Certain Relationships, Related Transactions and Director Independence 24
ITEM 14. Principal Accountant Fees and Services 25
     
  PART IV  
ITEM 15. Exhibits, Financial Statement and Schedules 26
ITEM 16. Form 10–K Summary 26
     
SIGNATURES 28

 

 

 
 

Cautionary Statement Regarding Forward-Looking Information

 

This report includes “forward-looking statements” that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements including continued compliance with government regulations, changing legislation or regulatory environments; any statements of expectation or belief and any statements of assumptions underlying any of the foregoing. These risks, uncertainties and other factors, and the general risks associated with the businesses of the Company described in the reports and other documents filed with the SEC, could cause actual results to differ materially from those referred to in the forward-looking statements. The Company cautions readers not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to the Company and are qualified in their entirety by this cautionary statement. The Company anticipates that subsequent events and developments may cause its views to change. The information contained in this report speaks as of the date hereof and the Company has or undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise unless required by law.

 

PART I

 

ITEM 1. BUSINESS

 

Evolutionary Genomics, Inc. (the "registrant" or "Company") was incorporated under the laws of the state of Minnesota in November 1990 under the name Fonahome Corporation. On March 24, 2009, the Company reincorporated in the state of Nevada and merged with its wholly-owned subsidiary, Fona, Inc., adopting the surviving company’s name, Fona, Inc. and simultaneously adopted the capital structure of Fona Inc., which includes total authorized capital stock of 800,000,000 shares, of which 780,000,000 are common stock and 20,000,000 are blank check preferred stock. The preferred stock may be issued from time to time in one or more series with such designations, preferences and relative participating, optional or other special rights and qualifications, limitations or restrictions thereof, as shall be stated in the resolutions adopted by the Corporation’s Board providing for the issuance of such preferred stock or series thereof.

 

On June 6, 2014, Evolutionary Genomics, Inc., a Delaware corporation merged with Fona, Inc. treated as a reverse acquisition with Evolutionary Genomics, Inc. as the acquirer and Fona as the acquired party. Subsequent to the Merger, Fona, Inc. was renamed Evolutionary Genomics, Inc. and our subsidiary was renamed from Evolutionary Genomics, Inc. to EG Crop Science, Inc. On May 9, 2016, we formed ICAM Therapeutics, Inc. (a Delaware corporation) as a wholly owned subsidiary of Evolutionary Genomics, Inc. We have not incurred any transactions in this company nor have we established any business plan for the future.

 

The Company maintains headquarters at the office of its Chief Executive Officer. The Company maintains a website at www.evolgen.com. The Company is not required to deliver an annual report to security holders and at this time does not anticipate the distribution of such a report. The Company will file reports with the SEC.

 

The public may read and copy any materials the Company files with the SEC in the SEC’s Public Reference Section, Room 1580, 100 F Street N.E, Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Section by calling the SEC at 1-800-SEC-0330. Additionally, the SEC maintains an Internet site that contains reports, proxy, and information statements, and other information regarding issuers that file electronically with the SEC, which can be found at http://www.sec.gov.

 

GENERAL BUSINESS PLAN

 

On August 14, 2000, the Company was issued patent number 6274319, titled “Methods to identify evolutionarily significant changes in polynucleotide and polypeptide sequences in domestic plants and animals”. On June 1, 2004, the Company was issued patent number 6743580, titled “Methods for producing transgenic plants containing evolutionarily significant polynucleotides”. These patents are for the core Adapted Traits Platform that we use for the discovery of genes in humans, animals and commercial crops. The Company has applied the Adapted Traits Platform in research projects including identifying genes believed to be responsible for increases in yield in corn, increases in yield in rice, salt tolerance and sugar content in tomatoes and pest/disease resistance in soybeans, bananas and multiple other crops.

 

1 
 

EG Technology – The Adapted Traits Platform (“ATP’)

 

Genomics research generates vast amounts of sequence data for thousands of genes. Some companies use this sequence data to try to predict the function of each gene and its potential to impact key traits. Others try to match the thousands of random deoxyribonucleic acid (“DNA”) changes between individuals with differences in traits. Evolutionary Genomics’ approach is to first narrow the search to genes that have undergone adaptive evolution (positively selected genes) in an organism that has an adapted trait of potential commercial value. To identify genes with impact on commercially desirable traits, Evolutionary Genomics screens first for positively selected genes. Evolutionary Genomics then focuses functional genomics efforts on demonstrating the effects of these genes on the desired traits.

 

Evolutionary Genomics uses the Adapted Traits Platform to perform high throughput molecular evolution analysis to identify positively selected genes based on Ka/Ks analysis (as defined below). Ka/Ks analysis was developed to document the role of positive selection on known protein coding genes. Molecular-level adaptive evolution is indicated when comparisons of homologous protein coding sequences from closely related species show that the number of amino acid differences fixed due to selection exceeds what can be expected by neutral evolution. Molecular-level positive selection can be detected in protein-coding genes by pairwise comparisons of the ratios of non-synonymous nucleotide substitutions per non-synonymous site (Ka) to synonymous substitutions per synonymous site (Ks). The algorithm, by comparing substitutions per site, takes into account, in rigorous fashion, the effect of bias and degeneracy in the genetic code, and also compensates for the effects of multiple hits at the same site. Ka/Ks ratios significantly greater than unity strongly suggest that positive selection has fixed greater numbers of amino acid replacements than can be expected as a result of chance alone.

 

Dr. Walter Messier, a Company founder and our Chief Technology Officer, published a seminal paper in the field: Messier and Stewart (1997) “Episodic adaptive evolution of primate lysozymes” Nature 385:151-154. The work described in this publication demonstrated that a known lysozyme gene that had been recruited for a new function to aid in digestion of leaves as a food source in certain monkeys had the kind of adaptive genetic changes indicating that the lysozyme gene had evolved more rapidly than the neutral substitution rate, indicating Darwinian positive selection. Many groups have used such methods to document Darwinian positive selection in other proteins. It was Dr. Messier’s insight that genes controlling a trait of interest could be identified by using molecular evolution analysis as a screen, comparing genes in a species with a trait to genes of a closely related species lacking the trait. The adapted genes found in such a screen could then be validated to determine their role in the presence or absence of the trait of interest.

 

Agricultural Industry

 

In the past century, agriculture has been characterized by enhanced productivity, the use of synthetic fertilizers and pesticides, selective breeding, mechanization, water contamination, and farm subsidies. Proponents of organic farming such as Sir Albert Howard argued in the early 20th century that the overuse of pesticides and synthetic fertilizers damages the long-term fertility of the soil. While this feeling lay dormant for decades, as environmental awareness has increased in the 21st century there has been a movement towards sustainable agriculture by some farmers, consumers, and policymakers.

 

Advances in genetic research and modification of crop species have led to increased yield, drought tolerance and disease/pest resistance. These advances have also led to an increased concentration within the providers of seed and production companies. The top companies control much of the implementation of new plant varieties through patents and licensing agreements. Genetic traits providers, like Evolutionary Genomics, identify and develop genes that impact traits of interest to the industry and market those genes to these companies.

 

Business Model

 

Evolutionary Genomics’ primary source of revenue through March 31, 2020 had been contract services revenue for research performed by Evolutionary Genomics on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant making foundations for research performed. Ownership of the intellectual property in these projects varies from Evolutionary Genomics retaining all intellectual property rights to retaining none of the developed intellectual property for the crop that is the subject of the project. In addition to contract services revenue for research, Evolutionary Genomics intends to continue to pursue grant funding from governmental agencies, industry associations and grant making foundations. These sources of funding are often subject to limitations in available funds, funding priorities in areas other than our area of focus, political uncertainties, long approval processes and competition with other research proposals.

 

2 
 

The single most valuable step in the process of crop improvement is the identification of the key genes among the 30,000 or more in the genome that have the desired impact. The Company has identified pest/disease resistance genes in bananas, soybeans and other commercially valuable crops. If validation testing of these genes is successful, we market them to the industry. This strategy requires Evolutionary Genomics to incur significant research costs prior to any confirmation of commercial viability and there can be no guarantee that the desired results can be achieved or that commercialization can be reached.

 

Licensing revenue can be lump sum payments, milestone payments upon achievement of defined goals and/or percentages of revenue or per plant payments for products sold by licensee. These payments are often many years after completion of gene identification project as licensees engage in significant additional testing including field trials prior to integration into licensee commercial germplasm lines. There can be no guarantee that these licensing agreements will result in any additional revenue for Evolutionary Genomics as further development of licensed intellectual property is mostly controlled by the licensee.

 

The goal of the grant funded research projects was to discover genetic intellectual properties with commercial value. Evolutionary Genomics’ soybean pest resistance project is a multiple year illustration of the evolution of a project from concept through marketing to seed companies. The project has yielded identified genes for pest resistance in soybeans with partial validation complete. Evolutionary Genomics has partially completed two generation, whole plant validation testing but has decided to postpone further testing indefinitely to focus resources on our banana project. The Company has extended this soybean pest resistance research to other crops including beans, tomatoes, cotton and maize and has identified candidate genes. Further research on these crops is dependent on revenue from our banana project or additional capital funding. If we are able to complete additional validation testing, we intend to market these genes to the industry.

 

Evolutionary Genomics’ Banana Genes

 

Our banana pest resistance project is another project illustration. We identified a gene (FusR1) in bananas that appears to confer resistance to Fusarium Fungus which leads to Panama Disease. We marketed the gene to banana companies and, in August 2020, executed a Development and Commercialization Agreement (“DCA”) with Dole Food Company (“Dole”) which includes development work funded by Dole and the framework for a long-term licensing relationship. While Dole is supplying significant funding for the development of this banana gene in the form of promissory notes, there can be no assurance that this development work will lead to licensing revenue as there are many risks involved in genetic trait development.

 

During the 1950s the global banana industry was devastated by a disease (caused by Fusarium fungus) that effectively wiped out the predominate variety of commercial bananas known as Gros Michel, leading to the development of the Cavendish banana, which makes up well over 90% of the commercial banana market today. Cavendish was resistant to the strain of Fusarium that wiped out the Gros Michel variety but, in recent years, is being challenged by a new race of Fusarium that threatens to, once again, devastate the global banana industry. The recent emergence of Panama Disease TR4 in the Western Hemisphere makes a swift solution to the crisis even more urgent. A substantial part of the banana market consists of exports from Central and South America to the United States and elsewhere.

 

In 2018, the Company began a project to identify genes in wild banana relatives that are resistant to Fusarium. We have previously used our technology to identify genes in common beans and, in our project for the Bill and Melinda Gates Foundation in common beans, proved that these genes provided increased resistance to Fusarium fungus. We used our platform to isolate a banana gene that controls Fusarium Wilt (FW), aka Panama Disease, Tropical Race 4. The gene, which we have named FusR1 (Fusarium Resistance 1), is a native gene in Musa species, including cultivated bananas. We have found that, for all FW-resistant banana cultivars/species that we have tested, one version of our gene exists while, in all FW-sensitive banana cultivars/species that we have tested, there is a different version of FusR1. And notably, a third version exists in semi-resistant varieties that has allowed us to identify the particular nucleotide changes that are crucial for resistance to Fusarium Wilt.

 

3 
 

We believe that this native banana gene can be introduced into cultivated bananas, particularly the Fusarium-sensitive Cavendish cultivar in order to make these cultivars resistant to Fusarium Wilt. We believe that a gene transformation approach would be faster and easier than traditional breeding which may take many years to complete. Given the threat of possible extinction for Cavendish, more rapid approaches are not only warranted but essential and minimally genetically edited or modified bananas will likely be accepted. Transfer of this native banana gene to cultivated bananas can be accomplished with CRISPR technology or traditional genetically modified approaches, which allow a targeted, clean, and efficient transfer and which, as compared to traditional breeding, minimizes potential side effects. We believe that Cavendish bananas can be rendered Fusarium Wilt resistant by changing only a few base pairs. These sorts of minimal changes have been allowed by the USDA and FDA in several crops. Even in Europe, use of CRISPR technology has gained substantial traction.

 

On June 26, 2019, we filed a United States patent application titled IDENTIFICATION AND RESISTANCE GENES FROM WILD RELATIVES OF BANANA AND THEIR USES IN CONTROLLING PANAMA DISEASE. We are awaiting review of these patents by the United States Patent Office. In December 2021, we filed patents in Europe, Africa, South and Central America, Australia and Asia.

 

On August 19, 2020, the Company entered into a Development and Commercialization Agreement (“DCA”) with Dole Food Company for the development of plant varieties within the Musa genus of the Musaceae family (including the Cavendish variety of banana) that exhibit resistance to Fusarium Wilt Tropical Race 4 (popularly known as TR4 Panama Disease). Subject to compliance with various provisions of the agreement, the agreement includes partial working capital funding from Dole to the Company through 2024. In addition to working capital funding, Dole reimburses the Company for the development of banana plants and Dole will incur additional costs for the commercialization of plants upon successful completion of the development portion of this project. In the year ended December 31, 2021, the Company received $800,000 of working capital funding and $647,916 of reimbursement of development costs pursuant to this agreement. In the year ended December 31, 2020, the Company received $800,000 of working capital funding and $1,295,831 of reimbursement of development costs pursuant to this agreement. Per the Agreement, 50% of future royalties from Dole to the Company may be offset by reductions in the notes payable due from the Company to Dole under this DCA. In the event that Dole terminates the agreement for material breach by the Company or the Company’s bankruptcy, the Company must repay all funding provided by Dole within six months of termination. The parties have agreed to negotiate the terms of the long-term license agreement upon successful completion of the development portion of this project.

 

During 2021, the University of Wisconsin successfully transformed banana plants using our FusR1 gene and we currently have banana plants from multiple gene constructs growing in greenhouses. During 2022, in accordance with our DCA with Dole, we are engaged in testing these plants to determine if our FusR1 gene successfully conferred resistance to Fusarium Fungus and Panama Disease. Upon successful completion of validation testing and field trials by Dole, under the terms of the agreement with Dole, we expect to negotiate a long-term royalty contract for the commercialization of banana plants using our genes. This licensing arrangement will likely be exclusively with Dole and contain royalty payments based on the number of plants and/or hectares of plants. Even if EG’s genes are proven to be effective, it is difficult to predict the future revenue stream that any licensing arrangement can generate and will be heavily dependent upon the speed with which Panama Disease spreads throughout the world and any changes in the price of bananas based on supply and demand. Many articles are available in the public realm detailing the significance of the disease and the spread throughout the world.

 

Since bananas are seedless, they are propagated by clones which allows for very rapid production of plants. An initial batch of 100 successful plants can generate a secondary propagation of over 15,000 plants in one year (enough for 10 hectares) and 15 million in the next generation. There are over 400,000 hectares of banana production in Latin America from Mexico to Peru. Adoption of the new variety will be dependent upon its effectiveness and the infection rate of Panama disease.

 

There are many risks associated with achieving these desired results including but not limited to:

 

-We may not be able to adequately establish patent protection for our intellectual property or others may have competing claims.
-Others may develop alternative approaches to compete with our genes.
-Our genes may cause unforeseen and undesirable changes beyond the pest resistance such as yield degradation or changes in the appearance or taste of the fruit.
-Our genes may fail to deliver the desired results of resistance to disease.
-Global regulations and/or consumer preference may prevent the successful commercial launch of genetically modified bananas using our methods.
-We will be dependent on others for the successful production and marketing of bananas with our genes and many factors will be outside of our control.

 

4 
 
-Our expected future royalty revenue will be highly dependent upon the successful execution of the banana development project in the DCA with Dole and the negotiation of a long-term royalty licensing agreement.

 

While Panama Disease is potentially existential to the banana industry but is not yet widespread, Black Sigatoka Disease is a different disease that is very wide-spread and is treated with toxins at a cost of up to $2,300 per hectare per year. We spent the last two years researching wild banana plants to identify a gene that could potentially be used to develop plants that are resistant to Black Sigatoka with no or reduced use of toxins. On October 21, 2021, we filed a United States patent application titled IDENTIFICATION AND RESISTANCE GENES FROM WILD RELATIVES OF BANANA AND THEIR USES IN CONTROLLING BLACK SIGATOKA DISEASE. We are awaiting review of these patents by the United States Patent Office. We are in the early stages of developing this gene and others are working on competing approaches. There is no guarantee that this will lead to commercial success. Like our FusR1 project, transformation and validation can be very expensive and we will need funding from grants, potential customers or additional capital from investors, none of which can be assured.

 

Evolutionary Genomics’ Soybean Genes

 

On April 29, 2014, the United States Patent and Trademark Office issued patent 8,710,300 titled EXPRESSION OF DIRIGENT GENE EG261 AND ITS ORTHOLOGS AND PARALOGS ENHANCES PATHOGEN RESISTANCE IN PLANTS. Several additional related patents have been issued in the United States, Argentina, Canada and Brazil and other patents are pending. On January 16, 2020, the Company filed a patent application on its second soybean pest/disease resistance gene, EG19, and has included that gene in its ongoing two generation, whole plant validation research. The Company has also discovered additional candidate genes that may impact pathogen resistance. There can be no assurance that any of these genes will be proven effective in validation testing or lead to licensing agreements or revenue.

 

We entered into a Service Agreement with WCIC under which they have transformed soybeans using our genes and helped to establish the right combinations to achieve a range of expression. WCIC grew events from seven constructs of EG261 and EG19 in their greenhouses. The testing of these T2 generation seeds at the University of Missouri is partially complete but we have indefinitely suspended work on these genes to focus our resources on our banana projects. If we resume these projects and results from the whole plant validation trials confirm the findings of the University of Wisconsin-Madison for EG261 and the effectiveness of the new gene, EG19, the Company intends to enter negotiations for a long-term research collaboration and licensing agreement with seed companies. The testing phase includes field trials which may proceed for several years prior to generating licensing revenue. There are many risks in this process including some that are outside of Evolutionary Genomics’ control and there can be no guarantee that we will ever generate any revenue from these potential agreements.

 

Competition

 

Evolutionary Genomics’ competition is very broad from the largest seed companies and producing companies to the smallest grower who is successful in breeding new, improved varieties. These same competitors are also Evolutionary Genomics customers as we seek to license intellectual property for commercialization into their production lines. Many of these companies are exponentially larger with many more resources at their disposal and there can be no assurance that EG can continue to compete with them or interest them in licensing our intellectual property.

 

5 
 

Patents

 

Evolutionary Genomics is the owner of the following issued patents:

 

Patent/App Serial # Jurisdiction Title Filing Date Issue Date Expire Date
8710300 / 13949035 United States EXPRESSION OF DIRIGENT GENE EG261 AND ITS ORTHOLOGS AND PARALOGS ENHANCES PATHOGEN RESISTANCE IN PLANTS 7/23/2013 4/29/2014 7/23/2033
9834783 / 13901071 United States DIRIGENT GENE EG261 AND ITS ORTHOLOGS AND PARALOGS AND THEIR USES FOR PATHOGEN RESISTANCE IN PLANTS 5/23/2013 12/5/2017 5/23/2033
10577625 / 15800179 United States DIRIGENT GENE EG261 AND ITS ORTHOLOGS AND PARALOGS AND THEIR USES FOR PATHOGEN RESISTANCE IN PLANTS 11/1/2017 3/3/2020 11/1/2037
9,605,274 / 14/479,550 United States DIRIGENT GENE EG261 AND ITS ORTHOLOGS AND PARALOGS AND THEIR USES FOR PATHOGEN RESISTANCE IN PLANTS 9/8/2014 3/28/2017 9/8/2034
AR091160B1 / P130101827 Argentina DIRIGENT GENE EG261 AND ITS ORTHOLOGS AND PARALOGS AND THEIR USES FOR PATHOGEN RESISTANCE IN PLANTS 5/24/2013 6/8/2021 5/24/2033
2872128 Canada DIRIGENT GENE EG261 AND ITS ORTHOLOGS AND PARALOGS AND THEIR USES FOR PATHOGEN RESISTANCE IN PLANTS 5/23/2013 9/19/2017 5/23/2033
112014029381-3 Brazil DIRIGENT GENE EG261 AND ITS ORTHOLOGS AND PARALOGS AND THEIR USES FOR PATHOGEN RESISTANCE IN PLANTS 5/23/2013 9/19/2017 5/23/2033
ZL201380039727.4 China DIRIGENT GENE EG261 AND ITS ORTHOLOGS AND PARALOGS AND THEIR USES FOR PATHOGEN RESISTANCE IN PLANTS 5/23/2013 7/25/2017 5/23/2033

 

Material Agreements

 

Effective March 1, 2012, Evolutionary Genomics entered into an Agreement for Contract Services with Smith Bucklin Corporation (the “Contractor”) on behalf of the United Soybean Board. The contract includes the payment of certain royalties, as defined in the Agreement. Evolutionary Genomics retains all ownership of patents and intellectual property developed in the project and is obligated to pay royalties to the United Soybean Board of ten percent of the sale of products derived from the soybean genes that were the subject of the research performed or from royalties received from the sale of products by a third party not to exceed 150% of the total amount paid to Evolutionary Genomics under this Agreement. Evolutionary Genomics recognized revenue of $262,476 from this contract, thus limiting any future royalties to a total of $393,714. The project term has expired but the royalty provisions remain in perpetuity.

 

On February 21, 2015 the Company entered into the Sponsored Research Contract with The Curators of the University of Missouri for phenotyping of transgenic soybean samples on a per unit basis. We expect to continue this contract and will likely have additional amounts payable but the amount is indeterminable. Evolutionary Genomics retains sole ownership of all patents and intellectual property, royalty free for all materials (including previously identified genes) related to this project.

 

6 
 

On August 19, 2020, the Company entered into the DCA with Dole for the development of our banana genes. The DCA provides for payments from Dole to the Company of $800,000 upon execution, $800,000 by the twelve-month anniversary, $250,000 by the thirty-six month anniversary and $250,000 by the forty-eight month anniversary. Dole will also reimburse the Company for costs incurred at the University of Wisconsin-Madison (“UW”) not to exceed $2,200,000 in coordination with the Standard Research Agreement that the Company entered into with UW on September 18, 2020 which includes payments from the Company to UW in the amount of $2,159,719 over the two-year expected term of the project. If the UW research is successful, Dole expects to incur costs of $750,000 to perform field trials.

 

The DCA also specifies that the Company will execute notes payable to Dole for the funding that Dole is providing up to $5,050,000. Through December 31, 2021, the Company executed notes for $800,000, $800,000, $1,295,831 and $647,916 under this DCA and recorded them as a long-term notes payable for financial statement purposes. The notes are non-interest bearing and allow Dole to offset fifty percent of future royalty payments to the Company by reducing the amount of principal due on these notes. Other than this offset of future royalty payments, repayment of principal and interest is only required in the case of termination of the DCA by Dole for cause.

 

On September 18, 2020, the Company entered into a Standard Research Agreement with WCIC for the development of our banana genes. The agreement includes payments from the Company in the amount of $2,159,719 over the two-year expected term of the project. These costs will be reimbursed, in the form of notes payable by Dole in accordance with our DCA.

 

Trademarks

 

Evolutionary Genomics has no registered trademarks.

 

Employees

 

Evolutionary Genomics had two full time employees and one part time employee as of December 31, 2021.

 

Facilities

 

The Company leases its operating facility on a month-to-month basis, with monthly rental installments of $2,378. Renewals are by mutual agreement.

 

Legal Proceedings

 

Evolutionary Genomics is not currently involved in or aware of any threatened or actual legal proceedings.

 

Capitalization

 

The Company is authorized to issue up to 780,000,000 shares of Common Stock and up to 20,000,000 shares of preferred stock. As of December 31, 2021, the Company had 5,881,898 shares of Common Stock outstanding, 577,063 shares of Series A-1 Preferred Stock (“Series A-1”) outstanding and 102,860 shares of Series A-2 Preferred Stock (“Series A-2”) outstanding. Both Series A-1 and Series A-2 are convertible into shares of Common Stock on a one share for one share basis. 1,400,000 shares of common stock have been reserved for issuance pursuant to the Company’s 2015 Stock Incentive Plan. Option grants have been issued for 340,000 shares of common stock at an exercise price of $0.55 per share, 490,000 shares of common stock at an exercise price of $1.50 per share, 150,000 shares of common stock at an exercise price of $1.65 per share, 180,000 shares of common stock at an exercise price of $3.00 per share, 100,000 shares of common stock at an exercise price of $3.30 per share and 100,000 shares of common stock at an exercise price of $3.50 per share. Options for 120,000 shares have been exercised, 158,333 have been cancelled and option grants of 1,081,667 shares remain outstanding as of December 31, 2021.

 

Liquidation: Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of the Series A-1 and Series A-2 shall be entitled to receive out of the assets of the Company for each share of Series A-1 and Series A-2 an amount equal to its stated value, $5.25 per share plus any accrued but unpaid dividends before any distribution or payment shall be made to the holders of any other class or series of stock of the Company that ranks junior to the Series A-1 and Series A-2. The holders shall be entitled to convert their shares of Series A-1 and Series A-2 into Common Stock at any time prior to the consummation of a Liquidation.

 

7 
 

The Corporation is required to establish a segregated non-interest bearing trust account (the “Sinking Fund Account”) for the benefit of the Holders. 50% of all licensing fees received by the Corporation shall be deposited in the Sinking Fund Account within five (5) Business Days of receipt of any such fees by the Corporation. In the event that the amount of cash in the Sinking Fund Account exceeds the liquidation preference of all issued and outstanding shares of Series A-1 and Series A-2 Preferred Stock not previously redeemed or converted pursuant to the terms hereof, the Corporation shall deliver a notice to the Holders (the “Mandatory Redemption Notice” and the date such notice is deemed delivered hereunder, the “Mandatory Redemption Notice Date”) of its obligation to redeem all of the then outstanding shares of Series A-1 and Series A-2 Preferred Stock (i) for cash in an amount equal to the liquidation preference per share and (ii) by issuing such number of fully paid and nonassessable whole shares of Common Stock as is obtained by multiplying (x) the number of shares of Series A-1 and Series A-2 Preferred Stock so to be redeemed by (y) the liquidation preference per share of the Series A-1 and Series A-2 Preferred Stock, and then by dividing such product by (z) the conversion price per share, payable and issuable, respectively, in full on the 5th Trading Day following the Mandatory Redemption Notice Date. This is considered a contingent redemption feature.

 

Conversion: The holders of Series A-1 and Series A-2 may convert their shares at any time into shares of Common Stock at any time prior to the consummation of a liquidation, at the option of the holder, on a one-share-for-one-share basis and shall be subject to certain adjustments.

 

Optional Redemption; Sinking Fund Account: The Company may elect to redeem some or all of the then outstanding shares of Series A-1 and Series A-2, (i) for cash in an amount equal to the liquidation preference per share, $5.25 per share as of December 31, 2020, subject to adjustment and (ii) by issuing one share, subject to adjustment, of Common Stock for each share of Series A-1 and Series A-2 outstanding being redeemed. 50% of all licensing fees received by the Company will be deposited into a separate sinking fund for use in an optional redemption. As of December 31, 2021, no licensing revenue has been received under these provisions and no sinking fund account has been established.

 

Dividends: The Company shall pay to the holders of the Series A-1 and Series A-2 dividends at the rate of 8% per annum multiplied by the amount invested. The dividend amount shall accrue and shall be payable in shares of Common Stock upon the conversion of the Series A-1 and Series A-2, or upon the redemption of the Series A-1 and Series A-2. No dividends shall be paid on any Common Stock of the Company or any capital stock of the Company that ranks junior to the Series A-1 and Series A-2 until dividends of Series A-1 and Series A-2 has been paid. As of December 31, 2021, there were $1,522,970 in accrued preferred stock dividends.

 

Voting: The holders of the Series A-1 and Series A-2 are entitled to vote on all matters submitted to the stockholders for a vote on an as-if-converted to Common Stock basis, with all stockholders voting as a single class.

 

8 
 

ITEM 1A. RISK FACTORS

 

Impacts of COVID-19 on our business

 

The impact of a novel strain of coronavirus (COVID-19) and measures to prevent its spread are affecting the macroeconomic environment and while the full impact is uncertain, our business and results of operations could be materially adversely affected. The impact on our business will depend on a number of factors such as the duration and extent of COVID-19, governmental actions, changes in consumer behavior, responses of our third-party business partners that offer our content through their platforms, and general economic activity.

 

We are attempting to conduct business as usual to the extent possible and are complying with the applicable orders issued by the Governor of Colorado. The Company has been granted the status of essential operations and our staff continues to work in our lab while staggering working hours to limit exposure.

 

The impact of the COVID-19 outbreak may also exacerbate other risks.

 

We may require substantial additional funding and may be unable to raise capital when needed, which could force us to delay, reduce or eliminate planned activities or result in our inability to continue as a going concern.

 

As of December 31, 2021, the Company had $214,009 in operating cash and during 2021 used $1,583,139 of cash in operations. Subsequent to the year ended December 31, 2021, the Company issued an additional 76,953 shares of Series A-2 stock at $5.25 per share and received proceeds of $404,003. The Company’s current projections for 2022 requires cash of $578,143. These factors raise substantial doubt as to the Company’s ability to continue as a going concern.

 

To address these factors, management believes that it will secure additional funding to meet prospective cash requirements. Management believes the Company’s existing cash balances along with funding from our agreement with Dole and the issuance of Series A-2 stock will provide the necessary liquidity to meet our obligations as they come due over the next year. In addition, exercise of employee stock options, prospective funding from marketing additional genes, reductions in operating expenses, grant funding and additional shareholder contributions may provide the additional liquidity to meet our obligations as they come due. We expect that the funding from these sources will be more than enough to cover our obligations for the next twelve months. Additional shareholder funding could result in dilution to existing shareholders. If the funding does not arrive, the Company may not be able to meet its obligations as they become due.

 

Our future capital requirements will depend on, and could increase significantly as a result of, many factors, including:

 

·the duration and results of the research projects;

 

·unexpected delays or costs incurred in the acquisition of plant materials needed in these research projects and with subcontracts that perform various parts of these projects;

 

·the time and cost in preparing, filing, prosecuting, maintaining and enforcing patent claims;

 

·other unexpected developments encountered in implementing our business development, research development and commercialization strategies; and

 

·further arrangements, if any, with collaborators.

 

We may attempt to raise additional funds through public or private financings, collaborations with other companies or financing from other sources. Additional funding may not be available on terms which are acceptable to us or at all. If adequate funding is not available to us on reasonable terms, we may need to delay, reduce or eliminate one or more of our research and development projects or obtain funds on terms less favorable than we would otherwise accept. To the extent that additional capital is raised through the sale of equity securities or securities convertible into or exchangeable for equity securities, the issuance of those securities could result in dilution to our stockholders. Moreover, the incurrence of debt financing could result in a substantial portion of our future operating cash flow, if any, being dedicated to the payment of principal and interest on such indebtedness and could impose restrictions on our operations. This could render us more vulnerable to competitive pressures and economic downturns.

 

9 
 

In addition, if we do not meet our payment obligations to third parties as they come due, we may be subject to litigation claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and may result in unfavorable results that could further adversely impact our financial condition.

 

We have relied on the availability of grant funding to fund some of our research efforts and our inability to compete successfully for these limited grant funding opportunities may significantly affect our results of operations and our ability to complete research projects.

 

We have traditionally funded many of our research projects, partially or wholly, using grant funding provided by government programs, industry associations and grant making institutions. The availability of these funds is impacted by many factors including changing political priorities, fiscal budget issues, agency priorities, availability of funds and competition from other grant seekers. Our ability to present proposals that fit within grant making guidelines and which are attractive relative to other proposals submitted may significantly impact our ability to fund our research projects.

 

Efforts to protect our intellectual property rights and to defend claims against us can increase our costs and will not always succeed; any failures could adversely affect profitability or restrict our ability to do business.

 

Intellectual property rights are crucial to our business. We endeavor to obtain and protect our intellectual property rights in jurisdictions in which products are produced from the biotechnology that we produce and in jurisdictions into which those products are imported. Different nations may provide limited rights and inconsistent duration of protection for our intellectual property. We may be unable to obtain protection for our intellectual property in key jurisdictions. Even if protection is obtained, competitors, farmers or others may raise legal challenges to our rights or illegally infringe on our rights, including through means that may be difficult to prevent or detect. In addition, because of the rapid pace of technological change, and the confidentiality of patent applications in some jurisdictions, competitors may be issued patents from applications that were unknown to us prior to issuance. These patents could reduce the value of our commercial or pipeline biotechnology or, to the extent they cover key technologies on which we have unknowingly relied, require that we seek to obtain licenses or cease using the technology, no matter how valuable to our business. We cannot assure we would be able to obtain such a license on acceptable terms. In addition, patent laws are subject to change and any change in our ability to protect the intellectual property that we develop may impact our ability to commercialize that intellectual property. The extent to which we succeed or fail in our efforts to protect our intellectual property will affect our costs, sales and other results of operations.

 

Genes that we have discovered and may discover in the future with expected desirable impact on traits may, upon further research and field trials, be revealed to also have undesirable impact on traits.

 

Evolutionary Genomics’ gene discovery process focuses on the identification of positively selected genes that impact the trait of interest that we are working on. When we further test them in lab validation, we are again focused on whether they have the desired impact on the trait of interest and we are specifically testing for that outcome. Laboratory experiments are under more ideal circumstances than field trials and use in production and there can be no guarantee that the lab result will be repeated under those conditions. Additional field trials and use in production may also reveal undesirable impacts on other traits that were not a focused part of our research. For example, the soybean or banana genes that we have discovered may be found to have a negative impact on yield. These may impact our ability to realize revenue from the commercialization of our biotechnology and may expose us to liability for undesirable outcomes that we don’t anticipate.

 

Undesirable results from our ongoing research may result in expensing of our acquired research in progress.

 

We currently carry $4,016,596 (gross) of acquired research in progress on our balance sheet as an intangible asset subject to amortization. Upon executing our DCA with Dole, we began amortization of this asset in the year ended December 31, 2020. If this project produces undesirable results, we may need to expense the intangible asset.

 

Others may find additional genes or other methods of accomplishing the same desired outcome that our biotechnology does, rendering our biotechnology less valuable or commercializable.

 

There are many other companies pursuing similar gene discovery programs and other approaches to solving the same issues that we are addressing and many of these companies have vastly more resources than we do. Even when we identify genes that impact desired traits, there may be other genes that have a similar or greater effect on these traits. For example, one or more of the other genes in soybeans and bananas may have an impact on pest/disease resistance similar to our genes or there may be other orthologs of the genes that we have discovered in other varieties that have a greater impact. In addition, other companies may develop commercial chemicals that compete with genetic changes to solve the issues that we are addressing. Any of these may impact our ability to realize revenue from the commercialization of our biotechnology.

 

10 
 

The successful development of our research efforts and commercialization of our biotechnology will be necessary for our growth and profitability.

 

We intend to use recent successes in which we have identified genes that may have an impact on pest/disease resistance in soybeans and bananas and look for similar genes in other crops. This research may result in significant costs incurred without any commercial value produced. We also intend to attempt to improve the potential pest/disease resistance genes we have identified. Even if we find effective genes, we may not be able to find a commercial market for them. There can be no assurance we will be able to achieve any improvement and performing this research may also result in significant costs incurred without any commercial value produced. The processes of breeding, biotechnology trait discovery and development and trait integration are lengthy and a very small percentage of the genes identified in research are selected for commercialization. The length of time and the risk associated with the breeding and biotech pipelines are interlinked because both are required as a package for commercial success in markets where biotech traits are approved for growers. Commercial success frequently depends on being the first company to the market, and many of our competitors are also making considerable investments in similar new biotechnology. Consequently, if we are not able to fund extensive research and development activities and deliver new products to the markets we serve on a timely basis, our growth and operations will be harmed including, but not limited to, the possible impairment of our intangible assets.

 

We rely heavily on our founder, Walter Messier, our current Chief Science Officer. The loss of his services would have a material adverse effect upon us and our business and prospects.

 

Our success depends, to a significant extent, upon the continued services of Walter Messier, who is a founder of Evolutionary Genomics and our current Chief Science Officer. Since inception, we have been dependent upon Dr. Messier, who is the inventor on most of our patents and responsible for the development of our core Adapted Traits Platform. If Dr. Messier or any key management personnel resign to join a competitor or form a competing company, the loss of such personnel, together with the loss of any customers or potential customers due to such executive’s departure, could materially and adversely affect our business and results of operations.

 

We are dependent on a technically trained workforce and an inability to retain or effectively recruit such employees could have a material adverse effect on our business, financial condition and results of operations.

 

Our ability to compete effectively depends largely on our ability to attract and retain certain key personnel, including additional researchers that we intend to hire in order to pursue our planned research projects. Industry demand for such skilled employees, however, exceeds the number of personnel available, and the competition for attracting and retaining these employees is intense. Because of this intense competition for skilled employees, we may be unable to retain our existing personnel or attract additional qualified employees to keep up with future business needs. If this should happen, our business, operating results and financial condition could be adversely affected.

 

In addition, we intend to hire business development and marketing personnel and advisors to promote and market the biotechnology that we develop. We cannot assure you that we will be able to recruit and retain qualified personnel and advisors to perform these functions. Our inability to hire and then retain such personnel, advisors and scientists could have a materially adverse effect on our business and our projects.

 

We may not obtain the necessary permits and authorizations to operate our business.

 

We may not be able to obtain or maintain the necessary licenses, permits, authorizations or accreditations, or may only be able to do so at great cost. In addition, we may not be able to comply fully with the wide variety of laws and regulations applicable to the agricultural industry. Failure to comply with or to obtain the necessary licenses, permits, authorizations or accreditations could result in restrictions on our ability to operate our business, which could have a material adverse effect on our business.

 

11 
 

Competition in agricultural biotechnology has significantly affected and will continue to affect our revenue and results of operations.

 

Many companies engage in research and development of plant biotechnology and breeding and speed in getting a new product to market can be a significant competitive advantage. Our competitors’ success could render the biotechnology that we identify as less competitive, resulting in reduced sales compared to our expectations or past results. We expect to see increasing competition from agricultural biotechnology firms and from major agrichemical, seed and food companies. The extent to which we can realize cash and profit from our business will depend on our ability to control research costs, predict and respond effectively to competitor products and marketing; and develop new products and services attractive to our customers.

 

Our customers are subject to extensive regulation affecting their use of our biotechnology, which may affect our revenue and profitability.

 

Regulatory and legislative requirements affect the development and distribution of products made from the biotechnology that we produce, including the testing and planting of seeds containing our biotechnology traits and the import of crops grown from those seeds, and non-compliance can harm our revenue and profitability. Obtaining testing, planting and import approvals for seeds or biotechnology traits can be time-consuming and costly, with no guarantee of success. The failure to receive necessary permits or approvals could have near- and long-term effects on our ability to sell some current and future biotechnology. Concern about unintended but unavoidable trace amounts (sometimes called “adventitious presence”) of commercial biotechnology traits in conventional (non-biotechnology) seed, or in the grain or products produced from conventional or organic crops, among other things, could lead to increased regulation or legislation, which may include: liability transfer mechanisms that may include financial protection insurance; possible restrictions or moratoria on testing, planting or use of biotechnology traits; and requirements for labeling and traceability, which requirements may cause food processors and food companies to avoid biotechnology and select non-biotechnology crop sources and can affect farmer seed purchase decisions and, ultimately the sale and use of the biotechnology that we produce. Legislation encouraging or discouraging the planting of specific crops can also harm our sales.

 

The degree of public acceptance or perceived public acceptance of products made from our biotechnology can affect our sales and results of operations by affecting planting approvals, regulatory requirements and farmer purchase decisions.

 

Some opponents of the use of biotechnology in agriculture raise public concern about the potential for adverse effects of products produced using genetic information that we provide to our customers on human or animal health, other plants and the environment. The potential for adventitious presence of commercial biotechnology traits in conventional seed, or in the grain or products produced from conventional or organic crops, is another factor that can affect general public acceptance of these traits. Public concern can affect the timing of, and whether our customers are able to obtain, government approvals. Even after approvals are granted, public concern may lead to increased regulation or legislation or litigation concerning prior regulatory approvals, which could affect our sales and results of operations by affecting planting approvals and may adversely affect sales of our customers’ products to farmers, due to their concerns about available markets for the sale of crops or other products derived from biotechnology which may lead to less demand from our customers. In addition, opponents of agricultural biotechnology have attacked farmers’ fields and facilities used by agricultural biotechnology companies and may launch future attacks against farmers’ fields and our field testing sites and research, production, or other facilities, which could affect our sales and our costs.

 

We are dependent upon other companies to integrate biotechnology that we have licensed to them into their breeding operations for our future license revenue.

 

We perform research for other entities under grant and research agreements that provide service revenue. In addition to the service revenue, our long-term profitability depends on the commercialization of the biotechnology that we provide to other companies for their commercial breeding lines. The extent to which our biotechnology is integrated into these breeding lines is largely outside of our control and can take many years. If our biotechnology is not integrated into breeding lines, we may not realize license revenue which may affect our results of operations.

 

12 
 

The biotechnology industry is subject to rapid technological change, and if we fail to keep up with such change, our results of operations and financial condition could be adversely impacted.

 

Biotechnology has undergone and is subject to rapid and significant change. We expect that the technologies associated with biotechnology research and development will continue to develop rapidly. Our failure to keep pace with such rapid change could result in our products becoming obsolete and we may be unable to recoup any expenses incurred with developing such products, which may adversely affect our future revenues and financial condition.

 

The Company may be required to expend substantial sums in order to bring it into compliance with the various reporting requirements applicable to public companies and/or to prepare required financial statements, and such efforts may harm operating results or be unsuccessful altogether.

 

We are subject to many of the requirements applicable to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, which requires that the Company evaluate and report on its system of internal controls. If the Company’s finance and accounting staff or internal controls over financial reporting are inadequate, it may be required to hire additional staff and incur substantial legal and accounting costs to address such inadequacies. Moreover, the Company cannot be certain that its remedial measures to correct current material weaknesses will be effective. Any failure to implement required or improved controls, or difficulties encountered in their implementation, could harm the Company’s operating results or increase its risk of material weaknesses in internal controls.

 

Members of our management team have significant influence over us.

 

Our officers and directors own, directly or indirectly approximately 34.2% of the outstanding shares of common and preferred stock, excluding options. Including options and warrants, our officers and directors own, directly or indirectly, approximately 42.0% of the outstanding shares of common stock. These stockholders, therefore, have a controlling influence in determining the outcome of any corporate transaction or other matters submitted to our stockholders for approval, including Mergers, consolidations and the sale of all or substantially all of our assets, election of directors, and other significant corporate actions. The interests of these stockholders may differ from the interests of our other stockholders.

 

Our certificate of incorporation and bylaws and Nevada law may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause our stock price to decline.

 

Our certificate of incorporation and bylaws and law could make it more difficult for a third party to acquire us, even if closing such a transaction would be beneficial to our stockholders. We are authorized to issue up to 20,000,000 shares of preferred stock. This preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by our board of directors without further action by stockholders. The terms of any series of preferred stock may include voting rights (including the right to vote as a series on particular matters), preferences as to dividend, liquidation, conversion and redemption rights and sinking fund provisions. We currently have 577,063 shares of Series A-1 preferred stock issued and outstanding and 102,860 shares of Series A-2 preferred stock issued and outstanding. The issuance of any preferred stock could materially adversely affect the rights of the holders of our common stock and existing holders of preferred stock, and therefore, reduce the value of those securities. In particular, specific rights granted to future holders of preferred stock could be used to restrict our ability to merge with, or sell our assets to, a third party and thereby preserve control by the present management.

 

Provisions of our certificate of incorporation and bylaws and law also could have the effect of discouraging potential acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. Such provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. In particular, the certificate of incorporation and bylaws and law, as applicable, among other things:

 

·provide the board of directors with the ability to alter the bylaws without stockholder approval;

 

·place limitations on the removal of directors;

 

·provide that the Board of Directors may change the size of the Board; and

 

·provide that vacancies on the board of directors may be filled by a majority of directors in office, although less than a quorum.

 

13 
 

These provisions may delay or prevent someone from acquiring or merging with us, which may cause the market price of our common stock to decline.

 

We do not foresee paying cash dividends in the foreseeable future and, as a result, our investors’ sole source of gain, if any, will depend on capital appreciation, if any.

 

We do not plan to declare or pay any cash dividends on our shares of common stock in the foreseeable future and currently intend to retain any future earnings for funding growth. As a result, investors should not rely on an investment in our securities if they require the investment to produce dividend income. Capital appreciation, if any after payments due to preferred shareholders, of our shares may be investors’ sole source of gain for the foreseeable future. Moreover, investors may not be able to resell their shares of our common stock at or above the price they paid for them.

 

Our ability to use our net operating loss carry-forwards and certain other tax attributes is limited by Sections 382 and 383 of the Internal Revenue Code.

 

Subject to certain limitations, a corporation may offset a net operating loss carryforward against profit earned in a future year to determine its U.S. federal income tax expenses for such year. Sections 382 and 383 of the Internal Revenue Code of 1986 limit a corporation’s ability to utilize its net operating loss carryforwards and certain other tax attributes (including research credits) to offset future federal taxable income or tax if, in general, the corporation experiences a cumulative ownership change of more than 50% over any rolling three-year period. State net operating loss carryforwards (and certain other tax attributes) may be similarly limited. For the year ended December 31, 2021, we recorded no state tax liability. An ownership change can therefore result in significantly greater tax liabilities than a corporation would incur in the absence of such a change and any increased liabilities could adversely affect the corporation’s business, results of operations, financial condition and cash flow.

 

As of December 31, 2020, we had available total federal and state net operating loss carryforwards of approximately $10,086,000 plus additional net operating losses generated in the year ending December 31, 2021. These NOL’s expire at various intervals through the year 2037 except for the NOL’s for the years ending after December 31, 2017 which have no expiration date.

 

Additional ownership changes may occur in the future as a result of additional equity offerings or events over which we will have little or no control, including purchases and sales of our equity by our five-percent security holders, the emergence of new five-percent security holders, redemptions of our securities or certain changes in the ownership of any of our five percent security holders.

 

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

 

The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no securities or industry analysts commence coverage of our company, the trading price for our stock would be negatively impacted. If we obtain securities or industry analyst coverage and if one or more of the analysts who covers us downgrades our stock, or publishes unfavorable research about our business, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which could cause our stock price and trading volume to decline.

 

 

14 
 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

Not applicable.

 

ITEM 2. PROPERTIES

 

The Company has no owned properties and at this time has no agreements to acquire any properties. The Company currently maintains a rent-free mailing address at 4220 Morning Star Drive, Castle Rock, CO 80108, which is the address of the office of its Chief Executive Officer and lab facilities on lease at 1801 Sunset Place, Unit C, Longmont CO 80501. The Company leases its operating facility on a month-to-month basis, with monthly rental installments of $2,378.

 

ITEM 3. LEGAL PROCEEDINGS

 

The Company is not a party to any pending legal proceedings, and no such proceedings are known to be contemplated.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

15 
 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES

 

There is only a very limited market for the Company's securities. The Company’s securities are included on the OTCQB under the symbol FNAM. As of December 31, 2021, there were outstanding options for 1,081,667 shares of common stock.

 

As of March 11, 2020, there were approximately 324 holders of the Company's common stock.

 

No cash dividends have been paid by the Company on any of its securities since the renewal of its charter and such cash dividends are not contemplated in the foreseeable future.

 

ITEM 6. [RESERVED]

 

Not Applicable.

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis should be read in conjunction with the Audited Financial Statements and related notes included elsewhere in this 10-K. The following discussion includes certain forward-looking statements. For a discussion of important factors which could cause actual results to differ materially from the results referred to in the forward-looking statements, see “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements”.

 

Recent Highlights of Evolutionary Genomics

 

·During 2019, we identified our FusR1 gene in bananas for disease resistance and filed a patent application.

 

·During 2020, WCIC completed a project for the Company to transform soybean plants using our EG261 and EG19 genes and to develop resulting plants through generation T2 seeds.

 

·During 2020, we entered into the DCA with Dole and a Research Agreement with WCIC for the development of the FusR1 gene and banana plants that are resistant to Panama Disease.

  

·During 2021, we were successful at the University of Wisconsin in transforming banana plants with our FusR1 gene and now have transformed plants growing in their greenhouses

 

·During 2021, we discovered our SigX gene in banana plants that may provide resistance to Black Sigatoka disease in bananas and filed patents on the gene.

 

16 
 

Consolidated Results of Operations:

 

   Year Ended December 31, 
   2021   2020 
   Amount   Percent of Revenue   Amount   Percent of Revenue 
Grant revenue  $—    N/A   $12,500    100.0%
  Research and development   1,234,215    N/A    1,793,145    14345.2%
  Salaries and benefits   369,920    N/A    495,518    3964.1%
  General and administrative   1,273,808    N/A    603,632    4829.1%
Total operating expenses   2,877,943    N/A    2,892,295    23138.4%
Operating loss   (2,877,943)   N/A    (2,879,795)   -23038.4%
Other income   83,999    N/A    180,559    1444.5%
Income Taxes   —    N/A    987,353    7898.8%
Net loss  $(2,793,944)   N/A   $(1,711,883)   -13695.1%
Preferred stock dividend   (285,568)   N/A    (285,567)   -2284.5%
Net loss attributable to common stockholders  $(3,079,512)   N/A   $(1,997,450)   -15979.6%

 

Grant Revenue

 

Grant revenue decreased $12,500, or 100.0%, to $0 for the year ended December 31, 2021 from $12,500 for the year ended December 31, 2020. The decrease was primarily due to the decrease in revenue received from the State of Colorado grant which was completed in the first quarter of 2020.

 

Operating Expenses

 

Operating expenses decreased $14,352, or 0.5%, to $2,877,943 for the year ended December 31, 2021 from $2,892,295 for the year ended December 31, 2020. Operating expenses consist of research and development expense, salaries and benefits and general and administrative expense. Changes in these items are described below.

 

Research and Development

 

Research and development decreased $558,930, or 31.2%, to $1,234,215 for the year ended December 31, 2021 from $1,793,145 for the year ended December 31, 2020. The decrease was primarily due to decreased costs incurred on our research agreement with UW for the development of our FusR1 banana gene, partially offset by increases in patent costs and lab supplies expense. Under the terms of our Development and Commercialization Agreement with Dole Food Company, Dole provides funding for our banana project expenses at the University of Wisconsin in the form of notes payable.

 

Salaries and Benefits

 

Salaries and benefits decreased $125,598, or 25.3%, to $369,920 for the year ended December 31, 2021 from $495,518 for the year ended December 31, 2020. The decrease was due to bonuses paid in the year ended December 31, 2020.

 

General and Administrative

 

General and administrative expenses increased $670,176, or 111.0%, to $1,273,808 for the year ended December 31, 2021 from $603,632 for the year ended December 31, 2020. The increase was primarily due to amortization of our intangible asset which began in the year ended December 31, 2020 and increased insurance costs.

 

Other Income and (Expenses)

 

Total other income and (expenses) decreased $96,560, or 53.5%, to $83,999 for the year ended December 31, 2021 from $180,559 for the year ended December 31, 2020. The decrease was primarily due to realized gains on investments that were sold in the year ended December 31, 2020.

 

17 
 

Income Taxes

 

Income tax benefit decreased $987,353 to $0 for the year ended December 31, 2021 from $987,353 for the year ended December 31, 2020. The decrease was the result of placing the in progress research and development into service in the year ended December 31, 2020.

 

Net Loss

 

Net loss increased $1,082,061, or 63.2%, to $2,793,944 for the year ended December 31, 2021 from $1,711,883 for the year ended December 31, 2020. The increase was primarily due to the income tax benefit recorded in the year ended December 31, 2020, increased costs for the amortization of our intangible asset, increases in patent costs and lab supplies expense and decreased gains on investments partially offset by decreased costs incurred on our research agreement with the University of Wisconsin for the development of our FusR1 banana gene and decreased bonuses.

 

Financial Condition

 

The Company’s working capital decreased $37,494 to $236,935 as of December 31, 2021 from $274,429 as of December 31, 2020 primarily due the net loss from operations partially offset by proceeds from notes payable from Dole, the PPP loan and the Economic Injury Disaster Loan (“EIDL”).

 

Liquidity and Capital Resources

 

The Company has historically financed operations through cash flows from operations and equity transactions. Net cash used in operating activities was $1,583,139 for the year ended December 31, 2021 compared to $2,297,317 for the year ended December 31, 2020. The $714,178, or 31.1%, decrease was primarily due to the decreased net operating loss. Net cash provided from the sale of investments was $0 for the year ended December 31, 2021 compared to $147,613 for the year ended December 31, 2020. Net cash provided from financing activities was $1,447,916 in proceeds from notes payable from Dole and $133,395 in proceeds from the PPP loan and the EIDL in the year ended December 31, 2021 compared to $2,095,831 in proceeds from notes payable from Dole and $224,268 in proceeds from the PPP loan and the EIDL in the year ended December 31, 2020.

 

As of December 31, 2021, the Company had $214,009 in operating cash and during 2021 used $1,583,139 of cash in operations. Subsequent to the year ended December 31, 2021, the Company issued an additional 76,953 shares of Series A-2 stock at $5.25 per share and received proceeds of $404,003. The Company’s current projections for 2022 requires cash of $578,143. These factors raise substantial doubt as to the Company’s ability to continue as a going concern.

 

To address these factors and in addition to the $404,000 of proceeds received subsequent to the year ended December 31, 2021 and funding from our agreement with Dole, management expects to receive additional funds from option exercises and will reduce operating expenses with employee salary deferrals to provide the necessary liquidity to meet our obligations as they come due over the next year. We expect that the funding from these sources will be sufficient to cover our obligations for the next twelve months. Additional shareholder funding could result in dilution to existing shareholders. If the funding does not arrive, the Company may not be able to meet its obligations as they become due.

 

Off-Balance Sheet Arrangements

 

The Company has no off-balance sheet arrangements that have a material current effect, or that are reasonably likely to have a material future effect, on its financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures, or capital resources.

 

Contractual Obligations

 

The Company leases its operating facility on a month-to-month basis, with monthly rental installments of $2,378. The Company’s rent expense for the years ended December 31, 2021 and 2020 was $28,535.

 

Critical Accounting Policies

 

For a review of our critical accounting policies, please refer to our audited financial statements.

 

18 
 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTAL DATA

 

The information required by this item appears beginning on page F-1 following the signature pages of this report and is incorporated herein by reference.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

There are no disagreements with the accountants on accounting and financial disclosures.

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Evaluation of disclosure controls and procedures

 

Under the supervision and with the participation of the Company’s management, including the principal executive officer and principal financial officer, as of the end of the period covered by this report, the Company conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be included in our reports to the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of the period covered by this report, our disclosure controls and procedures are not effective at these reasonable assurance levels for the reasons stated below.

 

The Company’s internal control system is designed to provide reasonable cost-effective assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States. There is no assurance that our disclosure controls or our internal controls over financial reporting can prevent all errors. An internal control system, no matter how well designed and operated, has inherent limitations, including the possibility of human error. Because of the inherent limitations in a cost-effective control system, misstatements due to error may occur and not be detected. We monitor our disclosure controls and internal controls and make modifications as we believe appropriate given our financial resources and limited level of activities. Our intent in this regard is that our disclosure controls and our internal controls will improve as systems change and conditions warrant.

 

Management’s Annual Report on Internal Control over Financial Reporting

 

The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives. Furthermore, smaller reporting companies such as the Company face additional limitations. Smaller reporting companies employ fewer individuals and find it difficult to properly segregate duties. Often, one or two individuals control every aspect of our operation and are in a position to override any system of internal control. Additionally, smaller reporting companies tend to utilize general accounting software packages that lack a rigorous set of software controls.

 

Our management, with the participation of the Chief Executive Officer, evaluated the effectiveness of our internal control over financial reporting as of December 31, 2021. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control — 2013 Integrated Framework. Based on this evaluation, our management, with the participation of the President, concluded that, as of December 31, 2021, our internal control over financial reporting was not effective due to the material weaknesses in the system of internal control described below.

 

19 
 

Specifically, management identified the following control deficiencies: (1) the Company has not properly segregated duties as one or two individuals initiate, authorize, and complete all transactions. The Company has not implemented measures that would prevent the individuals from overriding the internal control system. (2) The Company has installed accounting software that does not prevent erroneous or unauthorized changes to previous reporting periods and does not provide an adequate audit trail of entries made in the accounting software. (3) Due to the size of the Company and limited personnel, the Company has not hired an individual with technical accounting expertise within the accounting function.

 

Accordingly, while the Company has identified certain material weaknesses in its system of internal control over financial reporting, it believes that it has taken reasonable cost-effective steps to ascertain that the financial information contained in this report is in accordance with generally accepted accounting principles. Management has determined that current resources would be appropriately applied elsewhere and when resources permit, they will alleviate material weaknesses through various steps.

 

Changes in internal controls

 

Our Certifying Officers have indicated that there were no changes in our internal controls over financial reporting or other factors that could significantly affect such controls subsequent to the date of his evaluation, and there were no such control actions with regard to significant deficiencies and material weaknesses.

 

ITEM 9B. OTHER INFORMATION

 

None.

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

 

Not applicable.

 

20 
 

PART III.

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Officers and Directors

 

The following table sets forth certain information concerning each of the Company’s directors and executive officers:

 

Name   Age   Position
Steve B. Warnecke   65   Chairman of the Board, President, CEO, CFO
Walter Messier   66   Treasurer, Secretary
Virginia Orndorff   71   Director
Mark Boggess   61   Director

 

Compliance with Section 16 (a) of the Exchange Act

 

Section 16(a) of the Exchange Act requires our officers, directors and persons who beneficially own more than ten percent of our ordinary shares to file reports of ownership and changes in ownership with the SEC. These reporting persons are also required to furnish us with copies of all Section 16(a) forms they file. Based solely upon a review of such Forms, we believe that during the year ended December 31, 2021 there were no delinquent filers.

 

Code of Conduct

 

Committees

 

We have not formed an Audit Committee, Compensation Committee or Nominating and Corporate Governance Committee as of the filing of this report. Our Board of Directors performs the principal functions of an Audit Committee. We currently do not have an audit committee financial expert on our Board of Directors. We believe that an audit committee financial expert is not required because the cost of hiring an audit committee financial expert to act as one of our directors and to be a member of an Audit Committee outweighs the benefits of having an audit committee financial expert at this time. However, we intend to implement a comprehensive corporate governance program, including establishing various board committees in the future.

 

There are no agreements or understandings for any officer or director to resign at the request of another person and none of the above-named officers and directors are acting on behalf of or will act at the direction of any other person.

 

There is no family relationship between any director or executive officer of the Company.

 

The board of directors presently has no committees.

 

Set forth below are the names of all directors and executive officers of the Company, all positions and offices with the Company held by each such person, the period during which he has served as such, and the business experience of such persons during at least the last five years:

 

Steve B. Warnecke was appointed Chief Financial Officer, Treasurer, Secretary and member of the board of directors of the Company on June 6, 2014, and became its principal executive officer as President, Chief Executive Officer and Chairman of the Board on October 1, 2014. Mr. Warnecke has served as a member of the board of directors of Evolutionary Genomics since September 2010 and was appointed as Chief Executive Officer in November 2010. Mr. Warnecke has served part-time roles as Chairman of the Board of Directors and Chief Financial Officer for VetDC, Inc. since November 2012, President of CereScan Corp from November 2016 to August 2018 and Chairman of the Pink Lightning Foundation (supporting Children’s Hospitals and cystic fibrosis research) since November 2011. He has also served as Senior Vice-President of Children’s Hospital Colorado Foundation from 2003 through January 2017 and been a member of the Board of Directors of CereScan from 2014 to 2019. Previously, Mr. Warnecke served as Lead Independent Director and Audit Committee Chair for Evolving Systems, Inc. (NASDAQ: EVOL, an international telecom software company) from 2003 to 2011, as Chief Financial Officer of Targeted Medical Pharma, Inc. in 2011, as Chief Financial Officer and member of the Board of Directors for Bacterin International, Inc. (NASDAQ: BONE), a biologics and medical device company from 2008 to 2010, member of the Board of Directors of Emmaus Life Sciences, Inc. in 2011, member of the Board of Directors of Boppy Company from 2005 to 2008, Senior Vice-President of Strategic Planning for First Data/Western Union (NYSE: FDC) from 2001 to 2002 and Chief Financial Officer for Frontier Airlines (former NASDAQ company acquired by Republic Airways) from 1999 to 2001. Mr. Warnecke graduated from the University of Iowa with a BBA in Accounting, Finance and Management and passed the Certified Public Accountant exam in 1979.

 

21 
 

Virginia Orndorff was appointed as a director of the Company on October 1, 2014. She has served as a member of the Evolutionary Genomics board of directors since 2000. She served as Chief Executive Officer and President of Evolutionary Genomics from 2000 to November 2010. She is a founder and CEO of Sieyax, LLC, an early-stage oncology company. From February 2015 to February 2017, Ms. Orndorff served as Executive Director, Chief Executive Officer and Director of the Colorado Institute for Drug, Device and Diagnostic Development. She has served on Colorado’s State Board of Pharmacy from March 2012 to March 2015. 1997 to 2000, Ms. Orndorff served as Vice President then President and Chief Executive Officer of GenoPlex, Inc. of Denver and served as Director of Technology/Business Development of NeXstar Pharmaceuticals, Inc. of Boulder, Colorado, from 1993 to 1997. From 1989 to 1993 she served as the Director of Biotechnology Programs for the Colorado Advanced Technology Institute in Denver. Ms. Orndorff was employed by the Georgia Institute of Technology as Manager of a biotechnology start-up incubator (the Health Science Technology Center) from 1987 to 1989; prior to that for eight years by Genex Corporation of Gaithersburg, Maryland, first as a Laboratory Supervisor then as Manager of Technology Assessment. From 1975 to 1979, Ms. Orndorff had served as a Microbiologist at Stanford Research Institute. She received a BA in Biology from the University of California at Santa Cruz, an MA in Microbiology from California State University at San Jose, and an MBA from Loyola College (where she graduated second in her class).

 

Mark Boggess, Ph.D. was appointed as a director of the Company on October 1, 2014. He has served as a director of Evolutionary Genomics since 2010. Dr. Boggess has a diverse background in the animal sciences and animal industries. Born and raised on a traditional Iowa farm, he served as a swine and beef cattle extension specialist with the University of Idaho in Twin Falls from 1990 to 1994 where he was responsible for all swine extension and educational programming and served as the animal breeding resource specialist for the University beef extension team. From 1994 to 2004, Dr. Boggess served as President of Salmon Creek Farms, LLC where he was responsible for development of the Salmon Creek Farms Natural Pork program and branded product line, at Independent Meat Company in Twin Falls, ID. From 2004 to 2009, Dr. Boggess assumed the position of Director of Animal Science for the National Pork Board where he was responsible for program direction and industry funding coordination for research in pork quality; nutritional efficiency; sow lifetime productivity; genomics-genetics; alternatives to antimicrobials; production-management systems and biotechnology. Dr. Boggess also served as the National Pork Board liaison for animal science to producers, academia, media, regulators and the National Pork Producers Council and directed numerous pork industry based advisory groups. From 2009 to 2014, Dr. Boggess served as the National Program Leader for Food Animal Production and the National Program Leader for Pasture, Forage and Rangeland Systems for the USDA Agriculture Research Service in Beltsville, Maryland. In this role, he directed ARS research for diverse programs in genetics and genomics, nutrition, reproductive physiology, animal welfare and meat quality. Dr. Boggess also directed research to improve pasture and rangeland management practices and land-use strategies, improve and restore the ecology of western rangelands and improve the capacity and efficiency of forage-based food animal production systems. From 2014 to 2018, Dr. Boggess served as the Director of the U.S. Dairy Forage Research Center in Madison, WI. In this role Dr. Boggess directed the research programs for 21 scientists and 75 support staff. The USDFRC includes two research farms in rural Wisconsin as well as offices and laboratories on the campus of the University of Wisconsin. Currently, Dr. Boggess serves as the Director of the US Meat Animal Research Center, the largest meat animal-based research Center in the world. USMARC spans 34,000 acres and houses 25,000 head of beef, sheep and swine. The research programs include 45 scientists in five research units conducting research focused on genetics, genomics, physiology, nutrition, reproduction, food safety, meat quality, animal health, precision agriculture, and environmental quality. Dr. Boggess attended Iowa State University receiving a BS degree in Animal Science in 1983. After receiving an MS degree from Cornell University with a major in Animal Breeding in 1985, Dr. Boggess returned to Iowa State University, receiving his PhD in 1990, also in Animal Breeding.

 

Walter Messier, Ph.D. was appointed Secretary and Treasurer of the Company on October 1, 2014. He is a Founder of Evolutionary Genomics and has served as its Chief Technology Officer since 2000 and has served as its Secretary since 2007. Dr. Messier has published in such prestigious scientific journals as Nature, Nature Medicine, Current Biology, and Science. Dr. Messier is recognized as an authority on the use and interpretation of Ka/Ks algorithms. Dr. Messier’s research on the detection of molecular-level positive selection in the primates is well known. In addition to the research programs Dr. Messier developed and spearheads at Evolutionary Genomics, he is currently collaborating with colleagues in several areas, including identification and validation of novel targets for breast cancer therapeutics, identification and validation of novel targets for HIV/AIDS therapeutics, the role of molecular Darwinian selection in human speciation, and creation of more powerful algorithms for the detection of molecular Darwinian selection. Dr. Messier received his Masters of Science from the State University of New York at New Paltz, and his Ph.D. from the University of Albany (State University of New York).

 

22 
 

CONFLICTS OF INTEREST

 

The Company’s officers and directors have in the past and may in the future be officers and directors of other companies. Consequently, they may have potential inherent conflicts of interest in serving as officers and directors of the Company. Insofar as the officers and directors are engaged in other business activities, management anticipates it will not devote all of its time to the Company’s affairs. The officers and directors of the Company may in the future become shareholders, officers or directors of other companies which may be formed for the purpose of engaging in business activities similar to those conducted by the Company. The Company does not currently have a right of first refusal pertaining to opportunities that come to management’s attention even if the opportunities relate to the Company’s proposed business operations.

 

The officers and directors are under no obligation to make any opportunities that come to their attention in the performance of their duties for any other companies or in any other manner available to the Company. Except as set forth above, the Company has not adopted any other conflict of interest policy with respect to such transactions.

 

ITEM 11. EXECUTIVE COMPENSATION

 

The following table summarizes compensation of our executive officers:

 

               Option         
Name and Position  Year   Salary   Bonus   Awards   Other   Total 
Steve B. Warnecke   2021   $150,000   $—   $—   $10,000   $160,000 
Chief Executive Officer   2020   $150,000   $50,000   $—   $10,000   $210,000 
Chairman of the Board   2019   $150,000   $—   $151,846   $10,000   $311,846 
                               
Walter Messier   2021   $150,202   $—   $—   $—   $150,202 
Chief Technology Officer   2020   $150,000   $50,800   $—   $—   $200,800 
Secretary   2019   $150,000   $—   $310,598   $—   $460,598 
                               
Virginia Orndorff   2021   $—   $—   $—   $10,000   $10,000 
Director   2020   $—   $—   $—   $10,000   $10,000 
    2019   $—   $—   $46,590   $10,000   $56,590 
                               
Mark Boggess   2021   $—   $—   $—   $10,000   $10,000 
Director   2020   $—   $—   $—   $10,000   $10,000 
    2019   $—   $—   $46,590   $10,000   $56,590 

 

The Company had no employment agreements as of December 31, 2021 and paid cash compensation to each to its directors of $10,000 during the years ended December 31, 2021 and 2020, respectively. During the year ended December 31, 2019, Evolutionary Genomics issued option grants for 15,000 shares each to Virginia Orndorff and Mark Boggess, 300,000 shares to Walter Messier and 150,000 shares to Steve Warnecke. The amounts reported under “Option Awards” in the above table reflect the grant date fair value of these awards as determined in accordance with the Financial Accounting Standards Board’s Accounting Standards Codification Topic 718, Compensation – Stock Compensation, rather than amounts paid to or realized by the named individual.  The value of the option awards was estimated using the Black-Scholes option pricing model.  The valuation assumptions used in the valuation of options granted may be found in the Notes to our financial statements included in this annual report on Form 10-K.

 

23 
 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

Principal Stockholders

 

The following table sets forth certain information as of December 31, 2021 regarding the beneficial ownership of the Company’s common stock by (i) each stockholder known by the Company to be the beneficial owner of more than 5% of our common stock, (ii) by each director and executive officer of the Company and (iii) by all executive officers and directors of the Company as a group. Each of the persons named in the table has sole voting and investment power with respect to common stock beneficially owned. The percentage ownership is the number of shares of common stock owned compared to the combined number of shares of common and preferred stock outstanding. None of the officers or directors own any shares of preferred stock.

 

    Number of   Percentage
    Shares Owned   of Shares
Name and Address   or Controlled   Owned
         
Steve B. Warnecke   1,827,088 (1)   28.29%
4220 Morning Star Drive        
Castle Rock, CO  80108        
         
Virginia Orndorff   119,204 (2)   1.85%
4220 Morning Star Drive        
Castle Rock, CO  80108        
         
Mark Boggess   26,000 (3)   0.40%
4220 Morning Star Drive        
Castle Rock, CO  80108
         
Walter Messier   160,615 (4)   2.49%
4220 Morning Star Drive        
Castle Rock, CO  80108        
         
All Officers and Directors as a Group (1)   2,132,907   33.02%

———————

(1)Mr. Warnecke is Chief Executive Officer and Chairman of the Board of the Company. Mr. Warnecke holds options for 66,667 shares exercisable at $.55 per share, 100,000 shares exercisable at $3.30 per share and 150,000 shares exercisable at $1.65 per share.
(2)Ms. Orndorff is a Director of the Company. Ms. Orndorff holds options for 20,000 shares exercisable at $.55 per share, 15,000 shares exercisable at $3.00 per share and 45,000 shares exercisable at $1.50 per share.
(3)Mark Boggess is a Director of the Company. Mr. Boggess holds options for 15,000 shares exercisable at $3.00 per share and 45,000 shares exercisable at $1.50 per share.
(4)Dr. Messier is the Company’s Treasurer and Secretary. Dr. Messier holds options for 100,000 shares exercisable at $.55 per share, 100,000 shares exercisable at $3.00 per share and 300,000 shares exercisable at $1.50 per share..

 

24 
 

ITEMS 13. CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

 

We maintain a mailing address at the offices of our president, Steve B. Warnecke, located at 4220 Morning Star Drive, Castle Rock, CO 80108 for which we pay no rent. There have been no transactions or proposed transactions in which the amount involved exceeds $120,000 for the last two completed fiscal years in which any of our directors, executive officers of beneficial holders of more than 5% of the outstanding shares of common stock, or any of their respective relatives, spouses, associates or affiliates has had or will have any direct or material indirect interest.

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

Audit Fees

 

The aggregate fees billed during the years ended December 31, 2021 and 2020 for professional services rendered by our principal accountant, Plante & Moran PLLC, Denver, Colorado (PCAOB ID No. 166) for the audit of our annual financial statements and quarterly reviews were $65,000 and $42,000, respectively.

 

Audit Related Fees

 

The Company incurred no fees for the years ended December 31, 2021 and 2020 for audit related services by our principal accountant that were reasonably related to the performance of the audit or review of our financial statements, and not reported under Audit Fees above.

 

Tax Fees

 

For the years ended December 31, 2021 and 2020, there were no fees for professional services rendered by our principal accountant for tax preparation.

 

All Other Fees

 

We did not incur any fees for other professional services rendered by our principal accountant during the fiscal years ended December 31, 2021 and 2020.

 

 

 

25 
 

PART IV.

 

ITEM 15. EXHIBITS, FINANCIAL STATEMENTS AND SCHEDULES

 

(a)The following Exhibits are filed as part of this registration statement unless otherwise indicated:

 

          Incorporated by Reference  
Exhibit No.   Description     Form   Date     Number  
2.1   Amended and Restated Agreement and Plan of Merger, dated as of March 2, 2015, by and among Fona, Inc., Evolutionary Genomics, Inc., EG I, LLC, Fona Merger Sub, Inc. and Fona Merger Sub, LLC     10-K   3/5/2015     10.1  
3.1   Form of Amended and Restated Articles of Incorporation     8-K   10/23/2015     3.1  
3.2   Bylaws of the Company     10   9/23/2010     3.2  
3.3   Certificate of Designations, Preferences and Rights of Series A-1 Preferred Stock     8-K   2/25/2016     3.1  
3.4   Certificate of Designations, Preferences and Rights of Series A-2 Preferred Stock     10-K   3/30/2020     3.4  
4.1   Specimen Stock Certificate     8-K   10/23/2015     4.1  
10.1   Equity Incentive Plan     S-4   4/2/2015     10.1  
10.2   Tennessee State University Agreement     S-4/A   7/2/2015     10.2  
10.3   Tennessee State University Amendment     S-4/A   7/2/2015     10.3  
10.4   Fee for Services Agreement University of Missouri     S-4/A   7/2/2015     10.4  
10.5   Contract for Services University of Missouri     S-4/A   7/2/2015     10.5  
10.6   Bill and Melinda Gates Foundation MSA     S-4/A   7/2/2015     10.6  
10.7   Bill and Melinda Gates Foundation WO 1     S-4/A   7/2/2015     10.7  
10.8   State of Colorado Grant Agreement     10-K   2/19/2016     10.8  
10.9   Amendment 1 to the UM Nguyen Sponsored Research Contract     10-K   2/10/2017     10.9  
10.10   Amendment 2 to the UM Zhang Sponsored Research Contract     10-K   2/10/2017     10.10  
10.11   Wisconsin Crop Innovation Center Service Agreement and Amendment     10-K   4/1/2019     10.11  
10.12   State of Colorado Grant Agreement     10-K   4/1/2019     10.12  
10.13   Notice of Termination–Sponsored Research Agreement     10-K   3/30/2020     10.13  
10.14   Development and Commercialization Agreement, dated August 19, 2020, by and between EG Crop Science, Inc. and Dole Food Company, Inc.     10-Q   11/13/2020     10.1  
10.15   Standard Research Agreement, dated September 15, 2020, by and between the Board of Regents of the University of Wisconsin System on behalf of the University of Wisconsin-Madison and EG Crop Science, Inc.     10-Q   11/13/2020     10.2  
21.1   Subsidiaries of Evolutionary Genomics, Inc.     10-K   3/5/2018     21.1  
31.1   Certification of the Company’s Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                  
31.2   Certification of the Company’s Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                  
32.1   Certification of the Company’s Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                  
32.2   Certification of the Company’s Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                  
101.INS   Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)                  
101.SCH   Inline XBRL Taxonomy Extension Schema Document                  
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document                  
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document                  
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document                  
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document                  
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)                  

 

ITEM 16. FORM 10–K SUMMARY

 

Not applicable.

 

26 
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Castle Rock, State of Colorado on March 21, 2021.

 

  EVOLUTIONARY GENOMICS, INC.
     
March 21, 2021 By: /s/ Steve B. Warnecke
  Name: Steve B. Warnecke
  Title: Chief Executive Officer, Chief Financial Officer, President and Chairman of the Board

 

Pursuant to the requirements of the Securities Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Steve B. Warnecke      President, Chief Executive Officer, Chief Financial Officer, Director (Principal Executive Officer, Principal Financial/Accounting Officer)      March 21, 2021
Steve B. Warnecke      
         
         
/s/ Virginia Orndorff   Director   March 21, 2021
Virginia Orndorff        
         
         
/s/ Mark Boggess   Director   March 21, 2021
Mark Boggess        

 

 

 

27 
 

Evolutionary Genomics, Inc. and Subsidiary

Consolidated Financial Statements

December 31, 2021 and 2020

 

 

 

 

 

Contents

 

 

Report of Independent Registered Public Accounting Firm (PCAOB ID #166) F-2
   
Consolidated Balance Sheets F-4
   
Consolidated Statements of Operations F-5
   
Consolidated Statement of Stockholders’ Deficit F-6
   
Consolidated Statements of Cash Flows F-7
   
Notes to Consolidated Financial Statements F-8

 

 

 

 

 

 

 

 

F-1 
 

Report of Independent Registered Public Accounting Firm

 

To the Stockholders and Board of Directors of Evolutionary Genomics, Inc. and Subsidiary

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Evolutionary Genomics, Inc. and Subsidiary (the “Company”) as of December 31, 2021 and 2020, the related consolidated statements of operations, stockholders' equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

The Company's management is responsible for these financial statements. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.

 

Controls and Procedures - Material Weakness - Refer to Item 9A to the form 10-K

 

Critical Audit Matter Description

 

Management has identified the following control deficiencies: (1) the Company has not properly segregated duties as one or two individuals initiate, authorize, and complete all transactions. The Company has not implemented measures that would prevent the individuals from overriding the internal control system. (2) The Company uses accounting software that neither prevent erroneous or unauthorized changes to previous reporting periods or provide an adequate audit trail of entries made in the accounting software. (3) Due to the size of the Company and limited personnel, the Company has not hired an individual with the appropriate level of knowledge, experience and training in financial reporting.

 

Given these deficiencies in the lack of proper segregation of duties, weakness within accounting software, and lack of technical accounting expertise which have a pervasive impact to all financial account balances and disclosures, a significant change in our audit plan was required with an increase in audit effort.

 

F-2 
 

 

How the Critical Audit Matter was Addressed in the Audit

 

Our audit procedures related to mitigating the risks of the internal control deficiencies include the following:

·Performed a primarily substantive audit over significant account balances and disclosures. Utilized original source documents for audit evidence, rather than system reports or other information.
·Performed additional procedures to mitigate any increased fraud risks, including:
1)lowered the threshold for investigating differences between recorded amounts and independent expectations developed by us that we would have otherwise used,
2)increased the number of selections we would have otherwise made if the Company’s controls were designed and operating effectively,
3)utilized experienced staff on the engagement team and emphasized the heightened fraud risks with the team members, and
4)performed procedures in verifying the accuracy and completeness for disbursements transactions, inclusive of any potential related party considerations.

 

Going Concern – Refer to Note 13 to the consolidated financial statements

 

Critical Audit Matter Description

 

The determination as to whether the Company can continue as a going concern includes consideration of management’s operating plan and anticipated timing of future cash flows.  Management is required to make subjective judgments and assumptions in concluding on going concern uncertainty.

 

Auditing the Company’s going concern assessment is complex because it involves a high degree of auditor judgment to assess the reasonableness of the cash flow forecasts used in the Company’s going concern analysis. In particular, the cash flows are sensitive to changes related to significant assumptions, such as the estimation of the future cash to be used in operations and the ability of the Company to secure additional financing.

 

How the Critical Audit Matter was Addressed in the Audit

 

Our audit procedures related to analyzing the ability to continue as a going concern include the following:

·Gained an understanding of the internal controls related to the Company’s going concern assessment,

 

·Evaluated the reasonableness of the Company’s forecasted operating expenses by obtaining an understanding of the Company’s operations and strategy, inquiring about the Company’s research and development activities, comparing the forecasted operating expenses to historical operating expenses, assessing expected costs, and confirmed any deferral of expenses with the payee, and

 

·Assessed management’s ability to forecast operating expenses by comparing prior year forecasts to actual financial results.

 

 

We have served as the Company’s auditor since 2014.

 

/s/ Plante & Moran, PLLC

 

Denver, Colorado

March 21, 2022

 

F-3 
 

 

Evolutionary Genomics, Inc. and Subsidiary

Consolidated Balance Sheets

December 31, 2021 and 2020

 

         
   2021   2020 
         
ASSETS          
           
Current assets          
Cash  $214,009   $215,836 
Prepaid expenses   41,792    61,757 
          Total current assets   255,801    277,593 
           
Non-current assets          
Property and equipment, net   18,698    50,763 
Intangible assets, net   2,657,592    3,664,343 
          Total non-current assets   2,676,290    3,715,106 
Total assets  $2,932,091   $3,992,699 
           
LIABILITIES AND STOCKHOLDERS'  DEFICIT          
          
Current liabilities          
Accounts payable and accrued expenses  $18,866   $3,164 
          Total current liabilities   18,866    3,164 
           
Long-term liabilities          
Notes payable   3,743,747    2,245,831 
                Total liabilities   3,762,613    2,248,995 
Commitments and contingencies          
Preferred Stock subject to possible redemption, $0.001 par value, 20,000,000 authorized at December 31, 2021 and 2020          
Series A-1 Convertible Preferred Stock, $0.001 par value; 600,000 shares authorized, 577,063 shares issued and outstanding at December 31, 2021 and 2020; liquidation preference at December 31, 2021 of $4,438,687   3,029,579    3,029,579 
Series A-2 Convertible Preferred Stock, $0.001 par value; 200,000 shares authorized, 102,860 shares issued and outstanding at December 31, 2021 and 2020; liquidation preference at December 31, 2021 of $653,877   540,015    540,015 
           Total preferred stock subject to possible redemption   3,569,594    3,569,594 
Stockholders' deficit          
Preferred Stock   1,521,796    1,236,228 
Common Stock, $0.001 par value; 780,000,000 shares authorized, 5,881,898 shares issued and outstanding at December 31, 2021 and 2020   5,882    5,882 
Additional paid-in capital   11,949,702    12,015,552 
Accumulated deficit   (17,877,496)   (15,083,552)
          Total stockholders' deficit   (4,400,116)   (1,825,890)
Total liabilities and stockholders' deficit  $2,932,091   $3,992,699 

 

See notes to consolidated financial statements

F-4 
 

 

Evolutionary Genomics, Inc. and Subsidiary

Consolidated Statements of Operations

For the years ended December 31, 2021 and 2020

 

         
   2021   2020 
         
Grant revenue  $—   $12,500 
           
Operating expenses          
  Research and development   1,234,215    1,793,145 
  Salaries and benefits   369,920    495,518 
  General and administrative   1,273,808    603,632 
          Total operating expenses   2,877,943    2,892,295 
           
Operating loss   (2,877,943)   (2,879,795)
           
Other income          
  Investment income   604    372 
  Loan forgiveness   83,395    74,268 
  Gain on investments   —    105,919 
          Total other income   83,999    180,559 
Loss before income taxes   (2,793,944)   (2,699,236)
Income tax benefit   —    987,353 
Net loss   (2,793,944)   (1,711,883)
Preferred stock dividend   (285,568)   (285,567)
Net loss attributable to common stockholders  $(3,079,512)  $(1,997,450)
           
Net loss per common share, basic and diluted  $(0.52)  $(0.34)
           
Weighted average common shares outstanding, basic and diluted   5,881,898    5,881,898 

 

See notes to consolidated financial statements

 

 

 

F-5 
 

Evolutionary Genomics, Inc. and Subsidiary

Condensed and Consolidated Statement of Stockholders' Deficit

 

                               
   Twelve Months Ended December 31, 2021 
   Common Stock   Preferred  

Additional Paid-In

   Accumulated   Stockholders' 
   Shares   Amount   Dividend   Capital   Deficit   Deficit 
                         
Balance, December 31, 2020   5,881,898   $5,882   $1,236,228   $12,015,552   $(15,083,552)  $(1,825,890)
Stock compensation   —    —    —    54,930    —    54,930 
Preferred stock dividends   —    —    71,392    (71,392)   —    — 
Net loss   —    —    —    —    (513,742)   (513,742)
Balance, March 31, 2021   5,881,898   $5,882   $1,307,620   $11,999,090   $(15,597,294)  $(2,284,702)
Stock compensation   —    —    —    54,929    —    54,929 
Preferred stock dividends   —    —    71,392    (71,392)   —    — 
Net loss   —    —    —    —    (553,701)   (553,701)
Balance, June 30, 2021   5,881,898   $5,882   $1,379,012   $11,982,627   $(16,150,995)  $(2,783,474)
Stock compensation   —    —    —    54,930    —    54,930 
Preferred stock dividends   —    —    71,392    (71,392)   —    — 
Net loss   —    —    —    —    (1,058,657)   (1,058,657)
Balance, September 30, 2021   5,881,898   $5,882   $1,450,404   $11,966,165   $(17,209,652)  $(3,787,201)
Stock compensation   —    —    —    54,929    —    54,929 
Preferred stock dividends   —    —    71,392    (71,392)   —    — 
Net loss   —    —    —    —    (667,844)   (667,844)
Balance, December 31, 2021   5,881,898   $5,882   $1,521,796   $11,949,702   $(17,877,496)  $(4,400,116)

 

   Twelve Months Ended December 31, 2020 
   Common Stock   Preferred   Additional Paid-In   Accumulated   Stockholders' 
   Shares   Amount   Dividend   Capital   Deficit   Deficit 
                         
Balance, December 31, 2019   5,881,898   $5,882   $950,661   $12,081,401   $(13,371,669)  $(333,725)
Stock compensation   —    —    —    54,930    —    54,930 
Preferred stock dividends   —    —    71,391    (71,391)   —    — 
Net loss   —    —    —    —    (241,816)   (241,816)
Balance, March 31, 2020   5,881,898   $5,882   $1,022,052   $12,064,940   $(13,613,485)  $(520,611)
Stock compensation   —    —    —    54,929    —    54,929 
Preferred stock dividends   —    —    71,392    (71,392)   —    — 
Net loss   —    —    —    —    (294,798)   (294,798)
Balance, June 30, 2020   5,881,898   $5,882   $1,093,444   $12,048,477   $(13,908,283)  $(760,480)
Stock compensation   —    —    —    54,930    —    54,930 
Preferred stock dividends   —    —    71,392    (71,392)   —    — 
Net income   —    —    —    —    535,885    535,885 
Balance, September 30, 2020   5,881,898   $5,882   $1,164,836   $12,032,015   $(13,372,398)  $(169,665)
Stock compensation   —    —    —    54,929    —    54,929 
Preferred stock dividends   —    —    71,392    (71,392)   —    — 
Net income   —    —    —    —    (1,711,154)   (1,711,154)
Balance, December 31, 2020   5,881,898   $5,882   $1,236,228   $12,015,552   $(15,083,552)  $(1,825,890)

 

See notes to consolidated financial statements

 

F-6 
 

Evolutionary Genomics, Inc. and Subsidiary

Condensed and Consolidated Statements of Cash Flows

For the years ended December 31, 2021 and 2020

 

           
   2021   2020 
Cash flows from operating activities:          
  Net loss  $(2,793,944)  $(1,711,883)
  Adjustments to reconcile net loss to net cash flows from operating activities          
    Depreciation and amortization   1,038,816    409,368 
    Stock-based compensation   219,718    219,718 
    Unrealized gain on investments   —    (74,268)
    PPP loan forgiveness   (83,395)   (105,919)
    Deferred tax benefit        (987,353)
Changes in operating assets and liabilities:          
      Accounts receivable   —    6,845 
      Prepaid expenses   19,965    (37,574)
      Accounts payable and accrued expenses   15,702    (16,251)
        Cash flows from operating activities   (1,583,138)   (2,297,317)
           
Cash flows from investing activities:          
     Proceeds from sale of investments   —    147,613 
        Cash flows from investing activities   —    147,613 
           
Cash flows from financing activities:          
  Proceeds from issuance of notes payable   1,447,916    2,095,831 
  Proceeds from EIDL and PPP loans   133,395    224,268 
        Cash flows from financing activities   1,581,311    2,320,099 
           
Net change in cash   (1,827)   170,395 
           
Cash, beginning of period   215,836    45,441 
           
Cash, end of period  $214,009   $215,836 
           
Supplemental cash flow information          
        Preferred stock dividend accrual  $285,568   $285,567 

 

See notes to consolidated financial statements

 

 

F-7 
 

 

Evolutionary Genomics, Inc. and Subsidiary

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

 

Note 1: Business Activity

 

Evolutionary Genomics, Inc. (the “Company,” “We,” or “Our”) has developed a technology platform, the Adapted Traits Platform (“ATP”), to identify commercially valuable genes that control important traits in animals and plants. We are using the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. Our platform identifies key genes that have changed successfully to impart new or improved traits.

 

In the past, the Company performed research on behalf of governmental organizations, non-profit foundations and commercial entities and received revenue from grants and commercial research contracts. We have not received any revenue from these grant arrangements since early 2020. The Company now focuses on research projects that may lead to long-term licensing arrangements with agricultural seed companies and crop producers as with our soybean and banana projects. These projects take several years to develop, and successful commercialization may take many years to produce license royalty payments. Our banana project, in cooperation with Dole Food Company is an example that has resulted in notes payable funding for the development phase of our banana genes and may result in a long-term royalty bearing license once the development phase is complete.

 

During 2014, the Company purchased 75.16% of the outstanding stock of Fona, Inc., (“Fona”) a public shell company. Since Fona was a public shell company which did not constitute a business and the purchase was done in contemplation of a reverse merger, the Company accounted for the payment as a distribution to Fona shareholders. The Company also entered into an Agreement and Plan of Merger (the “Merger”), which was consummated on October 19, 2015. As a result of the Merger, Evolutionary Genomics, Inc. became a wholly owned subsidiary of Fona. For accounting purposes, the merger was treated as a reverse acquisition with Evolutionary Genomics, Inc. as the acquirer and Fona as the acquired party. Subsequent to the Merger, Fona was renamed Evolutionary Genomics, Inc. and our subsidiary was renamed from Evolutionary Genomics, Inc. to EG Crop Science, Inc.

 

Note 2: Summary of Significant Accounting Policies

 

Principals of Consolidation: These consolidated financial statements include the accounts of Evolutionary Genomics, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated.

 

Use of Estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

 

These consolidated financial statements have been prepared on the basis of going concern. Management’s plans to address the Company’s liquidity are discussed further in Note 13.

 

Cash: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.

 

Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided for by the straight-line method over three- to seven-year estimated useful lives of software, furniture and fixtures and equipment. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized.

 

Long-Lived Assets: The long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. An impairment loss is measured and recorded to the extent that the carrying amount of the asset exceeds its estimated fair value. No asset impairment was recorded during the years ended December 31, 2021 and 2020.

 

F-8 

Evolutionary Genomics, Inc. and Subsidiary

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

 

Intangible Assets: Intangible assets include acquired research in progress and patents on the Company’s core technology for gene identification. Previously acquired patents were capitalized and are amortized over their expected useful life of 20 years using the straight-line method. Acquired research in progress was placed into service on August 19, 2020 in conjunction with the Development and Commercialization Agreement and is being amortized over four years consistent with the term of the Dole agreement using the straight-line method. Costs incurred to renew intangible assets and to file new patent applications are expensed in the period incurred, while costs incurred to extend the lives of patents are capitalized and amortized over the remaining useful life of the asset. Intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any intangible assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. No impairment was recorded during the years ended December 31, 2021 and 2020.

 

Revenue Recognition: Grant revenue consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by us. However, these amounts are subject to change upon review by federal and non-profit foundations prior to receipt of invoice amounts submitted. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed.

 

Income Taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Management regularly assesses the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established, increased or decreased, an income tax charge or benefit is included in the consolidated financial statements and net deferred tax assets are adjusted accordingly. As of December 31, 2021 and 2020, a full valuation allowance has been established on the net deferred tax asset.

 

Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits.

 

Stock-Based Compensation: The Company accounts for stock option awards in accordance with ASC 718. The estimated grant-date fair value of stock-based awards is expensed over the requisite service period, which is typically equivalent to the vesting term of the award.

 

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.

 

Research and Development: Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed.

 

Net Loss Per Common Share: Basic net (loss) income per common share excludes any dilutive effects of equity instruments. We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the period. We compute diluted net (loss) income per common share using the weighted average number of common shares and common stock equivalents outstanding during the period. For the years ended December 31, 2021 and 2020, common stock equivalents including 679,923 shares of convertible preferred stock and options for 1,081,667 shares of common stock were excluded because their effect was anti-dilutive.

 

F-9 

Evolutionary Genomics, Inc. and Subsidiary

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

 

Note 3: New Accounting Standards

 

Recently Issued Accounting Standards

 

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments,” which requires entities to estimate all expected credit losses for certain types of financial instruments, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The updated guidance also expands the disclosure requirements to enable users of financial statements to understand the entity’s assumptions, models and methods for estimating expected credit losses over the entire contractual term of the instrument from the date of initial recognition of that instrument. This guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within that reporting period and is not expected to have an impact on the Company’s consolidated financial statements.

 

Note 4: Property and Equipment

 

Property and equipment is comprised of the following:

 

          
   December 31,   December 31, 
   2021   2020 
Equipment  $432,499   $432,499 
Software   63,179    63,179 
Furniture and fixtures   7,987    7,987 
    503,665    503,665 
Accumulated depreciation   (484,967)   (452,902)
Property and equipment, net  $18,698   $50,763 

 

Depreciation expense for the years ended December 31, 2021 and 2020 was $32,065 and 38,119, respectively.

 

Note 5: Intangible Assets

 

Intangible assets are comprised of the following:

 

          
   December 31,   December 31, 
   2021   2020 
Acquired research in progress - definite lived  $4,016,596   $4,016,596 
Patents   52,045    52,045 
Accumulated amortization   (1,411,049)   (404,298)
Intangible assets, net  $2,657,592   $3,664,343 

 

The Company expects to recognize amortization expense related to its acquired research in progress and patents according to the following:

 

      
Year Ending   Amortization 
December 31, 2022   $1,006,751 
December 31, 2023    1,006,751 
December 31, 2024    638,105 
December 31, 2025    2,602 
December 31, 2026    2,602 
Thereafter    781 
    Total   $2,657,592 

 

F-10 

Evolutionary Genomics, Inc. and Subsidiary

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

 

Amortization expense for the acquired research in progress and patents during the year ended December 31, 2021 and 2020 was $1,006,751 and $371,248, respectively.

 

In its merger completed on October 19, 2015, the Company acquired research in progress. The value of the acquired research in progress was based upon several factors including, evaluation of other intangible assets, the purchase price, estimated future cash flows, and the amounts expended on the research to date. The research in progress was the identification and validation of genes to provide pest and disease resistance to plants performed by EG I. With the banana development project contract in place, the Company placed this asset in service on August 19, 2020. Additional costs to complete the soybean research are expected to be approximately $33,000, which will be expensed as incurred. The timing and cost of additional research may vary from these estimates as the success of the research is subject to many factors outside of the Company’s control.

 

Note 6: Income Taxes

 

The Company’s income tax benefit consists of the following for the years ended December 31, 2021 and 2020:

 

          
   2021   2020 
Current income tax benefit:  $—   $— 
   U.S. Federal   —    — 
   U.S. States   —    — 
     Total current income tax benefit   —    — 
           
Deferred income tax benefit:          
   U.S. Federal   —    840,812 
   U.S. States   —    146,541 
     Total deferred income tax benefit   —    987,353 
     Total income tax benefit  $—   $987,353 

 

For the years ended December 31, 2021 and 2020, the reconciliation between the income tax benefit computed by applying the statutory U.S. federal income tax rate of 21.0% to the pre-tax loss before income taxes, and total income tax expense recognized in the financial statements is as follows

 

          
   2021   2020 
Income tax benefit at statutory U.S. federal rate  $586,728   $566,840 
Income tax benefit attributable to U.S. states   99,325    98,792 
Research and development credits   137,728    49,338 
Non-taxable forgiveness of PPP and EIDL loans   20,478    18,314 
Non-deductible expenses   (300)   (334)
Stock- based compensation   (53,952)   (54,182)
Other   (15,182)   (3,790)
Change in valuation allowance   (774,825)   312,373 
     Total income tax expense  $—   $987,351 

 

F-11 

Evolutionary Genomics, Inc. and Subsidiary

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

 

As of December 31, 2021 and 2020, the components of deferred income tax assets and liabilities were as follows:

 

          
   2021   2020 
Deferred income tax assets:          
   Net operating loss carryforwards  $2,876,543   $2,585,042 
   Research and development credits   515,982    378,524 
   Long-term capital loss carryforward   94,728    — 
   Valuation allowance for deferred income tax assets   (2,835,108)   (2,060,283)
     Net deferred income tax assets   652,145    903,283 

 

Deferred income tax liabilities:          
   Intangible assets   (647,554)   (897,196)
   Property, equipment and other   (4,591)   (6,087)
     Total deferred income tax liabilities   (652,145)   (903,283)
Net deferred income tax assets  $—   $— 

 

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse.

 

The Company records a valuation allowance for certain temporary differences for which it is more likely than not that it will not receive future tax benefits. The Company assesses its past earnings history and trends and projections of future net income. The Company recorded a valuation allowance for the entire amount of the net deferred tax asset at December 31, 2021 and 2020. As of December 31, 2021, the Company had a total valuation allowance of approximately $2,835,000 for its deferred tax assets. The Company will continue to review this valuation allowance and make adjustments as appropriate.

 

As of December 31, 2021, the Company had net operating loss (“NOL”) carryforwards of approximately $11,715,000, consisting of $5,295,000 that have an indefinite carryover period and $6,420,000 that expire at various intervals through 2037. Use of NOL carryforwards is limited by the provisions of Section 382 of the Internal Revenue Code. At this point, the Company has not performed an analysis to determine whether an ownership change (as defined under Section 382) occurred during this year or preceding year(s). A determination of the potential impact these provisions might have on the utilization of net operating losses will be made when the net operating loss is projected to be utilized. As of December 31, 2021, the Company also has a capital loss carryforward of approximately $386,000 that expires in 2025, and a research and development credit carryforward of approximately $515,000 that will expire at various intervals through 2040.

 

The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. At this time, the Company does not have any uncertain tax positions to assess.

 

Note 7: Notes Payable

 

Small Business Administration (“SBA”) Paycheck Protection Program: On April 17, 2020, the Company received $71,268 and on February 22, 2021 the Company received $76,395 in proceeds from the SBA Paycheck Protection Program, which was created under the Coronavirus Aid, Relief and Economic Security Act (CARES). Under the program, the Company received $71,268 forgiveness of the debt from the SBA based on the use of the proceeds over the 24-week period following funding of the loan in the year ended December 31, 2020 and $76,395 in the year ended December 31, 2021. The forgiveness was recorded as loan forgiveness in other income on the consolidated statement of operations.

 

F-12 

Evolutionary Genomics, Inc. and Subsidiary

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

 

Although management considers it probable that the Company was initially eligible for the loan and subsequent forgiveness, the SBA has the ability to review the Company’s loan file for a period subsequent to the date the loan was forgiven and could request additional documentation to support the Company’s initial eligibility for the loan and request for loan forgiveness. In the event the SBA subsequently determines the Company did not meet the initial; eligibility requirements for the PPP loan or did not qualify for loan forgiveness, the SBA may pursue legal remedies at its discretion.

 

SBA Economic Injury Disaster Loan: On June 5, 2020, the Company received a $3,000 Economic Injury Disaster Loan (“EIDL”) advance and $150,000 in proceeds from the SBA’s EIDL Program. On July 20, 2021, the Company received an additional $7,000 SBA EIDL Advance which has been forgiven and, on July 14, 2021, the Company received a $50,000 increase in the SBA EIDL Loan. Installment payments, including interest at the rate of 3.75% per annum, of $1,022 monthly over thirty years from the date of the original promissory note will begin on June 5, 2022. The Company granted to the SBA a continuing security interest in all tangible and intangible personal property. The Company may not make any distribution of assets of the Company to any shareholder without the written consent of the SBA. As of December 31, 2021, the Company recognized $9,760 of accrued interest on the note.

 

Dole Food Company:

 

On August 19, 2020, the Company entered into a Development and Commercialization Agreement (“DCA”) with Dole Food Company (“Dole”) for the development of our banana genes. The DCA provides for payments from Dole to the Company of $800,000 upon execution, $800,000 by the twelve-month anniversary, $250,000 by the thirty-six month anniversary and $250,000 by the forty-eight month anniversary. Dole also reimburses the Company for costs incurred at the University of Wisconsin-Madison (“UW”) not to exceed $2,200,000 in coordination with the Standard Research Agreement that the Company entered into with UW on September 18, 2020. The agreement with UW includes payments from the Company to UW in the amount of $2,159,719 over the two-year expected term of the project. If the UW research is successful, Dole expects to incur costs of approximately $750,000 to perform field trials.

 

The DCA also specifies that the Company will execute notes payable to Dole for the funding that Dole is providing up to $5,050,000. Upon receipt of $800,000 on August 26, 2020, $800,000 on July 28, 2021, $1,295,831 on December 29, 2020 and $647,916 on September 29, 2021, the Company executed the notes under this DCA and recorded them as long-term notes payable for financial statement purposes. The notes are non-interest bearing and allow Dole to offset fifty percent of future royalty payments to the Company by reducing the amount of principal due on these notes. Other than this offset of future royalty payments, repayment of principal and interest is only required in the case of termination of the DCA by Dole for cause.

 

Note 8: Stockholders’ Equity

 

The Amended and Restated Certificate of Incorporation of the Company dated October 19, 2015 authorized the issuance of 800,000,000 shares of all classes of stock including 780,000,000 shares of Common Stock having a par value of $0.001 per share and 20,000,000 shares of Preferred Stock having a par value of $0.001 per share, 600,000 of which were designated as Series A-1 Convertible Preferred Stock (“Series A-1”) and 200,000 of which were designated as Series A-2 Convertible Preferred Stock (“Series A-2”). The Board of Directors, without a vote of the shareholders, is authorized to issue additional shares of Preferred Stock in series and to establish the characteristics thereof.

 

Subsequent to the year ended December 31, 2021, the Company issued an additional 76,953 shares of Series A-2 stock at $5.25 per share and received proceeds of $404,003. The Company has 20,187 shares of Series A-2 stock remaining available for issuance.

 

Liquidation: Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of the Series A-1 and Series A-2 shall be entitled to receive out of the assets of the Company for each share of Series A-1 and Series A-2 an amount equal to its stated value, $5.25 per share as of December 31, 2021 and 2020, plus any accrued but unpaid dividends before any distribution or payment shall be made to the holders of any other class or series of stock of the Company that ranks junior to the Series A-1 and Series A-2. The holders shall be entitled to convert their shares of Series A-1 and Series A-2 into Common Stock at any time prior to the consummation of a Liquidation. This is considered a contingent redemption feature.

 

F-13 

Evolutionary Genomics, Inc. and Subsidiary

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

 

Conversion: The holders of Series A-1 and Series A-2 may convert their shares into shares of Common Stock, at the option of the holder, on a one-share-for-one-share basis and shall be subject to certain adjustments at any time.

 

Optional Redemption; Sinking Fund Account: The Company may elect to redeem some or all of the then outstanding shares of Series A-1, (i) for cash in an amount equal to the liquidation preference per share, $5.25 per share as of December 31, 2021, subject to adjustment and (ii) by issuing one share, subject to adjustment, of Common Stock for each share of Series A-1 and Series A-2 outstanding being redeemed. 50% of all licensing fees received by the Company will be deposited into a separate sinking fund for use in an optional redemption. As of December 31, 2021, no licensing revenue has been received under these provisions and no sinking fund account has been established.

 

Dividends: The Company shall pay to the holders of the Series A-1 and Series A-2 dividends at the rate of 8% per annum and the Company has accrued these dividends since issuance of the Series A-1 and Series A-2. The dividend amount shall accrue and shall be payable in shares of Common Stock upon the conversion of the Series A-1 and Series A-2, or upon the redemption of the Series A-1 and Series A-2. No dividends shall be paid on any Common Stock of the Company or any capital stock of the Company that ranks junior to the Series A-1 and Series A-2 until dividends of Series A-1 and Series A-2 been paid. As of December 31, 2021, there were $1,522,970 in accrued stock dividends.

 

Voting: The holders of the Series A-1 and Series A-2 are entitled to vote on all matters submitted to the stockholders for a vote on an as-if-converted to Common Stock basis, with all stockholders voting as a single class.

 

Note 9: Stock-Based Compensation

 

The Company grants stock-based instruments under the 2015 Stock Incentive Plan (“Plan”) for which 1,400,000 shares of the Company’s Common Stock has been reserved. The Plan allows for the issuance of incentive stock options and non-qualified stock options with a maximum contractual term of 10 years. Shares and options that are cancelled are available for reissuance under the Plan. For years ended December 31, 2021 and 2020, the Company recorded compensation costs for stock options of $219,718 and $219,718, respectively. Stock options are generally issued with an exercise price at or above the estimated per-share value of the Company’s Common Stock. The Company granted no options during the years ended December 31, 2021 and 2020.

 

Management has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the issuance of the outstanding options, there was not a public market for the Company’s shares. Accordingly, the Company utilized the value obtained in equity transactions with unrelated parties to estimate the fair value of the Company’s Common Stock on the date of grant. Volatility of the underlying common shares was determined based on the historical volatility for similar companies that are actively traded in the public markets for a term consistent with the expected life of the options. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options on the date of the grant. Due to the lack of sufficient historical activity, the expected life of the options was estimated using the formula set forth in Securities and Exchange Commission SAB 107.

 

The following table summarizes the status of the Company’s aggregate stock options granted:

 

                     
    Number of Options   Weighted Average Exercise Price   Weighted Average Remaining Term(Years)   Total Intrinsic Value 
                  
Balance, January 1, 2020    1,081,667   $1.74    7.67      
Granted    —    —    —      
Exercised    —    —    —      
Cancelled    —    —    —      
                      
Balance, December 31, 2020    1,081,667   $1.74    6.67      
                      
Balance, January 1, 2021    1,081,667   $1.74    6.67      
Granted    —    —    —      
Exercised    —    —    —      
Cancelled    —    —    —      
                      
Balance, December 31, 2021    1,081,667   $1.74    5.67   $— 
                      
Exercisable at December 31, 2021    868,332   $1.79    5.14   $28,000 

 

F-14 

Evolutionary Genomics, Inc. and Subsidiary

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

 

During the years ended December 31, 2021 and 2020, options for 180,000 and 179,999 shares vested, respectively. As of December 31, 2021, there was $185,731 unrecognized compensation cost related to share-based compensation arrangements that will be recognized through the year ending December 31, 2022.

 

Note 10: Commitments and Contingencies

 

Officer Indemnification: Under the Company’s organizational documents, the Company’s officers, employees, and directors are indemnified against certain liabilities arising out of the performance of their duties. The Company’s maximum exposure under these arrangements is unknown, as this would involve future claims that may be made against the Company that have not yet occurred. However, based on experience, the Company expects any risk of loss to be remote. The Company also has an insurance policy for its directors and officers to insure them against liabilities arising from their performance in their positions with the Company.

 

Lease Commitments: The Company leases its operating facility and pays its rent in monthly installments. The lease was renewed in June 2016 for a period of twelve months and monthly rentals for the period of July 1, 2016 through December 31, 2021 are $2,378 per month which continues on a month-to-month basis. There is no minimum lease commitment as of December 31, 2021. Renewals after June 30, 2017 are by mutual agreement. The Company’s rent expense for the years ended December 31, 2021 and 2020 was $28,535.

 

Royalty: Effective March 1, 2012, the Company entered into an Agreement for Contract Services with SmithBucklin Corporation (the “Contractor”) on behalf of the United Soybean Board. The contract includes the payment of certain royalties, as defined in the Agreement.

 

The Company is obligated to pay royalties to the United Soybean Board of 10% of the sale of products derived from the soybean genes that were the subject of the research performed by the Contractor or from royalties received by the Company from the sale of products by a third party not to exceed 150% of the total amount paid to the Contractor under this Agreement. The Company has recognized to date grant revenue from the contract of $262,400 as of December 31, 2020, thus limiting any future royalties as of December 31, 2021 to a total of $393,600. The Company has not accrued or paid any royalties under the terms of the Agreement as of and during the years ended December 31, 2021 and 2020 because it has not received any revenue from the sale of products to date.

 

Other Commitments: On September 18, 2020, the Company entered into a Standard Research Agreement with WCIC for the development of our banana genes. The agreement includes payments from the Company in the amount of $2,159,719 over the two-year expected term of the project. These costs will be reimbursed, in the form of notes payable by Dole in accordance with our DCA.

 

Note 11: Related Parties and Transactions

 

Steve B. Warnecke: Mr. Warnecke is the Company’s Chief Executive Officer and Chairman of the Board and owns, directly or indirectly, 1,827,088 shares or 28.3% of the Common Stock outstanding as of December 31, 2021.

 

Note 12: Concentrations

 

Considerations of Credit Risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains its cash balances at high-credit, quality financial institutions. The balances, at times, may exceed federally insured limits. The Company routinely monitors the credit quality of its customers.

 

F-15 

Evolutionary Genomics, Inc. and Subsidiary

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

 

Note 13: Liquidity

 

As of December 31, 2021, the Company had $214,009 in operating cash and during 2021 used $1,583,139 of cash in operations. Subsequent to the year ended December 31, 2021, the Company issued an additional 76,953 shares of Series A-2 stock at $5.25 per share and received proceeds of $404,003. The Company’s current projections for 2022 requires cash of $578,143. These factors raise substantial doubt as to the Company’s ability to continue as a going concern.

 

To address these factors and in addition to the $404,000 of proceeds received subsequent to the year ended December 31, 2021 and funding from our agreement with Dole, management expects to receive additional funds from option exercises and will reduce operating expenses with employee salary deferrals to provide the necessary liquidity to meet our obligations as they come due over the next year. We expect that the funding from these sources will be sufficient to cover our obligations for the next twelve months. Additional shareholder funding could result in dilution to existing shareholders. If the funding does not arrive, the Company may not be able to meet its obligations as they become due.

 

 

 

F-16

 

 

 EX-31.1 2 fnam_ex31z1.htm CERTIFICATION

EXHIBIT 31.1

CERTIFICATION

I, Steve Warnecke, certify that:

1. I have reviewed this annual report on Form 10-K of Evolutionary Genomics, Inc.

2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting, to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting .

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information ; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

  March 21, 2022
   
BY:   /s/ Steve Warnecke
  Steve Warnecke
  Chief Executive Officer
  (principal executive officer)

 

 

 EX-31.2 3 fnam_ex31z2.htm CERTIFICATION

EXHIBIT 31.2

CERTIFICATION

I, Steve Warnecke, certify that:

1. I have reviewed this annual report on Form 10-K of Evolutionary Genomics, Inc.

2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting, to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting .

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information ; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

  March 21, 2022
   
BY:   /s/ Steve Warnecke
  Steve Warnecke
  Chief Financial Officer
  (principal financial officer)

 

 

 EX-32.1 4 fnam_ex32z1.htm CERTIFICATION

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Evolutionary Genomics, Inc. (the "Company") on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Steve B Warnecke, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

BY:   /s/ Steve B Warnecke
  Steve B Warnecke
  Chief Executive Officer
  (principal executive officer)
  March 21, 2022

 

 

 EX-32.2 5 fnam_ex32z2.htm CERTIFICATION

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Evolutionary Genomics, Inc. (the "Company") on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Steve B Warnecke, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

BY:   /s/ Steve B Warnecke
  Steve B Warnecke
  Chief Financial Officer
  (principal financial officer)
  March 21, 2022

 

 

 EX-101.SCH 6 fnam-20211231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed and Consolidated Statement of Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed and Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Business Activity link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Related Parties and Transactions link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Concentrations link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Intangible Assets (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Income Taxes (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Income Taxes (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Related Parties and Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Liquidity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 fnam-20211231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 fnam-20211231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 fnam-20211231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A-1 Preferred Stock [Member] Series A-2 Preferred Stock [Member] Series A Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Preferred Dividend [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Antidilutive Securities [Axis] Convertible Debt Securities [Member] Share-based Payment Arrangement, Option [Member] Long-Lived Tangible Asset [Axis] Equipment [Member] Software and Software Development Costs [Member] Furniture and Fixtures [Member] Finite-Lived Intangible Assets by Major Class [Axis] In Process Research and Development [Member] Patents [Member] Debt Instrument [Axis] S B A Paycheck Protection Program [Member] Economic Injury Disaster Loan [Member] E I D L Program [Member] D C A Dole [Member] Research Agreement University Of Wisconsin Madison [Member] Convertible Preferred Stock [Member] Convertible Preferred Stock Series A 2 [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Standard Research Agreement [Member] Related Party Transaction [Axis] Chief Executive Officer [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Auditor Name Auditor Location Auditor Firm ID Statement [Table] Statement [Line Items] ASSETS Current assets Cash Prepaid expenses           Total current assets Non-current assets Property and equipment, net Intangible assets, net           Total non-current assets Total assets LIABILITIES AND STOCKHOLDERS'  DEFICIT Current liabilities Accounts payable and accrued expenses           Total current liabilities Long-term liabilities Notes payable                 Total liabilities Commitments and contingencies            Total preferred stock subject to possible redemption Stockholders' deficit Preferred Stock Common Stock, $0.001 par value; 780,000,000 shares authorized, 5,881,898 shares issued and outstanding at December 31, 2021 and 2020 Additional paid-in capital Accumulated deficit           Total stockholders' deficit Total liabilities and stockholders' deficit Preferred stock, par or stated value per share Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Preferred stock, liquidation preference, value Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Grant revenue Operating expenses   Research and development   Salaries and benefits   General and administrative           Total operating expenses Operating loss Other income   Investment income   Loan forgiveness   Gain on investments           Total other income Loss before income taxes Income tax benefit Net loss Preferred stock dividend Net loss attributable to common stockholders Net loss per common share, basic and diluted Weighted average common shares outstanding, basic and diluted Beginning balance, value Beginning balance, shares Stock compensation Preferred stock dividends Net income Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities:   Net loss   Adjustments to reconcile net loss to net cash flows from operating activities     Depreciation and amortization     Stock-based compensation     Unrealized gain on investments     PPP loan forgiveness     Deferred tax benefit Changes in operating assets and liabilities:       Accounts receivable       Prepaid expenses       Accounts payable and accrued expenses         Cash flows from operating activities Cash flows from investing activities:      Proceeds from sale of investments         Cash flows from investing activities Cash flows from financing activities:   Proceeds from issuance of notes payable   Proceeds from EIDL and PPP loans         Cash flows from financing activities Net change in cash Cash, beginning of period Cash, end of period Supplemental cash flow information         Preferred stock dividend accrual Accounting Policies [Abstract] Business Activity Organization, Consolidation and Presentation of Financial Statements [Abstract] Summary of Significant Accounting Policies Accounting Changes and Error Corrections [Abstract] New Accounting Standards Property, Plant and Equipment [Abstract] Property and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Income Tax Disclosure [Abstract] Income Taxes Debt Disclosure [Abstract] Notes Payable Equity [Abstract] Stockholders’ Equity Share-based Payment Arrangement [Abstract] Stock-Based Compensation Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Related Party Transactions [Abstract] Related Parties and Transactions Risks and Uncertainties [Abstract] Concentrations Liquidity Principals of Consolidation Use of Estimates Cash Property and Equipment Long-Lived Assets Intangible Assets Revenue Recognition Income Taxes Stock-Based Compensation Research and Development Net Loss Per Common Share Schedule of Property and Equipment Schedule of Intangible Assets Schedule of Intangible Assets Amortization Schedule of income tax expense from continuing operations Schedule of income tax rate reconciliation Schedule of deferred tax assets and liabilities Schedule of Stock Option Activity Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Asset impairment charges Antidilutive shares Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and equipment, gross Accumulated depreciation Depreciation expense Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Intangible assets, gross Intangible assets, accumulated amortization December 31, 2021 December 31, 2022 December 31, 2023 December 31, 2024 December 31, 2025 Thereafter Total Amortization Additional expected costs to complete research Current income tax benefit:    U.S. Federal    U.S. States      Total current income tax benefit Deferred income tax benefit:    U.S. Federal    U.S. States      Total deferred income tax benefit      Total income tax benefit Income tax benefit at statutory U.S. federal rate Income tax benefit attributable to U.S. states Research and development credits Non-taxable forgiveness of PPP and EIDL loans Non-deductible expenses Stock- based compensation Other Change in valuation allowance      Total income tax expense Deferred income tax assets:    Net operating loss carryforwards    Research and development credits    Long-term capital loss carryforward    Valuation allowance for deferred income tax assets      Net deferred income tax assets Deferred income tax liabilities:    Intangible assets    Property, equipment and other      Total deferred income tax liabilities Net deferred income tax assets Future federal statutory tax rate Increase (decrease) in Valuation Allowance Net operating loss Indefinite Carry-forward Capital Loss credits R&D credits Schedule of Short-term Debt [Table] Short-term Debt [Line Items] Proceeds Forgiveness of debt Loans Interest rate Monthly payment Accrued interest Payment upon execution Payment twelve-month anniversary Payment thirty six month anniversary Payment forty eight month anniversary Reimbursement of costs Expected payments University of Wisconsin-Madison Expected field trial costs Notes payable for dole funding Payment upon receipt Schedule of Stock by Class [Table] Class of Stock [Line Items] Capital stock, authorized shares Common stock, authorized shares Preferred stock, authorized shares Preferred stock, par value Additional shares Preferred stock per share Proceeds of preferred stock shares Issuance of preferred shares Stated per share value of preferred stock Dividend rate Dividends accrued Balance, beginning Balance, beginning Outstanding beginning, contractual term Granted Granted Exercised Exercised Cancelled Cancelled Balance, ending Balance, ending Outstanding ending, contractual term Exercisable Exercisable Exercisable, contractual term Exercisable, intrinsic value Number of shares reserved for issuance under 2015 Stock Incentive Plan Expiration period for stock options Compensation costs for stock options Stock options granted during period Number of shares vested during the period Unrecognized compensation cost related to share-based compensation arrangements Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Monthly rent payment Rent expense Total amount of grant revenue recognized to date Total possible future royalties owed Payments for royalties Term Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Number of common stock shares outstanding owned by related party Percentage of common stock shares outstanding owned by related party Operating cash Cash Stock Issued During Period, Shares, New Issues Sale of Stock, Price Per Share Proceeds of stock issued Series A-2 Preferred Stock [Member] SBA Paycheck Protection Program Member Economic Injury Disaster Loan Member EIDL Program Member Payment upon execution DCA Dole [Member] Payment twelve month anniversary Payment thirty six month anniversary Payment forty eight month anniversary Reimbursement of costs Expected payments University of Wisconsin-Madison Research Agreement University Of Wisconsin Madison [Member] Expected field trial costs Notes payable for Dole funding Total number of preferred and common stock authorized. Convertible Preferred Stock Series A-2 [Member] Monthly rent payment. Total amount of grant revenue recognized to date. Total possible future royalties owed. Number of common stock shares outstanding owned by related party. Percentage of common stock shares outstanding owned by related party. Stated per share value of preferred stock. Assets, Current Assets, Noncurrent Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Revenues Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense (Benefit) Preferred Stock Dividends, Income Statement Impact Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding Unrealized Gain (Loss) on Investments PppLoanForgiveness Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Goodwill and Intangible Assets, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Share-based Payment Arrangement [Policy Text Block] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Tax Assets, Valuation Allowance Deferred Tax Liabilities, Intangible Assets Property, Plant and Equipment, Other, Gross Deferred Tax Liabilities, Gross Deferred Tax Liabilities, Net Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Other Cash Equivalents, at Carrying Value EX-101.PRE 10 fnam-20211231_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2021
Feb. 17, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2021    
Current Fiscal Year End Date --12-31    
Entity File Number 000-54129    
Entity Registrant Name Evolutionary Genomics, Inc.    
Entity Central Index Key 0000884363    
Entity Tax Identification Number 26-4369698    
Entity Incorporation, State or Country Code NV    
Entity Address, Address Line One 4220 Morning Star Drive    
Entity Address, City or Town Castle Rock    
Entity Address, State or Province CO    
Entity Address, Postal Zip Code 80108    
City Area Code (720)    
Local Phone Number 900-8666    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 4,636,289
Entity Common Stock, Shares Outstanding   5,881,898  
Auditor Name Plante & Moran PLLC    
Auditor Location Denver, Colorado    
Auditor Firm ID 166    
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Current assets    
Cash $ 214,009 $ 215,836
Prepaid expenses 41,792 61,757
          Total current assets 255,801 277,593
Non-current assets    
Property and equipment, net 18,698 50,763
Intangible assets, net 2,657,592 3,664,343
          Total non-current assets 2,676,290 3,715,106
Total assets 2,932,091 3,992,699
Current liabilities    
Accounts payable and accrued expenses 18,866 3,164
          Total current liabilities 18,866 3,164
Long-term liabilities    
Notes payable 3,743,747 2,245,831
                Total liabilities 3,762,613 2,248,995
           Total preferred stock subject to possible redemption 3,569,594 3,569,594
Stockholders' deficit    
Preferred Stock 1,521,796 1,236,228
Common Stock, $0.001 par value; 780,000,000 shares authorized, 5,881,898 shares issued and outstanding at December 31, 2021 and 2020 5,882 5,882
Additional paid-in capital 11,949,702 12,015,552
Accumulated deficit (17,877,496) (15,083,552)
          Total stockholders' deficit (4,400,116) (1,825,890)
Total liabilities and stockholders' deficit 2,932,091 3,992,699
Series A-1 Preferred Stock [Member]    
Long-term liabilities    
           Total preferred stock subject to possible redemption 3,029,579 3,029,579
Series A-2 Preferred Stock [Member]    
Long-term liabilities    
           Total preferred stock subject to possible redemption $ 540,015 $ 540,015
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Preferred stock, par or stated value per share $ 0.001 $ 0.001
Preferred stock, shares authorized 20,000,000 20,000,000
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 780,000,000 780,000,000
Common stock, shares issued 5,881,898 5,881,898
Common stock, shares outstanding 5,881,898 5,881,898
Series A Preferred Stock [Member]    
Preferred stock, par or stated value per share $ 0.001 $ 0.001
Preferred stock, shares authorized 600,000 600,000
Preferred stock, shares issued 577,063 577,063
Preferred stock, shares outstanding 577,063 577,063
Preferred stock, liquidation preference, value $ 4,438,687  
Series A-2 Preferred Stock [Member]    
Preferred stock, par or stated value per share $ 0.001 $ 0.001
Preferred stock, shares authorized 200,000 200,000
Preferred stock, shares issued 102,860 102,860
Preferred stock, shares outstanding 102,860 102,860
Preferred stock, liquidation preference, value $ 653,877  
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]    
Grant revenue $ 12,500
Operating expenses    
  Research and development 1,234,215 1,793,145
  Salaries and benefits 369,920 495,518
  General and administrative 1,273,808 603,632
          Total operating expenses 2,877,943 2,892,295
Operating loss (2,877,943) (2,879,795)
Other income    
  Investment income 604 372
  Loan forgiveness 83,395 74,268
  Gain on investments 105,919
          Total other income 83,999 180,559
Loss before income taxes (2,793,944) (2,699,236)
Income tax benefit 987,353
Net loss (2,793,944) (1,711,883)
Preferred stock dividend (285,568) (285,567)
Net loss attributable to common stockholders $ (3,079,512) $ (1,997,450)
Net loss per common share, basic and diluted $ (0.52) $ (0.34)
Weighted average common shares outstanding, basic and diluted 5,881,898 5,881,898
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed and Consolidated Statement of Stockholders' Deficit - USD ($)
Common Stock [Member]
Preferred Dividend [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 5,882 $ 950,661 $ 12,081,401 $ (13,371,669) $ (333,725)
Beginning balance, shares at Dec. 31, 2019 5,881,898        
Stock compensation 54,930 54,930
Preferred stock dividends 71,391 (71,391)
Net income (241,816) (241,816)
Ending balance, value at Mar. 31, 2020 $ 5,882 1,022,052 12,064,940 (13,613,485) (520,611)
Ending balance, shares at Mar. 31, 2020 5,881,898        
Stock compensation 54,929 54,929
Preferred stock dividends 71,392 (71,392)
Net income (294,798) (294,798)
Ending balance, value at Jun. 30, 2020 $ 5,882 1,093,444 12,048,477 (13,908,283) (760,480)
Ending balance, shares at Jun. 30, 2020 5,881,898        
Stock compensation 54,930 54,930
Preferred stock dividends 71,392 (71,392)
Net income 535,885 535,885
Ending balance, value at Sep. 30, 2020 $ 5,882 1,164,836 12,032,015 (13,372,398) (169,665)
Ending balance, shares at Sep. 30, 2020 5,881,898        
Stock compensation 54,929 54,929
Preferred stock dividends 71,392 (71,392)
Net income (1,711,154) (1,711,154)
Ending balance, value at Dec. 31, 2020 $ 5,882 1,236,228 12,015,552 (15,083,552) (1,825,890)
Ending balance, shares at Dec. 31, 2020 5,881,898        
Stock compensation 54,930 54,930
Preferred stock dividends 71,392 (71,392)
Net income (513,742) (513,742)
Ending balance, value at Mar. 31, 2021 $ 5,882 1,307,620 11,999,090 (15,597,294) (2,284,702)
Ending balance, shares at Mar. 31, 2021 5,881,898        
Stock compensation 54,929 54,929
Preferred stock dividends 71,392 (71,392)
Net income (553,701) (553,701)
Ending balance, value at Jun. 30, 2021 $ 5,882 1,379,012 11,982,627 (16,150,995) (2,783,474)
Ending balance, shares at Jun. 30, 2021 5,881,898        
Stock compensation 54,930 54,930
Preferred stock dividends 71,392 (71,392)
Net income (1,058,657) (1,058,657)
Ending balance, value at Sep. 30, 2021 $ 5,882 1,450,404 11,966,165 (17,209,652) (3,787,201)
Ending balance, shares at Sep. 30, 2021 5,881,898        
Stock compensation 54,929 54,929
Preferred stock dividends 71,392 (71,392)
Net income (667,844) (667,844)
Ending balance, value at Dec. 31, 2021 $ 5,882 $ 1,521,796 $ 11,949,702 $ (17,877,496) $ (4,400,116)
Ending balance, shares at Dec. 31, 2021 5,881,898        
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed and Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:    
  Net loss $ (2,793,944) $ (1,711,883)
  Adjustments to reconcile net loss to net cash flows from operating activities    
    Depreciation and amortization 1,038,816 409,368
    Stock-based compensation 219,718 219,718
    Unrealized gain on investments (74,268)
    PPP loan forgiveness (83,395) (105,919)
    Deferred tax benefit   (987,353)
Changes in operating assets and liabilities:    
      Accounts receivable 6,845
      Prepaid expenses 19,965 (37,574)
      Accounts payable and accrued expenses 15,702 (16,251)
        Cash flows from operating activities (1,583,138) (2,297,317)
Cash flows from investing activities:    
     Proceeds from sale of investments 147,613
        Cash flows from investing activities 147,613
Cash flows from financing activities:    
  Proceeds from issuance of notes payable 1,447,916 2,095,831
  Proceeds from EIDL and PPP loans 133,395 224,268
        Cash flows from financing activities 1,581,311 2,320,099
Net change in cash (1,827) 170,395
Cash, beginning of period 215,836 45,441
Cash, end of period 214,009 215,836
Supplemental cash flow information    
        Preferred stock dividend accrual $ 285,568 $ 285,567
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Business Activity
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Business Activity

Note 1: Business Activity

 

Evolutionary Genomics, Inc. (the “Company,” “We,” or “Our”) has developed a technology platform, the Adapted Traits Platform (“ATP”), to identify commercially valuable genes that control important traits in animals and plants. We are using the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. Our platform identifies key genes that have changed successfully to impart new or improved traits.

 

In the past, the Company performed research on behalf of governmental organizations, non-profit foundations and commercial entities and received revenue from grants and commercial research contracts. We have not received any revenue from these grant arrangements since early 2020. The Company now focuses on research projects that may lead to long-term licensing arrangements with agricultural seed companies and crop producers as with our soybean and banana projects. These projects take several years to develop, and successful commercialization may take many years to produce license royalty payments. Our banana project, in cooperation with Dole Food Company is an example that has resulted in notes payable funding for the development phase of our banana genes and may result in a long-term royalty bearing license once the development phase is complete.

 

During 2014, the Company purchased 75.16% of the outstanding stock of Fona, Inc., (“Fona”) a public shell company. Since Fona was a public shell company which did not constitute a business and the purchase was done in contemplation of a reverse merger, the Company accounted for the payment as a distribution to Fona shareholders. The Company also entered into an Agreement and Plan of Merger (the “Merger”), which was consummated on October 19, 2015. As a result of the Merger, Evolutionary Genomics, Inc. became a wholly owned subsidiary of Fona. For accounting purposes, the merger was treated as a reverse acquisition with Evolutionary Genomics, Inc. as the acquirer and Fona as the acquired party. Subsequent to the Merger, Fona was renamed Evolutionary Genomics, Inc. and our subsidiary was renamed from Evolutionary Genomics, Inc. to EG Crop Science, Inc.

 
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Significant Accounting Policies

Note 2: Summary of Significant Accounting Policies

 

Principals of Consolidation: These consolidated financial statements include the accounts of Evolutionary Genomics, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated.

 

Use of Estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

 

These consolidated financial statements have been prepared on the basis of going concern. Management’s plans to address the Company’s liquidity are discussed further in Note 13.

 

Cash: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.

 

Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided for by the straight-line method over three- to seven-year estimated useful lives of software, furniture and fixtures and equipment. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized.

 

Long-Lived Assets: The long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. An impairment loss is measured and recorded to the extent that the carrying amount of the asset exceeds its estimated fair value. No asset impairment was recorded during the years ended December 31, 2021 and 2020.

 

Intangible Assets: Intangible assets include acquired research in progress and patents on the Company’s core technology for gene identification. Previously acquired patents were capitalized and are amortized over their expected useful life of 20 years using the straight-line method. Acquired research in progress was placed into service on August 19, 2020 in conjunction with the Development and Commercialization Agreement and is being amortized over four years consistent with the term of the Dole agreement using the straight-line method. Costs incurred to renew intangible assets and to file new patent applications are expensed in the period incurred, while costs incurred to extend the lives of patents are capitalized and amortized over the remaining useful life of the asset. Intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any intangible assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. No impairment was recorded during the years ended December 31, 2021 and 2020.

 

Revenue Recognition: Grant revenue consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by us. However, these amounts are subject to change upon review by federal and non-profit foundations prior to receipt of invoice amounts submitted. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed.

 

Income Taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Management regularly assesses the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established, increased or decreased, an income tax charge or benefit is included in the consolidated financial statements and net deferred tax assets are adjusted accordingly. As of December 31, 2021 and 2020, a full valuation allowance has been established on the net deferred tax asset.

 

Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits.

 

Stock-Based Compensation: The Company accounts for stock option awards in accordance with ASC 718. The estimated grant-date fair value of stock-based awards is expensed over the requisite service period, which is typically equivalent to the vesting term of the award.

 

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.

 

Research and Development: Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed.

 

Net Loss Per Common Share: Basic net (loss) income per common share excludes any dilutive effects of equity instruments. We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the period. We compute diluted net (loss) income per common share using the weighted average number of common shares and common stock equivalents outstanding during the period. For the years ended December 31, 2021 and 2020, common stock equivalents including 679,923 shares of convertible preferred stock and options for 1,081,667 shares of common stock were excluded because their effect was anti-dilutive.

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.1
New Accounting Standards
 12 Months Ended
Dec. 31, 2021
Accounting Changes and Error Corrections [Abstract]  
New Accounting Standards

Note 3: New Accounting Standards

 

Recently Issued Accounting Standards

 

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments,” which requires entities to estimate all expected credit losses for certain types of financial instruments, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The updated guidance also expands the disclosure requirements to enable users of financial statements to understand the entity’s assumptions, models and methods for estimating expected credit losses over the entire contractual term of the instrument from the date of initial recognition of that instrument. This guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within that reporting period and is not expected to have an impact on the Company’s consolidated financial statements.

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment

Note 4: Property and Equipment

 

Property and equipment is comprised of the following:

 

          
   December 31,   December 31, 
   2021   2020 
Equipment  $432,499   $432,499 
Software   63,179    63,179 
Furniture and fixtures   7,987    7,987 
    503,665    503,665 
Accumulated depreciation   (484,967)   (452,902)
Property and equipment, net  $18,698   $50,763 

 

Depreciation expense for the years ended December 31, 2021 and 2020 was $32,065 and 38,119, respectively.

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

Note 5: Intangible Assets

 

Intangible assets are comprised of the following:

 

          
   December 31,   December 31, 
   2021   2020 
Acquired research in progress - definite lived  $4,016,596   $4,016,596 
Patents   52,045    52,045 
Accumulated amortization   (1,411,049)   (404,298)
Intangible assets, net  $2,657,592   $3,664,343 

 

The Company expects to recognize amortization expense related to its acquired research in progress and patents according to the following:

 

      
Year Ending   Amortization 
December 31, 2022   $1,006,751 
December 31, 2023    1,006,751 
December 31, 2024    638,105 
December 31, 2025    2,602 
December 31, 2026    2,602 
Thereafter    781 
    Total   $2,657,592 

 

Amortization expense for the acquired research in progress and patents during the year ended December 31, 2021 and 2020 was $1,006,751 and $371,248, respectively.

 

In its merger completed on October 19, 2015, the Company acquired research in progress. The value of the acquired research in progress was based upon several factors including, evaluation of other intangible assets, the purchase price, estimated future cash flows, and the amounts expended on the research to date. The research in progress was the identification and validation of genes to provide pest and disease resistance to plants performed by EG I. With the banana development project contract in place, the Company placed this asset in service on August 19, 2020. Additional costs to complete the soybean research are expected to be approximately $33,000, which will be expensed as incurred. The timing and cost of additional research may vary from these estimates as the success of the research is subject to many factors outside of the Company’s control.

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

Note 6: Income Taxes

 

The Company’s income tax benefit consists of the following for the years ended December 31, 2021 and 2020:

 

          
   2021   2020 
Current income tax benefit:  $—   $— 
   U.S. Federal   —    — 
   U.S. States   —    — 
     Total current income tax benefit   —    — 
           
Deferred income tax benefit:          
   U.S. Federal   —    840,812 
   U.S. States   —    146,541 
     Total deferred income tax benefit   —    987,353 
     Total income tax benefit  $—   $987,353 

 

For the years ended December 31, 2021 and 2020, the reconciliation between the income tax benefit computed by applying the statutory U.S. federal income tax rate of 21.0% to the pre-tax loss before income taxes, and total income tax expense recognized in the financial statements is as follows

 

          
   2021   2020 
Income tax benefit at statutory U.S. federal rate  $586,728   $566,840 
Income tax benefit attributable to U.S. states   99,325    98,792 
Research and development credits   137,728    49,338 
Non-taxable forgiveness of PPP and EIDL loans   20,478    18,314 
Non-deductible expenses   (300)   (334)
Stock- based compensation   (53,952)   (54,182)
Other   (15,182)   (3,790)
Change in valuation allowance   (774,825)   312,373 
     Total income tax expense  $—   $987,351 

 

As of December 31, 2021 and 2020, the components of deferred income tax assets and liabilities were as follows:

 

          
   2021   2020 
Deferred income tax assets:          
   Net operating loss carryforwards  $2,876,543   $2,585,042 
   Research and development credits   515,982    378,524 
   Long-term capital loss carryforward   94,728    — 
   Valuation allowance for deferred income tax assets   (2,835,108)   (2,060,283)
     Net deferred income tax assets   652,145    903,283 

 

Deferred income tax liabilities:          
   Intangible assets   (647,554)   (897,196)
   Property, equipment and other   (4,591)   (6,087)
     Total deferred income tax liabilities   (652,145)   (903,283)
Net deferred income tax assets  $—   $— 

 

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse.

 

The Company records a valuation allowance for certain temporary differences for which it is more likely than not that it will not receive future tax benefits. The Company assesses its past earnings history and trends and projections of future net income. The Company recorded a valuation allowance for the entire amount of the net deferred tax asset at December 31, 2021 and 2020. As of December 31, 2021, the Company had a total valuation allowance of approximately $2,835,000 for its deferred tax assets. The Company will continue to review this valuation allowance and make adjustments as appropriate.

 

As of December 31, 2021, the Company had net operating loss (“NOL”) carryforwards of approximately $11,715,000, consisting of $5,295,000 that have an indefinite carryover period and $6,420,000 that expire at various intervals through 2037. Use of NOL carryforwards is limited by the provisions of Section 382 of the Internal Revenue Code. At this point, the Company has not performed an analysis to determine whether an ownership change (as defined under Section 382) occurred during this year or preceding year(s). A determination of the potential impact these provisions might have on the utilization of net operating losses will be made when the net operating loss is projected to be utilized. As of December 31, 2021, the Company also has a capital loss carryforward of approximately $386,000 that expires in 2025, and a research and development credit carryforward of approximately $515,000 that will expire at various intervals through 2040.

 

The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. At this time, the Company does not have any uncertain tax positions to assess.

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Notes Payable
 12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Notes Payable

Note 7: Notes Payable

 

Small Business Administration (“SBA”) Paycheck Protection Program: On April 17, 2020, the Company received $71,268 and on February 22, 2021 the Company received $76,395 in proceeds from the SBA Paycheck Protection Program, which was created under the Coronavirus Aid, Relief and Economic Security Act (CARES). Under the program, the Company received $71,268 forgiveness of the debt from the SBA based on the use of the proceeds over the 24-week period following funding of the loan in the year ended December 31, 2020 and $76,395 in the year ended December 31, 2021. The forgiveness was recorded as loan forgiveness in other income on the consolidated statement of operations.

 

Although management considers it probable that the Company was initially eligible for the loan and subsequent forgiveness, the SBA has the ability to review the Company’s loan file for a period subsequent to the date the loan was forgiven and could request additional documentation to support the Company’s initial eligibility for the loan and request for loan forgiveness. In the event the SBA subsequently determines the Company did not meet the initial; eligibility requirements for the PPP loan or did not qualify for loan forgiveness, the SBA may pursue legal remedies at its discretion.

 

SBA Economic Injury Disaster Loan: On June 5, 2020, the Company received a $3,000 Economic Injury Disaster Loan (“EIDL”) advance and $150,000 in proceeds from the SBA’s EIDL Program. On July 20, 2021, the Company received an additional $7,000 SBA EIDL Advance which has been forgiven and, on July 14, 2021, the Company received a $50,000 increase in the SBA EIDL Loan. Installment payments, including interest at the rate of 3.75% per annum, of $1,022 monthly over thirty years from the date of the original promissory note will begin on June 5, 2022. The Company granted to the SBA a continuing security interest in all tangible and intangible personal property. The Company may not make any distribution of assets of the Company to any shareholder without the written consent of the SBA. As of December 31, 2021, the Company recognized $9,760 of accrued interest on the note.

 

Dole Food Company:

 

On August 19, 2020, the Company entered into a Development and Commercialization Agreement (“DCA”) with Dole Food Company (“Dole”) for the development of our banana genes. The DCA provides for payments from Dole to the Company of $800,000 upon execution, $800,000 by the twelve-month anniversary, $250,000 by the thirty-six month anniversary and $250,000 by the forty-eight month anniversary. Dole also reimburses the Company for costs incurred at the University of Wisconsin-Madison (“UW”) not to exceed $2,200,000 in coordination with the Standard Research Agreement that the Company entered into with UW on September 18, 2020. The agreement with UW includes payments from the Company to UW in the amount of $2,159,719 over the two-year expected term of the project. If the UW research is successful, Dole expects to incur costs of approximately $750,000 to perform field trials.

 

The DCA also specifies that the Company will execute notes payable to Dole for the funding that Dole is providing up to $5,050,000. Upon receipt of $800,000 on August 26, 2020, $800,000 on July 28, 2021, $1,295,831 on December 29, 2020 and $647,916 on September 29, 2021, the Company executed the notes under this DCA and recorded them as long-term notes payable for financial statement purposes. The notes are non-interest bearing and allow Dole to offset fifty percent of future royalty payments to the Company by reducing the amount of principal due on these notes. Other than this offset of future royalty payments, repayment of principal and interest is only required in the case of termination of the DCA by Dole for cause.

 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Equity
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Stockholders’ Equity

Note 8: Stockholders’ Equity

 

The Amended and Restated Certificate of Incorporation of the Company dated October 19, 2015 authorized the issuance of 800,000,000 shares of all classes of stock including 780,000,000 shares of Common Stock having a par value of $0.001 per share and 20,000,000 shares of Preferred Stock having a par value of $0.001 per share, 600,000 of which were designated as Series A-1 Convertible Preferred Stock (“Series A-1”) and 200,000 of which were designated as Series A-2 Convertible Preferred Stock (“Series A-2”). The Board of Directors, without a vote of the shareholders, is authorized to issue additional shares of Preferred Stock in series and to establish the characteristics thereof.

 

Subsequent to the year ended December 31, 2021, the Company issued an additional 76,953 shares of Series A-2 stock at $5.25 per share and received proceeds of $404,003. The Company has 20,187 shares of Series A-2 stock remaining available for issuance.

 

Liquidation: Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of the Series A-1 and Series A-2 shall be entitled to receive out of the assets of the Company for each share of Series A-1 and Series A-2 an amount equal to its stated value, $5.25 per share as of December 31, 2021 and 2020, plus any accrued but unpaid dividends before any distribution or payment shall be made to the holders of any other class or series of stock of the Company that ranks junior to the Series A-1 and Series A-2. The holders shall be entitled to convert their shares of Series A-1 and Series A-2 into Common Stock at any time prior to the consummation of a Liquidation. This is considered a contingent redemption feature.

 

Conversion: The holders of Series A-1 and Series A-2 may convert their shares into shares of Common Stock, at the option of the holder, on a one-share-for-one-share basis and shall be subject to certain adjustments at any time.

 

Optional Redemption; Sinking Fund Account: The Company may elect to redeem some or all of the then outstanding shares of Series A-1, (i) for cash in an amount equal to the liquidation preference per share, $5.25 per share as of December 31, 2021, subject to adjustment and (ii) by issuing one share, subject to adjustment, of Common Stock for each share of Series A-1 and Series A-2 outstanding being redeemed. 50% of all licensing fees received by the Company will be deposited into a separate sinking fund for use in an optional redemption. As of December 31, 2021, no licensing revenue has been received under these provisions and no sinking fund account has been established.

 

Dividends: The Company shall pay to the holders of the Series A-1 and Series A-2 dividends at the rate of 8% per annum and the Company has accrued these dividends since issuance of the Series A-1 and Series A-2. The dividend amount shall accrue and shall be payable in shares of Common Stock upon the conversion of the Series A-1 and Series A-2, or upon the redemption of the Series A-1 and Series A-2. No dividends shall be paid on any Common Stock of the Company or any capital stock of the Company that ranks junior to the Series A-1 and Series A-2 until dividends of Series A-1 and Series A-2 been paid. As of December 31, 2021, there were $1,522,970 in accrued stock dividends.

 

Voting: The holders of the Series A-1 and Series A-2 are entitled to vote on all matters submitted to the stockholders for a vote on an as-if-converted to Common Stock basis, with all stockholders voting as a single class.

 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation

Note 9: Stock-Based Compensation

 

The Company grants stock-based instruments under the 2015 Stock Incentive Plan (“Plan”) for which 1,400,000 shares of the Company’s Common Stock has been reserved. The Plan allows for the issuance of incentive stock options and non-qualified stock options with a maximum contractual term of 10 years. Shares and options that are cancelled are available for reissuance under the Plan. For years ended December 31, 2021 and 2020, the Company recorded compensation costs for stock options of $219,718 and $219,718, respectively. Stock options are generally issued with an exercise price at or above the estimated per-share value of the Company’s Common Stock. The Company granted no options during the years ended December 31, 2021 and 2020.

 

Management has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the issuance of the outstanding options, there was not a public market for the Company’s shares. Accordingly, the Company utilized the value obtained in equity transactions with unrelated parties to estimate the fair value of the Company’s Common Stock on the date of grant. Volatility of the underlying common shares was determined based on the historical volatility for similar companies that are actively traded in the public markets for a term consistent with the expected life of the options. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options on the date of the grant. Due to the lack of sufficient historical activity, the expected life of the options was estimated using the formula set forth in Securities and Exchange Commission SAB 107.

 

The following table summarizes the status of the Company’s aggregate stock options granted:

 

                     
    Number of Options   Weighted Average Exercise Price   Weighted Average Remaining Term(Years)   Total Intrinsic Value 
                  
Balance, January 1, 2020    1,081,667   $1.74    7.67      
Granted    —    —    —      
Exercised    —    —    —      
Cancelled    —    —    —      
                      
Balance, December 31, 2020    1,081,667   $1.74    6.67      
                      
Balance, January 1, 2021    1,081,667   $1.74    6.67      
Granted    —    —    —      
Exercised    —    —    —      
Cancelled    —    —    —      
                      
Balance, December 31, 2021    1,081,667   $1.74    5.67   $— 
                      
Exercisable at December 31, 2021    868,332   $1.79    5.14   $28,000 

 

During the years ended December 31, 2021 and 2020, options for 180,000 and 179,999 shares vested, respectively. As of December 31, 2021, there was $185,731 unrecognized compensation cost related to share-based compensation arrangements that will be recognized through the year ending December 31, 2022.

 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 10: Commitments and Contingencies

 

Officer Indemnification: Under the Company’s organizational documents, the Company’s officers, employees, and directors are indemnified against certain liabilities arising out of the performance of their duties. The Company’s maximum exposure under these arrangements is unknown, as this would involve future claims that may be made against the Company that have not yet occurred. However, based on experience, the Company expects any risk of loss to be remote. The Company also has an insurance policy for its directors and officers to insure them against liabilities arising from their performance in their positions with the Company.

 

Lease Commitments: The Company leases its operating facility and pays its rent in monthly installments. The lease was renewed in June 2016 for a period of twelve months and monthly rentals for the period of July 1, 2016 through December 31, 2021 are $2,378 per month which continues on a month-to-month basis. There is no minimum lease commitment as of December 31, 2021. Renewals after June 30, 2017 are by mutual agreement. The Company’s rent expense for the years ended December 31, 2021 and 2020 was $28,535.

 

Royalty: Effective March 1, 2012, the Company entered into an Agreement for Contract Services with SmithBucklin Corporation (the “Contractor”) on behalf of the United Soybean Board. The contract includes the payment of certain royalties, as defined in the Agreement.

 

The Company is obligated to pay royalties to the United Soybean Board of 10% of the sale of products derived from the soybean genes that were the subject of the research performed by the Contractor or from royalties received by the Company from the sale of products by a third party not to exceed 150% of the total amount paid to the Contractor under this Agreement. The Company has recognized to date grant revenue from the contract of $262,400 as of December 31, 2020, thus limiting any future royalties as of December 31, 2021 to a total of $393,600. The Company has not accrued or paid any royalties under the terms of the Agreement as of and during the years ended December 31, 2021 and 2020 because it has not received any revenue from the sale of products to date.

 

Other Commitments: On September 18, 2020, the Company entered into a Standard Research Agreement with WCIC for the development of our banana genes. The agreement includes payments from the Company in the amount of $2,159,719 over the two-year expected term of the project. These costs will be reimbursed, in the form of notes payable by Dole in accordance with our DCA.

 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Related Parties and Transactions
 12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
Related Parties and Transactions

Note 11: Related Parties and Transactions

 

Steve B. Warnecke: Mr. Warnecke is the Company’s Chief Executive Officer and Chairman of the Board and owns, directly or indirectly, 1,827,088 shares or 28.3% of the Common Stock outstanding as of December 31, 2021.

 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Concentrations
 12 Months Ended
Dec. 31, 2021
Risks and Uncertainties [Abstract]  
Concentrations

Note 12: Concentrations

 

Considerations of Credit Risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains its cash balances at high-credit, quality financial institutions. The balances, at times, may exceed federally insured limits. The Company routinely monitors the credit quality of its customers.

 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Liquidity
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Liquidity

Note 13: Liquidity

 

As of December 31, 2021, the Company had $214,009 in operating cash and during 2021 used $1,583,139 of cash in operations. Subsequent to the year ended December 31, 2021, the Company issued an additional 76,953 shares of Series A-2 stock at $5.25 per share and received proceeds of $404,003. The Company’s current projections for 2022 requires cash of $578,143. These factors raise substantial doubt as to the Company’s ability to continue as a going concern.

 

To address these factors and in addition to the $404,000 of proceeds received subsequent to the year ended December 31, 2021 and funding from our agreement with Dole, management expects to receive additional funds from option exercises and will reduce operating expenses with employee salary deferrals to provide the necessary liquidity to meet our obligations as they come due over the next year. We expect that the funding from these sources will be sufficient to cover our obligations for the next twelve months. Additional shareholder funding could result in dilution to existing shareholders. If the funding does not arrive, the Company may not be able to meet its obligations as they become due.

 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Principals of Consolidation

Principals of Consolidation: These consolidated financial statements include the accounts of Evolutionary Genomics, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated.

 
Use of Estimates

Use of Estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

 

These consolidated financial statements have been prepared on the basis of going concern. Management’s plans to address the Company’s liquidity are discussed further in Note 13.

 
Cash

Cash: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.

 
Property and Equipment

Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided for by the straight-line method over three- to seven-year estimated useful lives of software, furniture and fixtures and equipment. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized.

 
Long-Lived Assets

Long-Lived Assets: The long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. An impairment loss is measured and recorded to the extent that the carrying amount of the asset exceeds its estimated fair value. No asset impairment was recorded during the years ended December 31, 2021 and 2020.

 
Intangible Assets

Intangible Assets: Intangible assets include acquired research in progress and patents on the Company’s core technology for gene identification. Previously acquired patents were capitalized and are amortized over their expected useful life of 20 years using the straight-line method. Acquired research in progress was placed into service on August 19, 2020 in conjunction with the Development and Commercialization Agreement and is being amortized over four years consistent with the term of the Dole agreement using the straight-line method. Costs incurred to renew intangible assets and to file new patent applications are expensed in the period incurred, while costs incurred to extend the lives of patents are capitalized and amortized over the remaining useful life of the asset. Intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any intangible assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. No impairment was recorded during the years ended December 31, 2021 and 2020.

 
Revenue Recognition

Revenue Recognition: Grant revenue consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by us. However, these amounts are subject to change upon review by federal and non-profit foundations prior to receipt of invoice amounts submitted. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed.

 
Income Taxes

Income Taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Management regularly assesses the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established, increased or decreased, an income tax charge or benefit is included in the consolidated financial statements and net deferred tax assets are adjusted accordingly. As of December 31, 2021 and 2020, a full valuation allowance has been established on the net deferred tax asset.

 

Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits.

 
Stock-Based Compensation

Stock-Based Compensation: The Company accounts for stock option awards in accordance with ASC 718. The estimated grant-date fair value of stock-based awards is expensed over the requisite service period, which is typically equivalent to the vesting term of the award.

 

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.

 
Research and Development

Research and Development: Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed.

 
Net Loss Per Common Share

Net Loss Per Common Share: Basic net (loss) income per common share excludes any dilutive effects of equity instruments. We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the period. We compute diluted net (loss) income per common share using the weighted average number of common shares and common stock equivalents outstanding during the period. For the years ended December 31, 2021 and 2020, common stock equivalents including 679,923 shares of convertible preferred stock and options for 1,081,667 shares of common stock were excluded because their effect was anti-dilutive.

 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
          
   December 31,   December 31, 
   2021   2020 
Equipment  $432,499   $432,499 
Software   63,179    63,179 
Furniture and fixtures   7,987    7,987 
    503,665    503,665 
Accumulated depreciation   (484,967)   (452,902)
Property and equipment, net  $18,698   $50,763 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
          
   December 31,   December 31, 
   2021   2020 
Acquired research in progress - definite lived  $4,016,596   $4,016,596 
Patents   52,045    52,045 
Accumulated amortization   (1,411,049)   (404,298)
Intangible assets, net  $2,657,592   $3,664,343 
Schedule of Intangible Assets Amortization
      
Year Ending   Amortization 
December 31, 2022   $1,006,751 
December 31, 2023    1,006,751 
December 31, 2024    638,105 
December 31, 2025    2,602 
December 31, 2026    2,602 
Thereafter    781 
    Total   $2,657,592 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of income tax expense from continuing operations
          
   2021   2020 
Current income tax benefit:  $—   $— 
   U.S. Federal   —    — 
   U.S. States   —    — 
     Total current income tax benefit   —    — 
           
Deferred income tax benefit:          
   U.S. Federal   —    840,812 
   U.S. States   —    146,541 
     Total deferred income tax benefit   —    987,353 
     Total income tax benefit  $—   $987,353 
Schedule of income tax rate reconciliation
          
   2021   2020 
Income tax benefit at statutory U.S. federal rate  $586,728   $566,840 
Income tax benefit attributable to U.S. states   99,325    98,792 
Research and development credits   137,728    49,338 
Non-taxable forgiveness of PPP and EIDL loans   20,478    18,314 
Non-deductible expenses   (300)   (334)
Stock- based compensation   (53,952)   (54,182)
Other   (15,182)   (3,790)
Change in valuation allowance   (774,825)   312,373 
     Total income tax expense  $—   $987,351 
Schedule of deferred tax assets and liabilities
          
   2021   2020 
Deferred income tax assets:          
   Net operating loss carryforwards  $2,876,543   $2,585,042 
   Research and development credits   515,982    378,524 
   Long-term capital loss carryforward   94,728    — 
   Valuation allowance for deferred income tax assets   (2,835,108)   (2,060,283)
     Net deferred income tax assets   652,145    903,283 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
                     
    Number of Options   Weighted Average Exercise Price   Weighted Average Remaining Term(Years)   Total Intrinsic Value 
                  
Balance, January 1, 2020    1,081,667   $1.74    7.67      
Granted    —    —    —      
Exercised    —    —    —      
Cancelled    —    —    —      
                      
Balance, December 31, 2020    1,081,667   $1.74    6.67      
                      
Balance, January 1, 2021    1,081,667   $1.74    6.67      
Granted    —    —    —      
Exercised    —    —    —      
Cancelled    —    —    —      
                      
Balance, December 31, 2021    1,081,667   $1.74    5.67   $— 
                      
Exercisable at December 31, 2021    868,332   $1.79    5.14   $28,000 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Asset impairment charges $ 0 $ 0
Convertible Debt Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares 679,923  
Share-based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares 1,081,667  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 503,665 $ 503,665
Accumulated depreciation (484,967) (452,902)
Property and equipment, net 18,698 50,763
Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 432,499 432,499
Software and Software Development Costs [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 63,179 63,179
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 7,987 $ 7,987
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 32,065 $ 38,119
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, accumulated amortization $ (1,411,049) $ (404,298)
Intangible assets, net 2,657,592 3,664,343
In Process Research and Development [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross 4,016,596 4,016,596
Patents [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross $ 52,045 $ 52,045
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets (Details 1) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]    
December 31, 2021 $ 1,006,751  
December 31, 2022 1,006,751  
December 31, 2023 638,105  
December 31, 2024 2,602  
December 31, 2025 2,602  
Thereafter 781  
Total $ 2,657,592 $ 3,664,343
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2022
Patents [Member]      
Finite-Lived Intangible Assets [Line Items]      
Amortization $ 1,006,751 $ 371,248  
In Process Research and Development [Member]      
Finite-Lived Intangible Assets [Line Items]      
Additional expected costs to complete research     $ 33,000
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Current income tax benefit:    
   U.S. Federal
   U.S. States
     Total current income tax benefit
Deferred income tax benefit:    
   U.S. Federal 840,812
   U.S. States 146,541
     Total deferred income tax benefit 987,353
     Total income tax benefit $ 987,353
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Details 1) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Income tax benefit at statutory U.S. federal rate $ 586,728 $ 566,840
Income tax benefit attributable to U.S. states 99,325 98,792
Research and development credits 137,728 49,338
Non-taxable forgiveness of PPP and EIDL loans 20,478 18,314
Non-deductible expenses (300) (334)
Stock- based compensation (53,952) (54,182)
Other (15,182) (3,790)
Change in valuation allowance (774,825) 312,373
     Total income tax expense $ 987,351
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Details 2) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Deferred income tax assets:    
   Net operating loss carryforwards $ 2,876,543 $ 2,585,042
   Research and development credits 515,982 378,524
   Long-term capital loss carryforward 94,728
   Valuation allowance for deferred income tax assets (2,835,108) (2,060,283)
     Net deferred income tax assets 652,145 903,283
Deferred income tax liabilities:    
   Intangible assets (647,554) (897,196)
   Property, equipment and other (4,591) (6,087)
     Total deferred income tax liabilities (652,145) (903,283)
Net deferred income tax assets
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Future federal statutory tax rate 21.00% 21.00%
Increase (decrease) in Valuation Allowance $ 2,835,000  
Net operating loss 11,715,000 $ 5,295,000
Indefinite Carry-forward   $ 6,420,000
Capital Loss credits 386,000  
R&D credits $ 515,000  
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Notes Payable (Details Narrative) - USD ($)
 1 Months Ended 4 Months Ended 12 Months Ended
Jun. 05, 2020
Feb. 22, 2021
Apr. 17, 2020
Dec. 31, 2021
Dec. 31, 2020
Sep. 29, 2021
Jul. 28, 2021
Dec. 29, 2020
Sep. 18, 2020
Aug. 26, 2020
Aug. 19, 2020
Short-term Debt [Line Items]                      
Proceeds       $ 1,447,916 $ 2,095,831            
S B A Paycheck Protection Program [Member]                      
Short-term Debt [Line Items]                      
Proceeds   $ 76,395 $ 71,268                
Forgiveness of debt   $ 71,268                  
Loans       76,395              
Economic Injury Disaster Loan [Member]                      
Short-term Debt [Line Items]                      
Proceeds $ 3,000     7,000              
E I D L Program [Member]                      
Short-term Debt [Line Items]                      
Proceeds $ 150,000     50,000              
Interest rate 3.75%                    
Monthly payment $ 1,022                    
Accrued interest       $ 9,760              
D C A Dole [Member]                      
Short-term Debt [Line Items]                      
Payment upon execution                     $ 800,000
Payment twelve-month anniversary                     800,000
Payment thirty six month anniversary                     250,000
Payment forty eight month anniversary                     250,000
Reimbursement of costs                     2,200,000
Expected field trial costs                     750,000
Notes payable for dole funding                     $ 5,050,000
Payment upon receipt           $ 647,916 $ 800,000 $ 1,295,831   $ 800,000  
Research Agreement University Of Wisconsin Madison [Member]                      
Short-term Debt [Line Items]                      
Expected payments University of Wisconsin-Madison                 $ 2,159,719    
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Equity (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Oct. 19, 2015
Class of Stock [Line Items]      
Capital stock, authorized shares     800,000,000
Common stock, authorized shares 780,000,000 780,000,000 780,000,000
Common stock, par value $ 0.001 $ 0.001 $ 0.001
Preferred stock, authorized shares 20,000,000 20,000,000 20,000,000
Preferred stock, par value $ 0.001 $ 0.001  
Dividends accrued $ 1,522,970    
Convertible Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, authorized shares     600,000
Preferred stock, par value     $ 0.001
Dividend rate 8.00%    
Convertible Preferred Stock Series A 2 [Member]      
Class of Stock [Line Items]      
Preferred stock, authorized shares     200,000
Additional shares $ 76,953    
Preferred stock per share $ 5.25    
Proceeds of preferred stock shares $ 404,003    
Issuance of preferred shares 20,187    
Dividend rate 8.00%    
Series A-2 Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, authorized shares 200,000 200,000  
Preferred stock, par value $ 0.001 $ 0.001  
Stated per share value of preferred stock $ 5.25 $ 5.25  
Series A Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, authorized shares 600,000 600,000  
Preferred stock, par value $ 0.001 $ 0.001  
Stated per share value of preferred stock $ 5.25 $ 5.25  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]    
Balance, beginning 1,081,667 1,081,667
Balance, beginning $ 1.74 $ 1.74
Outstanding beginning, contractual term 6 years 8 months 1 day 7 years 8 months 1 day
Granted
Granted
Exercised
Exercised
Cancelled
Cancelled
Balance, ending 1,081,667 1,081,667
Balance, ending $ 1.74 $ 1.74
Outstanding ending, contractual term 5 years 8 months 1 day 6 years 8 months 1 day
Exercisable 868,332  
Exercisable $ 1.79  
Exercisable, contractual term 5 years 1 month 20 days  
Exercisable, intrinsic value $ 28,000  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]    
Number of shares reserved for issuance under 2015 Stock Incentive Plan 1,400,000  
Expiration period for stock options 10 years  
Compensation costs for stock options $ 219,718 $ 219,718
Stock options granted during period 0 0
Number of shares vested during the period 180,000 179,999
Unrecognized compensation cost related to share-based compensation arrangements $ 185,731  
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 18, 2020
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Monthly rent payment   $ 2,378  
Rent expense   28,535 $ 28,535
Total amount of grant revenue recognized to date   262,400  
Total possible future royalties owed   $ 393,600  
Standard Research Agreement [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payments for royalties $ 2,159,719    
Term 2 years    
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Related Parties and Transactions (Details Narrative) - Chief Executive Officer [Member]
Dec. 31, 2021
shares
Related Party Transaction [Line Items]  
Number of common stock shares outstanding owned by related party 1,827,088
Percentage of common stock shares outstanding owned by related party 28.30%
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Liquidity (Details Narrative) - USD ($)
 3 Months Ended
Mar. 21, 2022
Dec. 31, 2021
Operating cash   $ 214,009
Cash   $ 1,583,139
Series A-2 Preferred Stock [Member] | Subsequent Event [Member]    
Stock Issued During Period, Shares, New Issues 76,953  
Sale of Stock, Price Per Share $ 5.25  
Proceeds of stock issued $ 404,003  
XML 52 fnam_10k_htm.xml IDEA: XBRL DOCUMENT 0000884363 2021-01-01 2021-12-31 0000884363 2021-06-30 0000884363 2022-02-17 0000884363 2021-12-31 0000884363 2020-12-31 0000884363 fnam:SeriesA1PreferredStockMember 2021-12-31 0000884363 fnam:SeriesA1PreferredStockMember 2020-12-31 0000884363 fnam:SeriesA2PreferredStockMember 2021-12-31 0000884363 fnam:SeriesA2PreferredStockMember 2020-12-31 0000884363 us-gaap:SeriesAPreferredStockMember 2021-12-31 0000884363 us-gaap:SeriesAPreferredStockMember 2020-12-31 0000884363 2020-01-01 2020-12-31 0000884363 us-gaap:CommonStockMember 2020-12-31 0000884363 fnam:PreferredDividendMember 2020-12-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000884363 us-gaap:RetainedEarningsMember 2020-12-31 0000884363 us-gaap:CommonStockMember 2021-03-31 0000884363 fnam:PreferredDividendMember 2021-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000884363 us-gaap:RetainedEarningsMember 2021-03-31 0000884363 2021-03-31 0000884363 us-gaap:CommonStockMember 2021-06-30 0000884363 fnam:PreferredDividendMember 2021-06-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000884363 us-gaap:RetainedEarningsMember 2021-06-30 0000884363 us-gaap:CommonStockMember 2021-09-30 0000884363 fnam:PreferredDividendMember 2021-09-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000884363 us-gaap:RetainedEarningsMember 2021-09-30 0000884363 2021-09-30 0000884363 us-gaap:CommonStockMember 2019-12-31 0000884363 fnam:PreferredDividendMember 2019-12-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000884363 us-gaap:RetainedEarningsMember 2019-12-31 0000884363 2019-12-31 0000884363 us-gaap:CommonStockMember 2020-03-31 0000884363 fnam:PreferredDividendMember 2020-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000884363 us-gaap:RetainedEarningsMember 2020-03-31 0000884363 2020-03-31 0000884363 us-gaap:CommonStockMember 2020-06-30 0000884363 fnam:PreferredDividendMember 2020-06-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000884363 us-gaap:RetainedEarningsMember 2020-06-30 0000884363 2020-06-30 0000884363 us-gaap:CommonStockMember 2020-09-30 0000884363 fnam:PreferredDividendMember 2020-09-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000884363 us-gaap:RetainedEarningsMember 2020-09-30 0000884363 2020-09-30 0000884363 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000884363 fnam:PreferredDividendMember 2021-01-01 2021-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000884363 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000884363 2021-01-01 2021-03-31 0000884363 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000884363 fnam:PreferredDividendMember 2021-04-01 2021-06-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000884363 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000884363 2021-04-01 2021-06-30 0000884363 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000884363 fnam:PreferredDividendMember 2021-07-01 2021-09-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000884363 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000884363 2021-07-01 2021-09-30 0000884363 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0000884363 fnam:PreferredDividendMember 2021-10-01 2021-12-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0000884363 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0000884363 2021-10-01 2021-12-31 0000884363 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000884363 fnam:PreferredDividendMember 2020-01-01 2020-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000884363 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000884363 2020-01-01 2020-03-31 0000884363 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000884363 fnam:PreferredDividendMember 2020-04-01 2020-06-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000884363 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000884363 2020-04-01 2020-06-30 0000884363 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000884363 fnam:PreferredDividendMember 2020-07-01 2020-09-30 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000884363 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000884363 2020-07-01 2020-09-30 0000884363 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0000884363 fnam:PreferredDividendMember 2020-10-01 2020-12-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0000884363 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0000884363 2020-10-01 2020-12-31 0000884363 us-gaap:CommonStockMember 2021-12-31 0000884363 fnam:PreferredDividendMember 2021-12-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000884363 us-gaap:RetainedEarningsMember 2021-12-31 0000884363 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-12-31 0000884363 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000884363 us-gaap:EquipmentMember 2021-12-31 0000884363 us-gaap:EquipmentMember 2020-12-31 0000884363 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-12-31 0000884363 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0000884363 us-gaap:FurnitureAndFixturesMember 2021-12-31 0000884363 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000884363 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0000884363 us-gaap:InProcessResearchAndDevelopmentMember 2020-12-31 0000884363 us-gaap:PatentsMember 2021-12-31 0000884363 us-gaap:PatentsMember 2020-12-31 0000884363 us-gaap:PatentsMember 2021-01-01 2021-12-31 0000884363 us-gaap:PatentsMember 2020-01-01 2020-12-31 0000884363 us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0000884363 fnam:SBAPaycheckProtectionProgramMember 2020-01-01 2020-04-17 0000884363 fnam:SBAPaycheckProtectionProgramMember 2021-02-01 2021-02-22 0000884363 fnam:SBAPaycheckProtectionProgramMember 2021-01-01 2021-12-31 0000884363 fnam:EconomicInjuryDisasterLoanMember 2020-06-04 2020-06-05 0000884363 fnam:EIDLProgramMember 2020-06-04 2020-06-05 0000884363 fnam:EconomicInjuryDisasterLoanMember 2021-01-01 2021-12-31 0000884363 fnam:EIDLProgramMember 2021-01-01 2021-12-31 0000884363 fnam:EIDLProgramMember 2020-06-05 0000884363 fnam:EIDLProgramMember 2021-12-31 0000884363 fnam:DCADoleMember 2020-08-19 0000884363 fnam:ResearchAgreementUniversityOfWisconsinMadisonMember 2020-09-18 0000884363 fnam:DCADoleMember 2020-08-26 0000884363 fnam:DCADoleMember 2021-07-28 0000884363 fnam:DCADoleMember 2020-12-29 0000884363 fnam:DCADoleMember 2021-09-29 0000884363 2015-10-19 0000884363 us-gaap:ConvertiblePreferredStockMember 2015-10-19 0000884363 fnam:ConvertiblePreferredStockSeriesA2Member 2015-10-19 0000884363 fnam:ConvertiblePreferredStockSeriesA2Member 2021-12-31 0000884363 fnam:ConvertiblePreferredStockSeriesA2Member 2021-01-01 2021-12-31 0000884363 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0000884363 fnam:StandardResearchAgreementMember 2020-09-01 2020-09-18 0000884363 srt:ChiefExecutiveOfficerMember 2021-12-31 0000884363 fnam:SeriesA2PreferredStockMember us-gaap:SubsequentEventMember 2022-01-01 2022-03-21 0000884363 fnam:SeriesA2PreferredStockMember us-gaap:SubsequentEventMember 2022-03-21 iso4217:USD shares iso4217:USD shares pure 0000884363 false FY 2021 10-K true 2021-12-31 --12-31 false Evolutionary Genomics, Inc. NV 000-54129 26-4369698 4220 Morning Star Drive Castle Rock CO 80108 (720) 900-8666 No No No Yes Yes Non-accelerated Filer true false false 4636289 5881898 Plante & Moran PLLC Denver, Colorado 166 214009 215836 41792 61757 255801 277593 18698 50763 2657592 3664343 2676290 3715106 2932091 3992699 18866 3164 18866 3164 3743747 2245831 3762613 2248995 0.001 0.001 20000000 20000000 0.001 0.001 600000 600000 577063 577063 577063 577063 4438687 3029579 3029579 0.001 0.001 200000 200000 102860 102860 102860 102860 653877 540015 540015 3569594 3569594 1521796 1236228 0.001 0.001 780000000 780000000 5881898 5881898 5881898 5881898 5882 5882 11949702 12015552 -17877496 -15083552 -4400116 -1825890 2932091 3992699 12500 1234215 1793145 369920 495518 1273808 603632 2877943 2892295 -2877943 -2879795 604 372 83395 74268 105919 83999 180559 -2793944 -2699236 -987353 -2793944 -1711883 285568 285567 -3079512 -1997450 -0.52 -0.34 5881898 5881898 5881898 5882 1236228 12015552 -15083552 -1825890 54930 54930 71392 -71392 -513742 -513742 5881898 5882 1307620 11999090 -15597294 -2284702 54929 54929 71392 -71392 -553701 -553701 5881898 5882 1379012 11982627 -16150995 -2783474 54930 54930 71392 -71392 -1058657 -1058657 5881898 5882 1450404 11966165 -17209652 -3787201 54929 54929 71392 -71392 -667844 -667844 5881898 5882 1521796 11949702 -17877496 -4400116 5881898 5882 950661 12081401 -13371669 -333725 54930 54930 71391 -71391 -241816 -241816 5881898 5882 1022052 12064940 -13613485 -520611 54929 54929 71392 -71392 -294798 -294798 5881898 5882 1093444 12048477 -13908283 -760480 54930 54930 71392 -71392 535885 535885 5881898 5882 1164836 12032015 -13372398 -169665 54929 54929 71392 -71392 -1711154 -1711154 5881898 5882 1236228 12015552 -15083552 -1825890 -2793944 -1711883 1038816 409368 219718 219718 74268 83395 105919 -987353 -6845 -19965 37574 15702 -16251 -1583138 -2297317 147613 147613 1447916 2095831 133395 224268 1581311 2320099 -1827 170395 215836 45441 214009 215836 285568 285567 <p id="xdx_807_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zAxqfFZVHTMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 1:<span id="xdx_82C_zdIepty6voMe"> Business Activity</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Evolutionary Genomics, Inc. (the “Company,” “We,” or “Our”) has developed a technology platform, the Adapted Traits Platform (“ATP”), to identify commercially valuable genes that control important traits in animals and plants. We are using the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. Our platform identifies key genes that have changed successfully to impart new or improved traits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the past, the Company performed research on behalf of governmental organizations, non-profit foundations and commercial entities and received revenue from grants and commercial research contracts. We have not received any revenue from these grant arrangements since early 2020. The Company now focuses on research projects that may lead to long-term licensing arrangements with agricultural seed companies and crop producers as with our soybean and banana projects. These projects take several years to develop, and successful commercialization may take many years to produce license royalty payments. Our banana project, in cooperation with Dole Food Company is an example that has resulted in notes payable funding for the development phase of our banana genes and may result in a long-term royalty bearing license once the development phase is complete.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During 2014, the Company purchased 75.16% of the outstanding stock of Fona, Inc., (“Fona”) a public shell company. Since Fona was a public shell company which did not constitute a business and the purchase was done in contemplation of a reverse merger, the Company accounted for the payment as a distribution to Fona shareholders. The Company also entered into an Agreement and Plan of Merger (the “Merger”), which was consummated on October 19, 2015. As a result of the Merger, Evolutionary Genomics, Inc. became a wholly owned subsidiary of Fona. For accounting purposes, the merger was treated as a reverse acquisition with Evolutionary Genomics, Inc. as the acquirer and Fona as the acquired party. Subsequent to the Merger, Fona was renamed Evolutionary Genomics, Inc. and our subsidiary was renamed from Evolutionary Genomics, Inc. to EG Crop Science, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_z2X23AJ89zWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 2:<span id="xdx_820_zfQW0QIZcUX2"> Summary of Significant Accounting Policies</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p id="xdx_847_eus-gaap--ConsolidationPolicyTextBlock_zMcv9GSxKfg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_86F_zDyfzCHfyghe">Principals of Consolidation</span></span>: These consolidated financial statements include the accounts of Evolutionary Genomics, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_847_eus-gaap--UseOfEstimates_z1e2pBZnIBp2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_86E_zfesp2PssK4b">Use of Estimates</span></span>: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">These consolidated financial statements have been prepared on the basis of going concern. Management’s plans to address the Company’s liquidity are discussed further in Note 13.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z5XT3sldOSb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_864_zz3Aq4f06xH7">Cash</span></span>: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zvauh00qwgl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_86B_zPTWSSqEaW1e">Property and Equipment</span></span>: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided for by the straight-line method over three- to seven-year estimated useful lives of software, furniture and fixtures and equipment. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zfSZ2U9DUbi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_Aci_Pg38"/><span style="text-decoration: underline"><span id="xdx_868_zkaS8MbPwI3l">Long-Lived Assets</span></span>: The long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. An impairment loss is measured and recorded to the extent that the carrying amount of the asset exceeds its estimated fair value. No asset impairment was recorded during the years ended December 31, 2021 and 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pc"> </p> <p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zwxWELz7WRDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_868_zfmo43Agv8Cd">Intangible Assets</span></span>: Intangible assets include acquired research in progress and patents on the Company’s core technology for gene identification. Previously acquired patents were capitalized and are amortized over their expected useful life of 20 years using the straight-line method. Acquired research in progress was placed into service on August 19, 2020 in conjunction with the Development and Commercialization Agreement and is being amortized over four years consistent with the term of the Dole agreement using the straight-line method. Costs incurred to renew intangible assets and to file new patent applications are expensed in the period incurred, while costs incurred to extend the lives of patents are capitalized and amortized over the remaining useful life of the asset. Intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any intangible assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. <span id="xdx_903_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20210101__20211231_zjIDoVoowtHl" title="Asset impairment charges"><span id="xdx_90C_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20200101__20201231_zLSXVFCXE3sc" title="Asset impairment charges">No</span></span> impairment was recorded during the years ended December 31, 2021 and 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84B_eus-gaap--RevenueRecognitionPolicyTextBlock_zTg3Gp08OaX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_86B_zdZl8F8O52p8">Revenue Recognition</span>:</span> Grant revenue consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by us. However, these amounts are subject to change upon review by federal and non-profit foundations prior to receipt of invoice amounts submitted. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_z07EOs0n8Mxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_869_zYBvAtjHMgg2">Income Taxes</span></span>: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Management regularly assesses the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established, increased or decreased, an income tax charge or benefit is included in the consolidated financial statements and net deferred tax assets are adjusted accordingly. As of December 31, 2021 and 2020, a full valuation allowance has been established on the net deferred tax asset.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zeHfbbpzvdHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_868_zEcoW4qrZge7">Stock-Based Compensation</span></span>: The Company accounts for stock option awards in accordance with ASC 718. The estimated grant-date fair value of stock-based awards is expensed over the requisite service period, which is typically equivalent to the vesting term of the award.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_z75JHWI7Nwy" style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><span id="a_Aci_Pg39"/><span style="text-decoration: underline"><span id="xdx_86D_zZDbY2DtHjN9">Research and Development</span></span>: Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_ztpEMBsnjy3j" style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_862_znoSs2ETijNk">Net Loss Per Common Share</span></span>: Basic net (loss) income per common share excludes any dilutive effects of equity instruments. We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the period. We compute diluted net (loss) income per common share using the weighted average number of common shares and common stock equivalents outstanding during the period. For the years ended December 31, 2021 and 2020, common stock equivalents including <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zBAwuYSIq6A4" title="Antidilutive shares">679,923</span> shares of convertible preferred stock and options for <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zuYGw6JGNFLj" title="Antidilutive shares">1,081,667</span> shares of common stock were excluded because their effect was anti-dilutive.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_847_eus-gaap--ConsolidationPolicyTextBlock_zMcv9GSxKfg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_86F_zDyfzCHfyghe">Principals of Consolidation</span></span>: These consolidated financial statements include the accounts of Evolutionary Genomics, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_847_eus-gaap--UseOfEstimates_z1e2pBZnIBp2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_86E_zfesp2PssK4b">Use of Estimates</span></span>: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">These consolidated financial statements have been prepared on the basis of going concern. Management’s plans to address the Company’s liquidity are discussed further in Note 13.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z5XT3sldOSb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_864_zz3Aq4f06xH7">Cash</span></span>: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zvauh00qwgl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_86B_zPTWSSqEaW1e">Property and Equipment</span></span>: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided for by the straight-line method over three- to seven-year estimated useful lives of software, furniture and fixtures and equipment. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zfSZ2U9DUbi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_Aci_Pg38"/><span style="text-decoration: underline"><span id="xdx_868_zkaS8MbPwI3l">Long-Lived Assets</span></span>: The long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. An impairment loss is measured and recorded to the extent that the carrying amount of the asset exceeds its estimated fair value. No asset impairment was recorded during the years ended December 31, 2021 and 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pc"> </p> <p id="xdx_845_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zwxWELz7WRDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_868_zfmo43Agv8Cd">Intangible Assets</span></span>: Intangible assets include acquired research in progress and patents on the Company’s core technology for gene identification. Previously acquired patents were capitalized and are amortized over their expected useful life of 20 years using the straight-line method. Acquired research in progress was placed into service on August 19, 2020 in conjunction with the Development and Commercialization Agreement and is being amortized over four years consistent with the term of the Dole agreement using the straight-line method. Costs incurred to renew intangible assets and to file new patent applications are expensed in the period incurred, while costs incurred to extend the lives of patents are capitalized and amortized over the remaining useful life of the asset. Intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any intangible assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. <span id="xdx_903_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20210101__20211231_zjIDoVoowtHl" title="Asset impairment charges"><span id="xdx_90C_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20200101__20201231_zLSXVFCXE3sc" title="Asset impairment charges">No</span></span> impairment was recorded during the years ended December 31, 2021 and 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 0 0 <p id="xdx_84B_eus-gaap--RevenueRecognitionPolicyTextBlock_zTg3Gp08OaX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_86B_zdZl8F8O52p8">Revenue Recognition</span>:</span> Grant revenue consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by us. However, these amounts are subject to change upon review by federal and non-profit foundations prior to receipt of invoice amounts submitted. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_z07EOs0n8Mxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_869_zYBvAtjHMgg2">Income Taxes</span></span>: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Management regularly assesses the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established, increased or decreased, an income tax charge or benefit is included in the consolidated financial statements and net deferred tax assets are adjusted accordingly. As of December 31, 2021 and 2020, a full valuation allowance has been established on the net deferred tax asset.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zeHfbbpzvdHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_868_zEcoW4qrZge7">Stock-Based Compensation</span></span>: The Company accounts for stock option awards in accordance with ASC 718. The estimated grant-date fair value of stock-based awards is expensed over the requisite service period, which is typically equivalent to the vesting term of the award.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_z75JHWI7Nwy" style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><span id="a_Aci_Pg39"/><span style="text-decoration: underline"><span id="xdx_86D_zZDbY2DtHjN9">Research and Development</span></span>: Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_ztpEMBsnjy3j" style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_862_znoSs2ETijNk">Net Loss Per Common Share</span></span>: Basic net (loss) income per common share excludes any dilutive effects of equity instruments. We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the period. We compute diluted net (loss) income per common share using the weighted average number of common shares and common stock equivalents outstanding during the period. For the years ended December 31, 2021 and 2020, common stock equivalents including <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zBAwuYSIq6A4" title="Antidilutive shares">679,923</span> shares of convertible preferred stock and options for <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zuYGw6JGNFLj" title="Antidilutive shares">1,081,667</span> shares of common stock were excluded because their effect was anti-dilutive.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"> </p> 679923 1081667 <p id="xdx_801_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zL0Y78AAhht6" style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 3:<span id="xdx_825_zRzET5KSh6o4"> New Accounting Standards</span></span></b></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Recently Issued Accounting Standards</span></b></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0">In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments,” which requires entities to estimate all expected credit losses for certain types of financial instruments, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The updated guidance also expands the disclosure requirements to enable users of financial statements to understand the entity’s assumptions, models and methods for estimating expected credit losses over the entire contractual term of the instrument from the date of initial recognition of that instrument. This guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within that reporting period and is not expected to have an impact on the Company’s consolidated financial statements.<span id="a_Aci_Pg40"/></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_809_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zk6341AOgIje" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 4:<span id="xdx_824_zNkHwiOPWJE8"> Property and Equipment</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment is comprised of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--PropertyPlantAndEquipmentTextBlock_zN9XrZMmAEA8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"> <tr style="vertical-align: bottom; background-color: transparent"> <td><span id="xdx_8B4_zfAPOiIh6Gcl" style="display: none">Schedule of Property and Equipment</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 74%">Equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_pp0p0" style="width: 10%; text-align: right" title="Property and equipment, gross">432,499</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_pp0p0" style="width: 10%; text-align: right" title="Property and equipment, gross">432,499</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td>Software</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_pp0p0" style="text-align: right" title="Property and equipment, gross">63,179</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_pp0p0" style="text-align: right" title="Property and equipment, gross">63,179</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 1pt">Furniture and fixtures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">7,987</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">7,987</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_c20211231_pp0p0" style="text-align: right" title="Property and equipment, gross">503,665</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20201231_pp0p0" style="text-align: right" title="Property and equipment, gross">503,665</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20211231_zwkMzlkAKHs6" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation">(484,967</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20201231_zOWkfOikNH0a" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation">(452,902</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">18,698</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">50,763</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Depreciation expense for the years ended December 31, 2021 and 2020 was $<span id="xdx_902_eus-gaap--Depreciation_c20210101__20211231_pp0p0" title="Depreciation expense">32,065</span> and <span id="xdx_90A_eus-gaap--Depreciation_pp0p0_c20200101__20201231_zOnA6ILIRy1k" title="Depreciation expense">38,119</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--PropertyPlantAndEquipmentTextBlock_zN9XrZMmAEA8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"> <tr style="vertical-align: bottom; background-color: transparent"> <td><span id="xdx_8B4_zfAPOiIh6Gcl" style="display: none">Schedule of Property and Equipment</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 74%">Equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_pp0p0" style="width: 10%; text-align: right" title="Property and equipment, gross">432,499</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_pp0p0" style="width: 10%; text-align: right" title="Property and equipment, gross">432,499</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td>Software</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_pp0p0" style="text-align: right" title="Property and equipment, gross">63,179</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_pp0p0" style="text-align: right" title="Property and equipment, gross">63,179</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 1pt">Furniture and fixtures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">7,987</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">7,987</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_c20211231_pp0p0" style="text-align: right" title="Property and equipment, gross">503,665</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20201231_pp0p0" style="text-align: right" title="Property and equipment, gross">503,665</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20211231_zwkMzlkAKHs6" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation">(484,967</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20201231_zOWkfOikNH0a" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation">(452,902</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">18,698</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">50,763</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 432499 432499 63179 63179 7987 7987 503665 503665 484967 452902 18698 50763 32065 38119 <p id="xdx_805_eus-gaap--IntangibleAssetsDisclosureTextBlock_zMSR82buS2fi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 5:<span id="xdx_82F_zniCAaq4D0D8"> Intangible Assets</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Intangible assets are comprised of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z1MVI7qWZkA5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom; background-color: transparent"> <td><span id="xdx_8B9_zGpjmzyxuG29" style="display: none">Schedule of Intangible Assets</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 74%; text-align: left">Acquired research in progress - definite lived</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_pp0p0" style="width: 10%; text-align: right" title="Intangible assets, gross">4,016,596</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_pp0p0" style="width: 10%; text-align: right" title="Intangible assets, gross">4,016,596</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td>Patents</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="text-align: right" title="Intangible assets, gross">52,045</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="text-align: right" title="Intangible assets, gross">52,045</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 1pt">Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20211231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets, accumulated amortization">(1,411,049</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets, accumulated amortization">(404,298</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">2,657,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">3,664,343</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expects to recognize amortization expense related to its acquired research in progress and patents according to the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z3w1bP81MfUf" style="font: 11pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - Intangible Assets (Details 1)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left"><span id="xdx_8BF_zexzFvMs6mS2" style="display: none">Schedule of Intangible Assets Amortization</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold">Year Ending</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right">Amortization</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; width: 49%; text-align: left"><span style="font-size: 11pt">December 31, 2022</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c20211231_pp0p0" style="width: 10%; text-align: right" title="December 31, 2021">1,006,751</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left"><span style="font-size: 11pt">December 31, 2023</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20211231_pp0p0" style="text-align: right" title="December 31, 2022">1,006,751</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left"><span style="font-size: 11pt">December 31, 2024</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c20211231_pp0p0" style="text-align: right" title="December 31, 2023">638,105</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left"><span style="font-size: 11pt">December 31, 2025</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c20211231_pp0p0" style="text-align: right" title="December 31, 2024">2,602</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left"><span style="font-size: 11pt">December 31, 2026</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c20211231_pp0p0" style="text-align: right" title="December 31, 2025">2,602</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left"><span style="font-size: 11pt">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_c20211231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">781</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left"><span style="font-size: 11pt">    Total</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20211231_zSxH6LsME7Ob" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,657,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span id="a_Hlk46476717"/>Amortization expense for the acquired research in progress and patents during the year ended December 31, 2021 and 2020 was $<span id="xdx_903_eus-gaap--AdjustmentForAmortization_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" title="Amortization">1,006,751</span> and $<span id="xdx_909_eus-gaap--AdjustmentForAmortization_pp0p0_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zmUKQx5bvr5i" title="Amortization">371,248</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">In its merger completed on October 19, 2015, the Company acquired research in progress. The value of the acquired research in progress was based upon several factors including, evaluation of other intangible assets, the purchase price, estimated future cash flows, and the amounts expended on the research to date. The research in progress was the identification and validation of genes to provide pest and disease resistance to plants performed by EG I. With the banana development project contract in place, the Company placed this asset in service on August 19, 2020. Additional costs to complete the soybean research are expected to be approximately $<span id="xdx_902_ecustom--AdditionalExpectedCostsToCompleteResearch_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zyaTuyJMiO55" title="Additional expected costs to complete research">33,000</span>, which will be expensed as incurred. The timing and cost of additional research may vary from these estimates as the success of the research is subject to many factors outside of the Company’s control.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z1MVI7qWZkA5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom; background-color: transparent"> <td><span id="xdx_8B9_zGpjmzyxuG29" style="display: none">Schedule of Intangible Assets</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 74%; text-align: left">Acquired research in progress - definite lived</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_pp0p0" style="width: 10%; text-align: right" title="Intangible assets, gross">4,016,596</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_pp0p0" style="width: 10%; text-align: right" title="Intangible assets, gross">4,016,596</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td>Patents</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="text-align: right" title="Intangible assets, gross">52,045</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="text-align: right" title="Intangible assets, gross">52,045</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 1pt">Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20211231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets, accumulated amortization">(1,411,049</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible assets, accumulated amortization">(404,298</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">2,657,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">3,664,343</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4016596 4016596 52045 52045 -1411049 -404298 2657592 3664343 <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z3w1bP81MfUf" style="font: 11pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - Intangible Assets (Details 1)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left"><span id="xdx_8BF_zexzFvMs6mS2" style="display: none">Schedule of Intangible Assets Amortization</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold">Year Ending</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right">Amortization</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; width: 49%; text-align: left"><span style="font-size: 11pt">December 31, 2022</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c20211231_pp0p0" style="width: 10%; text-align: right" title="December 31, 2021">1,006,751</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left"><span style="font-size: 11pt">December 31, 2023</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20211231_pp0p0" style="text-align: right" title="December 31, 2022">1,006,751</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left"><span style="font-size: 11pt">December 31, 2024</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c20211231_pp0p0" style="text-align: right" title="December 31, 2023">638,105</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left"><span style="font-size: 11pt">December 31, 2025</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c20211231_pp0p0" style="text-align: right" title="December 31, 2024">2,602</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left"><span style="font-size: 11pt">December 31, 2026</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c20211231_pp0p0" style="text-align: right" title="December 31, 2025">2,602</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left"><span style="font-size: 11pt">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_c20211231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">781</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left"><span style="font-size: 11pt">    Total</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20211231_zSxH6LsME7Ob" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,657,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1006751 1006751 638105 2602 2602 781 2657592 1006751 371248 33000 <p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_z6VtSRBzKIea" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_Aci_Pg42"/><b><span style="text-decoration: underline">Note 6:<span id="xdx_823_zXqi0mwxgZG9"> Income Taxes</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company’s income tax benefit consists of the following for the years ended December 31, 2021 and 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z06hceNcCWF5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left"><span id="xdx_8BF_zAJnk9iwcjg9" style="display: none">Schedule of income tax expense from continuing operations</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20210101__20211231_zBD5SJUUwi78" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20200101_20201231" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-size: 11pt"> </td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2020</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left">Current income tax benefit:</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pp0p0" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left">   U.S. Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0661">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0662">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="padding-bottom: 1pt; text-align: left">   U.S. States</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0664">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0665">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01_pp0p0_zFI6Jqe21yNf" style="vertical-align: bottom; background-color: transparent"> <td style="padding-bottom: 2.5pt; text-align: left">     Total current income tax benefit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0668">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left">Deferred income tax benefit:</td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 74%; text-align: left">   U.S. Federal</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0673">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">840,812</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pp0p0" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-bottom: 1pt">   U.S. States</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0676">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">146,541</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--TotalDeferredIncomeTaxBenefit_i01_pp0p0_zA8lfiicRPsj" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 1pt">     Total deferred income tax benefit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0679">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">987,353</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--TotalIncomeTaxBenefit_pp0p0_zP6pFmsSF6e9" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-bottom: 2.5pt">     Total income tax benefit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0682">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">987,353</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">For the years ended December 31, 2021 and 2020, the reconciliation between the income tax benefit computed by applying the statutory U.S. federal income tax rate of <span id="xdx_90B_ecustom--FutureFederalStatutoryTaxRates_iI_dp_c20211231_z3WszOrgCYqc" title="Future federal statutory tax rate"><span id="xdx_909_ecustom--FutureFederalStatutoryTaxRates_iI_dp_c20201231_zxhItH1Dc2b" title="Future federal statutory tax rate">21.0</span></span>% to the pre-tax loss before income taxes, and total income tax expense recognized in the financial statements is as follows</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbrlAl67OKs9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-left: 2.75pt"><span id="xdx_8BF_zVKWjVgFELV8" style="display: none">Schedule of income tax rate reconciliation</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20210101__20211231_zX9pis7vTJjd" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20200101__20201231_zBEpBkLm21V5" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-size: 11pt; text-align: center"> </td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationDispositionOfBusiness_zbugG4OF7fi2" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 74%; text-align: left; padding-left: 2.75pt">Income tax benefit at statutory U.S. federal rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">586,728</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">566,840</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ForeignIncomeTaxExpenseBenefitContinuingOperations_zEqhk2q3RoY4" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-left: 2.75pt">Income tax benefit attributable to U.S. states</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">99,325</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98,792</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_zYjKlQzvNNh2" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-left: 2.75pt">Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137,728</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,338</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--NontaxableForgivenessOfPppAndEidlLoans_zbJT0gFKdAl3" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-left: 2.75pt">Non-taxable forgiveness of PPP and EIDL loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,314</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--NondeductibleExpenses_zHmNZqbfT365" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-left: 2.75pt">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(300</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(334</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--StockOptionPlanExpense_ziWHGlk7wtIg" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-left: 2.75pt">Stock- based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(53,952</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(54,182</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zmaNTdvILRQ3" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="padding-left: 2.75pt">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(15,182</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,790</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zUXxBrB2vOvl" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 2.75pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(774,825</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">312,373</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredIncomeTaxesAndTaxCredits_z2fkwPkjiQi3" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.7pt">     Total income tax expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0715">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">987,351</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2021 and 2020, the components of deferred income tax assets and liabilities were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zcqw5L02GASl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left"><span id="xdx_8B4_zwbkBXDEFzd8" style="display: none">Schedule of deferred tax assets and liabilities</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20211231_zY5eGGeNRlN4" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20201231_zxVYlLwBhYz6" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-size: 11pt; text-align: center"> </td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNetAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left">Deferred income tax assets:</td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0" style="vertical-align: bottom; background-color: transparent"> <td style="width: 74%; text-align: left">   Net operating loss carryforwards</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,876,543</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,585,042</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left">   Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">515,982</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">378,524</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--LongtermCapitalLossCarryforward_i01I_pp0p0_zWnZI7DMpqZ1" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left">   Long-term capital loss carryforward</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,728</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0730">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_z4R93XDO0zx1" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 1pt">   Valuation allowance for deferred income tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,835,108</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,060,283</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_i01I_pp0p0_zNEjmLtG9xJa" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-bottom: 1pt">     Net deferred income tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">652,145</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">903,283</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left">Deferred income tax liabilities:</td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_i01NI_pp0p0_di_zTlQMejhcrBg" style="vertical-align: bottom; background-color: transparent"> <td style="width: 74%; text-align: left">   Intangible assets</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(647,554</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(897,196</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentOther_i01NI_pp0p0_di_zVrIfbsgLH9e" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 1pt">   Property, equipment and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,591</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,087</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxLiabilities_i01NI_pp0p0_di_z1kgGjHY13P" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-bottom: 1pt">     Total deferred income tax liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(652,145</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(903,283</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxLiabilities_iNI_pp0p0_di_zFdWE6ikHEc2" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred income tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0750">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0751">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company records a valuation allowance for certain temporary differences for which it is more likely than not that it will not receive future tax benefits. The Company assesses its past earnings history and trends and projections of future net income. The Company recorded a valuation allowance for the entire amount of the net deferred tax asset at December 31, 2021 and 2020. As of December 31, 2021, the Company had a total valuation allowance of approximately $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20210101__20211231_z7PmA7tHBAy6" title="Increase (decrease) in Valuation Allowance">2,835,000</span> for its deferred tax assets. The Company will continue to review this valuation allowance and make adjustments as appropriate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2021, the Company had net operating loss (“NOL”) carryforwards of approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231_zwLeKYHXjfS2" title="Estimated NOL Carry-forward">11,715,000</span>, consisting of $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20201231_zZcojLLKoC5g" title="Net operating loss">5,295,000</span> that have an indefinite carryover period and $<span id="xdx_906_ecustom--IndefiniteCarryforward_iI_pp0p0_c20201231_zdZsbN6Tlel2" title="Indefinite Carry-forward">6,420,000</span> that expire at various intervals through 2037. Use of NOL carryforwards is limited by the provisions of Section 382 of the Internal Revenue Code. At this point, the Company has not performed an analysis to determine whether an ownership change (as defined under Section 382) occurred during this year or preceding year(s). A determination of the potential impact these provisions might have on the utilization of net operating losses will be made when the net operating loss is projected to be utilized. As of December 31, 2021, the Company also has a capital loss carryforward of approximately $<span id="xdx_90B_ecustom--CapitalLossCredits_iI_pp0p0_c20211231_zWD4vBaQ5dDa" title="Capital Loss credits">386,000</span> that expires in 2025, and a research and development credit carryforward of approximately $<span id="xdx_908_eus-gaap--TaxCreditCarryforwardAmount_iI_pp0p0_c20211231_zuxzu5dcs0Rb" title="R&amp;D credits">515,000</span> that will expire at various intervals through 2040.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. At this time, the Company does not have any uncertain tax positions to assess.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z06hceNcCWF5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left"><span id="xdx_8BF_zAJnk9iwcjg9" style="display: none">Schedule of income tax expense from continuing operations</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20210101__20211231_zBD5SJUUwi78" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20200101_20201231" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-size: 11pt"> </td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2020</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left">Current income tax benefit:</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pp0p0" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left">   U.S. Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0661">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0662">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="padding-bottom: 1pt; text-align: left">   U.S. States</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0664">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0665">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01_pp0p0_zFI6Jqe21yNf" style="vertical-align: bottom; background-color: transparent"> <td style="padding-bottom: 2.5pt; text-align: left">     Total current income tax benefit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0668">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left">Deferred income tax benefit:</td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 74%; text-align: left">   U.S. Federal</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0673">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">840,812</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pp0p0" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-bottom: 1pt">   U.S. States</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0676">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">146,541</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--TotalDeferredIncomeTaxBenefit_i01_pp0p0_zA8lfiicRPsj" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 1pt">     Total deferred income tax benefit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0679">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">987,353</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--TotalIncomeTaxBenefit_pp0p0_zP6pFmsSF6e9" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-bottom: 2.5pt">     Total income tax benefit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0682">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">987,353</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 840812 146541 987353 987353 0.210 0.210 <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbrlAl67OKs9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-left: 2.75pt"><span id="xdx_8BF_zVKWjVgFELV8" style="display: none">Schedule of income tax rate reconciliation</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20210101__20211231_zX9pis7vTJjd" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20200101__20201231_zBEpBkLm21V5" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-size: 11pt; text-align: center"> </td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationDispositionOfBusiness_zbugG4OF7fi2" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 74%; text-align: left; padding-left: 2.75pt">Income tax benefit at statutory U.S. federal rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">586,728</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">566,840</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ForeignIncomeTaxExpenseBenefitContinuingOperations_zEqhk2q3RoY4" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-left: 2.75pt">Income tax benefit attributable to U.S. states</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">99,325</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98,792</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_zYjKlQzvNNh2" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-left: 2.75pt">Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137,728</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,338</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--NontaxableForgivenessOfPppAndEidlLoans_zbJT0gFKdAl3" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-left: 2.75pt">Non-taxable forgiveness of PPP and EIDL loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,314</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--NondeductibleExpenses_zHmNZqbfT365" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-left: 2.75pt">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(300</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(334</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--StockOptionPlanExpense_ziWHGlk7wtIg" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-left: 2.75pt">Stock- based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(53,952</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(54,182</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zmaNTdvILRQ3" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="padding-left: 2.75pt">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(15,182</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,790</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zUXxBrB2vOvl" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 2.75pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(774,825</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">312,373</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredIncomeTaxesAndTaxCredits_z2fkwPkjiQi3" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.7pt">     Total income tax expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0715">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">987,351</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 586728 566840 99325 98792 137728 49338 20478 18314 -300 -334 -53952 -54182 -15182 -3790 -774825 312373 987351 <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zcqw5L02GASl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left"><span id="xdx_8B4_zwbkBXDEFzd8" style="display: none">Schedule of deferred tax assets and liabilities</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20211231_zY5eGGeNRlN4" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20201231_zxVYlLwBhYz6" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-size: 11pt; text-align: center"> </td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNetAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left">Deferred income tax assets:</td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0" style="vertical-align: bottom; background-color: transparent"> <td style="width: 74%; text-align: left">   Net operating loss carryforwards</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,876,543</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,585,042</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left">   Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">515,982</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">378,524</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--LongtermCapitalLossCarryforward_i01I_pp0p0_zWnZI7DMpqZ1" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left">   Long-term capital loss carryforward</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,728</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0730">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_z4R93XDO0zx1" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 1pt">   Valuation allowance for deferred income tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,835,108</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,060,283</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_i01I_pp0p0_zNEjmLtG9xJa" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; padding-bottom: 1pt">     Net deferred income tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">652,145</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">903,283</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 2876543 2585042 515982 378524 94728 2835108 2060283 652145 903283 647554 897196 4591 6087 652145 903283 2835000 11715000 5295000 6420000 386000 515000 <p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_zB0idnMlqCfh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Note 7:<span id="xdx_82C_zCR8i7UixMQe"> Notes Payable</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="text-decoration: underline">Small Business Administration (“SBA”) Paycheck Protection Program:</span> On April 17, 2020, the Company received $<span id="xdx_900_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20200101__20200417__us-gaap--DebtInstrumentAxis__custom--SBAPaycheckProtectionProgramMember_zSLrvWUtfdte" title="Proceeds">71,268</span> and on February 22, 2021 the Company received $<span id="xdx_909_eus-gaap--ProceedsFromNotesPayable_c20210201__20210222__us-gaap--DebtInstrumentAxis__custom--SBAPaycheckProtectionProgramMember_pp0p0" title="Proceeds">76,395</span> in proceeds from the SBA Paycheck Protection Program, which was created under the Coronavirus Aid, Relief and Economic Security Act (CARES). Under the program, the Company received $<span id="xdx_90B_eus-gaap--DebtInstrumentDecreaseForgiveness_pp0p0_c20210201__20210222__us-gaap--DebtInstrumentAxis__custom--SBAPaycheckProtectionProgramMember_z5JSKEiYoFje" title="Forgiveness of debt">71,268</span> forgiveness of the debt from the SBA based on the use of the proceeds over the 24-week period following funding of the loan in the year ended December 31, 2020 and $<span id="xdx_905_eus-gaap--LoansAssumed1_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--SBAPaycheckProtectionProgramMember_z2JAKplXz6S8" title="Loans">76,395</span> in the year ended December 31, 2021. The forgiveness was recorded as loan forgiveness in other income on the consolidated statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Although management considers it probable that the Company was initially eligible for the loan and subsequent forgiveness, the SBA has the ability to review the Company’s loan file for a period subsequent to the date the loan was forgiven and could request additional documentation to support the Company’s initial eligibility for the loan and request for loan forgiveness. In the event the SBA subsequently determines the Company did not meet the initial; eligibility requirements for the PPP loan or did not qualify for loan forgiveness, the SBA may pursue legal remedies at its discretion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="text-decoration: underline">SBA Economic Injury Disaster Loan:</span> On June 5, 2020, the Company received a $<span id="xdx_905_eus-gaap--ProceedsFromNotesPayable_c20200604__20200605__us-gaap--DebtInstrumentAxis__custom--EconomicInjuryDisasterLoanMember_pp0p0" title="Proceeds">3,000</span> Economic Injury Disaster Loan (“EIDL”) advance and $<span id="xdx_904_eus-gaap--ProceedsFromNotesPayable_c20200604__20200605__us-gaap--DebtInstrumentAxis__custom--EIDLProgramMember_pp0p0" title="Proceeds">150,000</span> in proceeds from the SBA’s EIDL Program. On July 20, 2021, the Company received an additional $<span id="xdx_90E_eus-gaap--ProceedsFromNotesPayable_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--EconomicInjuryDisasterLoanMember_pp0p0" title="Proceeds">7,000</span> SBA EIDL Advance which has been forgiven and, on July 14, 2021, the Company received a $<span id="xdx_90F_eus-gaap--ProceedsFromNotesPayable_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--EIDLProgramMember_pp0p0" title="Proceeds">50,000</span> increase in the SBA EIDL Loan. Installment payments, including interest at the rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200605__us-gaap--DebtInstrumentAxis__custom--EIDLProgramMember_zfWXZ0Zo5Xr3" title="Interest rate">3.75</span>% per annum, of $<span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_c20200604__20200605__us-gaap--DebtInstrumentAxis__custom--EIDLProgramMember_pp0p0" title="Monthly payment">1,022</span> monthly over thirty years from the date of the original promissory note will begin on June 5, 2022. The Company granted to the SBA a continuing security interest in all tangible and intangible personal property. The Company may not make any distribution of assets of the Company to any shareholder without the written consent of the SBA. As of December 31, 2021, the Company recognized $<span id="xdx_900_eus-gaap--InterestPayableCurrent_c20211231__us-gaap--DebtInstrumentAxis__custom--EIDLProgramMember_pp0p0" title="Accrued interest">9,760</span> of accrued interest on the note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Dole Food Company:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_Hlk55191561"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">On August 19, 2020, the Company entered into a Development and Commercialization Agreement (“DCA”) with Dole Food Company (“Dole”) for the development of our banana genes. The DCA provides for payments from Dole to the Company of $<span id="xdx_906_ecustom--PaymentToCompanyUponExecution_c20200819__us-gaap--DebtInstrumentAxis__custom--DCADoleMember_pp0p0" title="Payment upon execution">800,000</span> upon execution, $<span id="xdx_90C_ecustom--PaymentToCompanyByTwelveMonthAnniversary_c20200819__us-gaap--DebtInstrumentAxis__custom--DCADoleMember_pp0p0" title="Payment twelve-month anniversary">800,000</span> by the twelve-month anniversary, $<span id="xdx_900_ecustom--PaymentToCompanyByThirtySxMonthAnniversary_c20200819__us-gaap--DebtInstrumentAxis__custom--DCADoleMember_pp0p0" title="Payment thirty six month anniversary">250,000</span> by the thirty-six month anniversary and $<span id="xdx_906_ecustom--PaymentToCompanyByFortyEightMonthAnniversary_c20200819__us-gaap--DebtInstrumentAxis__custom--DCADoleMember_pp0p0" title="Payment forty eight month anniversary">250,000</span> by the forty-eight month anniversary. Dole also reimburses the Company for costs incurred at the University of Wisconsin-Madison (“UW”) not to exceed $<span id="xdx_90C_ecustom--ReimbursedCostsIncurred_c20200819__us-gaap--DebtInstrumentAxis__custom--DCADoleMember_pp0p0" title="Reimbursement of costs">2,200,000</span> in coordination with the Standard Research Agreement that the Company entered into with UW on September 18, 2020. The agreement with UW includes payments from the Company to UW in the amount of $<span id="xdx_906_ecustom--ExpectedPaymentsToUnversityOfWisconsinMadisonTwoYearTerm_c20200918__us-gaap--DebtInstrumentAxis__custom--ResearchAgreementUniversityOfWisconsinMadisonMember_pp0p0" title="Expected payments University of Wisconsin-Madison">2,159,719</span> over the two-year expected term of the project. If the UW research is successful, Dole expects to incur costs of approximately $<span id="xdx_903_ecustom--ExpectedFieldTrialCosts_c20200819__us-gaap--DebtInstrumentAxis__custom--DCADoleMember_pp0p0" title="Expected field trial costs">750,000</span> to perform field trials.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">The DCA also specifies that the Company will execute notes payable to Dole for the funding that Dole is providing up to $<span id="xdx_90D_ecustom--NotesPayableForDoleFunding_c20200819__us-gaap--DebtInstrumentAxis__custom--DCADoleMember_pp0p0" title="Notes payable for dole funding">5,050,000</span>. Upon receipt of $<span id="xdx_901_ecustom--PaymentUponReceipt_iI_pp0p0_c20200826__us-gaap--DebtInstrumentAxis__custom--DCADoleMember_zHJKSn0VYKn7" title="Payment upon receipt">800,000</span> on August 26, 2020, $<span id="xdx_903_ecustom--PaymentUponReceipt_iI_pp0p0_c20210728__us-gaap--DebtInstrumentAxis__custom--DCADoleMember_z7Mz7J2Xw3Ba" title="Payment upon receipt">800,000</span> on July 28, 2021, $<span id="xdx_90A_ecustom--PaymentUponReceipt_iI_pp0p0_c20201229__us-gaap--DebtInstrumentAxis__custom--DCADoleMember_zsMZjORSwdib" title="Payment upon receipt">1,295,831</span> on December 29, 2020 and $<span id="xdx_907_ecustom--PaymentUponReceipt_iI_pp0p0_c20210929__us-gaap--DebtInstrumentAxis__custom--DCADoleMember_zP5dDaqjcF4k" title="Payment upon receipt">647,916</span> on September 29, 2021, the Company executed the notes under this DCA and recorded them as long-term notes payable for financial statement purposes. The notes are non-interest bearing and allow Dole to offset fifty percent of future royalty payments to the Company by reducing the amount of principal due on these notes. Other than this offset of future royalty payments, repayment of principal and interest is only required in the case of termination of the DCA by Dole for cause.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 71268 76395 71268 76395 3000 150000 7000 50000 0.0375 1022 9760 800000 800000 250000 250000 2200000 2159719 750000 5050000 800000 800000 1295831 647916 <p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zSYnwuaAvh08" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Note 8:<span id="xdx_828_z3ceLdtWjQE4"> Stockholders’ Equity</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">The Amended and Restated Certificate of Incorporation of the Company dated October 19, 2015 authorized the issuance of <span id="xdx_90A_ecustom--CapitalStockSharesAuthorized_c20151019_pdd" title="Capital stock, authorized shares">800,000,000</span> shares of all classes of stock including <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_c20151019_pdd" title="Common stock, authorized shares">780,000,000</span> shares of Common Stock having a par value of $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_c20151019_pdd" title="Common stock, par value">0.001</span> per share and <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_c20151019_pdd" title="Preferred stock, authorized shares">20,000,000</span> shares of Preferred Stock having a par value of $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_c20151019__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" title="Preferred stock, par value">0.001</span> per share, <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_c20151019__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" title="Preferred stock, authorized shares">600,000</span> of which were designated as Series A-1 Convertible Preferred Stock (“Series A-1”) and <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_c20151019__us-gaap--StatementClassOfStockAxis__custom--ConvertiblePreferredStockSeriesA2Member_pdd" title="Preferred stock, authorized shares">200,000</span> of which were designated as Series A-2 Convertible Preferred Stock (“Series A-2”). The Board of Directors, without a vote of the shareholders, is authorized to issue additional shares of Preferred Stock in series and to establish the characteristics thereof.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Subsequent to the year ended December 31, 2021, the Company issued an additional <span id="xdx_907_eus-gaap--AdditionalPaidInCapitalPreferredStock_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--ConvertiblePreferredStockSeriesA2Member_zkKYAa1PnNF3" title="Additional shares">76,953</span> shares of Series A-2 stock at $<span id="xdx_90F_eus-gaap--PreferredStockNoParValue_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--ConvertiblePreferredStockSeriesA2Member_z0lw62Q95COc" title="Preferred stock per share">5.25</span> per share and received proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--ConvertiblePreferredStockSeriesA2Member_z6dXWBcJpQF1" title="Proceeds of preferred stock shares">404,003</span>. The Company has <span id="xdx_909_eus-gaap--SharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--ConvertiblePreferredStockSeriesA2Member_zLYSmOQlcrfe" title="Issuance of preferred shares">20,187</span> shares of Series A-2 stock remaining available for issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="text-decoration: underline">Liquidation</span>: Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of the Series A-1 and Series A-2 shall be entitled to receive out of the assets of the Company for each share of Series A-1 and Series A-2 an amount equal to its stated value, $<span id="xdx_905_ecustom--StatedPerShareValueOfPreferredStock_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2PreferredStockMember_pdd" title="Stated per share value of preferred stock"><span id="xdx_904_ecustom--StatedPerShareValueOfPreferredStock_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2PreferredStockMember_pdd" title="Stated per share value of preferred stock">5.25</span></span> per share as of December 31, 2021 and 2020, plus any accrued but unpaid dividends before any distribution or payment shall be made to the holders of any other class or series of stock of the Company that ranks junior to the Series A-1 and Series A-2. The holders shall be entitled to convert their shares of Series A-1 and Series A-2 into Common Stock at any time prior to the consummation of a Liquidation. This is considered a contingent redemption feature.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="text-decoration: underline">Conversion</span>: The holders of Series A-1 and Series A-2 may convert their shares into shares of Common Stock, at the option of the holder, on a one-share-for-one-share basis and shall be subject to certain adjustments at any time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="text-decoration: underline">Optional Redemption; Sinking Fund Account:</span> The Company may elect to redeem some or all of the then outstanding shares of Series A-1, (i) for cash in an amount equal to the liquidation preference per share, $<span id="xdx_90C_ecustom--StatedPerShareValueOfPreferredStock_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Stated per share value of preferred stock"><span id="xdx_903_ecustom--StatedPerShareValueOfPreferredStock_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Stated per share value of preferred stock">5.25</span></span> per share as of December 31, 2021, subject to adjustment and (ii) by issuing one share, subject to adjustment, of Common Stock for each share of Series A-1 and Series A-2 outstanding being redeemed. 50% of all licensing fees received by the Company will be deposited into a separate sinking fund for use in an optional redemption. As of December 31, 2021, no licensing revenue has been received under these provisions and no sinking fund account has been established.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="text-decoration: underline">Dividends</span>: The Company shall pay to the holders of the Series A-1 and Series A-2 dividends at the rate of <span id="xdx_905_eus-gaap--PreferredStockDividendRatePercentage_dp_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zeBcKSzVHcNb" title="Dividend rate"><span id="xdx_907_eus-gaap--PreferredStockDividendRatePercentage_dp_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--ConvertiblePreferredStockSeriesA2Member_zWiKOjq28Fv4" title="Dividend rate">8</span></span>% per annum and the Company has accrued these dividends since issuance of the Series A-1 and Series A-2. The dividend amount shall accrue and shall be payable in shares of Common Stock upon the conversion of the Series A-1 and Series A-2, or upon the redemption of the Series A-1 and Series A-2. No dividends shall be paid on any Common Stock of the Company or any capital stock of the Company that ranks junior to the Series A-1 and Series A-2 until dividends of Series A-1 and Series A-2 been paid. As of December 31, 2021, there were $<span id="xdx_903_eus-gaap--DividendsPayableCurrent_c20211231_pp0p0" title="Dividends accrued">1,522,970</span> in accrued stock dividends.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="text-decoration: underline">Voting</span>: The holders of the Series A-1 and Series A-2 are entitled to vote on all matters submitted to the stockholders for a vote on an as-if-converted to Common Stock basis, with all stockholders voting as a single class.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 800000000 780000000 0.001 20000000 0.001 600000 200000 76953 5.25 404003 20187 5.25 5.25 5.25 5.25 0.08 0.08 1522970 <p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zCbfn3JGvcvj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 9:<span id="xdx_82D_zkB92Ufs7Lfg"> Stock-Based Compensation</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company grants stock-based instruments under the 2015 Stock Incentive Plan (“Plan”) for which <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20211231_pdd" title="Number of shares reserved for issuance under 2015 Stock Incentive Plan">1,400,000</span> shares of the Company’s Common Stock has been reserved. The Plan allows for the issuance of incentive stock options and non-qualified stock options with a maximum contractual term of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20210101__20211231_zzu56CFZGqHk" title="Expiration period for stock options">10</span> years. Shares and options that are cancelled are available for reissuance under the Plan. For years ended December 31, 2021 and 2020, the Company recorded compensation costs for stock options of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20210101__20211231_pp0p0" title="Compensation costs for stock options">219,718</span> and $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20201231_zmYkMqVBLMfd" title="Compensation costs for stock options">219,718</span>, respectively. Stock options are generally issued with an exercise price at or above the estimated per-share value of the Company’s Common Stock. The Company granted <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20210101__20211231_zzFdPsTzrdr" title="Stock options granted during period"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20200101__20201231_z1uW7TDakwSe" title="Stock options granted during period">no</span></span> options during the years ended December 31, 2021 and 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Management has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the issuance of the outstanding options, there was not a public market for the Company’s shares. Accordingly, the Company utilized the value obtained in equity transactions with unrelated parties to estimate the fair value of the Company’s Common Stock on the date of grant. Volatility of the underlying common shares was determined based on the historical volatility for similar companies that are actively traded in the public markets for a term consistent with the expected life of the options. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options on the date of the grant. Due to the lack of sufficient historical activity, the expected life of the options was estimated using the formula set forth in Securities and Exchange Commission SAB 107.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the Company’s aggregate stock options granted:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zdTZOgUFN3Hb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left"><span id="xdx_8BD_zKES4Zkd9qJc" style="display: none">Schedule of Stock Option Activity</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted Average Remaining Term(Years)</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Total Intrinsic Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; width: 19%; text-align: left">Balance, January 1, 2020</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zhDYa7N27wp" style="width: 17%; text-align: right" title="Balance, beginning">1,081,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zrHfVswFYA5c" style="width: 17%; text-align: right" title="Balance, beginning">1.74</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zTJQnGVjXUHa" title="Outstanding beginning, contractual term">7.67</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_pdd" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0873">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0875">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left">Exercised</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231_pdd" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0877">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0879">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left">Cancelled</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20200101__20201231_pdd" style="text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0881">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0883">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left">Balance, December 31, 2020</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20201231_zOXzxvHYQPm" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending">1,081,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200101__20201231_zqoolD6fdIL4" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending">1.74</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20200101__20201231_zkQOQ8lZSY27" title="Outstanding ending, contractual term">6.67</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left">Balance, January 1, 2021</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zJiTo01WKkU8" style="text-align: right" title="Balance, beginning">1,081,667</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zf7ZKRDaVQf6" style="text-align: right" title="Balance, beginning">1.74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zpBFNrAtQwJg" title="Outstanding beginning, contractual term">6.67</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_z2rKvBpcS7B2" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0897">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zqTWY5CYiMOe" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0899">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left">Exercised</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zVGMYQhG83Oh" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0901">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_z5iSIJ3jAiL5" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0903">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left">Cancelled</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20211231_zHqW1Kdoy1Bd" style="text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0905">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zWkdA492pUpa" style="text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0907">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left">Balance, December 31, 2021</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_zwtBdSE3Bo1e" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending">1,081,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_z8Gu0fvNtrW8" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending">1.74</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_zdiEJGdE0RKb" title="Outstanding ending, contractual term">5.67</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left">Exercisable at December 31, 2021</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231_zlZ7oLiTpW94" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable">868,332</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231_z3jOvRNByB81" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable">1.79</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zzhQuHk6WyY1" title="Exercisable, contractual term">5.14</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20211231_pp0p0" style="text-align: right" title="Exercisable, intrinsic value">28,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the years ended December 31, 2021 and 2020, options for <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20210101__20211231_pdd" title="Number of shares vested during the period">180,000</span> and <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20200101__20201231_zA2k5KAiKPMl" title="Number of shares vested during the period">179,999</span> shares vested, respectively. As of December 31, 2021, there was $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20211231_pp0p0" title="Unrecognized compensation cost related to share-based compensation arrangements">185,731 </span>unrecognized compensation cost related to share-based compensation arrangements that will be recognized through the year ending December 31, 2022.<span id="a_Aci_Pg45"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 1400000 P10Y 219718 219718 0 0 <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zdTZOgUFN3Hb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left"><span id="xdx_8BD_zKES4Zkd9qJc" style="display: none">Schedule of Stock Option Activity</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted Average Remaining Term(Years)</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Total Intrinsic Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; width: 19%; text-align: left">Balance, January 1, 2020</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zhDYa7N27wp" style="width: 17%; text-align: right" title="Balance, beginning">1,081,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zrHfVswFYA5c" style="width: 17%; text-align: right" title="Balance, beginning">1.74</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zTJQnGVjXUHa" title="Outstanding beginning, contractual term">7.67</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_pdd" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0873">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0875">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left">Exercised</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231_pdd" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0877">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0879">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left">Cancelled</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20200101__20201231_pdd" style="text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0881">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0883">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left">Balance, December 31, 2020</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20201231_zOXzxvHYQPm" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending">1,081,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200101__20201231_zqoolD6fdIL4" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending">1.74</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20200101__20201231_zkQOQ8lZSY27" title="Outstanding ending, contractual term">6.67</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left">Balance, January 1, 2021</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zJiTo01WKkU8" style="text-align: right" title="Balance, beginning">1,081,667</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zf7ZKRDaVQf6" style="text-align: right" title="Balance, beginning">1.74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zpBFNrAtQwJg" title="Outstanding beginning, contractual term">6.67</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_z2rKvBpcS7B2" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0897">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zqTWY5CYiMOe" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0899">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="vertical-align: top; text-align: left">Exercised</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zVGMYQhG83Oh" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0901">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_z5iSIJ3jAiL5" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0903">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left">Cancelled</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20211231_zHqW1Kdoy1Bd" style="text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0905">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zWkdA492pUpa" style="text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0907">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left">Balance, December 31, 2021</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_zwtBdSE3Bo1e" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending">1,081,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_z8Gu0fvNtrW8" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, ending">1.74</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_zdiEJGdE0RKb" title="Outstanding ending, contractual term">5.67</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left">Exercisable at December 31, 2021</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231_zlZ7oLiTpW94" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable">868,332</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231_z3jOvRNByB81" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable">1.79</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zzhQuHk6WyY1" title="Exercisable, contractual term">5.14</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20211231_pp0p0" style="text-align: right" title="Exercisable, intrinsic value">28,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1081667 1.74 P7Y8M1D 1081667 1.74 P6Y8M1D 1081667 1.74 P6Y8M1D 1081667 1.74 P5Y8M1D 868332 1.79 P5Y1M20D 28000 180000 179999 185731 <p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zoR9ISL32Ws4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 10:<span id="xdx_822_zeGHpyolQylg"> Commitments and Contingencies</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Officer Indemnification</span>: Under the Company’s organizational documents, the Company’s officers, employees, and directors are indemnified against certain liabilities arising out of the performance of their duties. The Company’s maximum exposure under these arrangements is unknown, as this would involve future claims that may be made against the Company that have not yet occurred. However, based on experience, the Company expects any risk of loss to be remote. The Company also has an insurance policy for its directors and officers to insure them against liabilities arising from their performance in their positions with the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Lease Commitments</span>: The Company leases its operating facility and pays its rent in monthly installments. The lease was renewed in June 2016 for a period of twelve months and monthly rentals for the period of July 1, 2016 through December 31, 2021 are $<span id="xdx_900_ecustom--MonthlyRentPayment_c20211231_pp0p0" title="Monthly rent payment">2,378</span> per month which continues on a month-to-month basis. There is no minimum lease commitment as of December 31, 2021. Renewals after June 30, 2017 are by mutual agreement. The Company’s rent expense for the years ended December 31, 2021 and 2020 was $<span id="xdx_903_eus-gaap--LeaseAndRentalExpense_c20210101__20211231_pp0p0" title="Rent expense"><span id="xdx_90D_eus-gaap--LeaseAndRentalExpense_pp0p0_c20200101__20201231_zes98XwGpG4e" title="Rent expense">28,535</span></span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Royalty</span>: Effective March 1, 2012, the Company entered into an Agreement for Contract Services with SmithBucklin Corporation (the “Contractor”) on behalf of the United Soybean Board. The contract includes the payment of certain royalties, as defined in the Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_Aci_Pg46"/>The Company is obligated to pay royalties to the United Soybean Board of 10% of the sale of products derived from the soybean genes that were the subject of the research performed by the Contractor or from royalties received by the Company from the sale of products by a third party not to exceed 150% of the total amount paid to the Contractor under this Agreement. The Company has recognized to date grant revenue from the contract of $<span id="xdx_90A_ecustom--TotalAmountOfGrantRevenueRecognizedToDate_c20211231_pp0p0" title="Total amount of grant revenue recognized to date">262,400</span> as of December 31, 2020, thus limiting any future royalties as of December 31, 2021 to a total of $<span id="xdx_906_ecustom--TotalPossibleFutureRoyaltiesOwed_c20211231_pp0p0" title="Total possible future royalties owed">393,600</span>. The Company has not accrued or paid any royalties under the terms of the Agreement as of and during the years ended December 31, 2021 and 2020 because it has not received any revenue from the sale of products to date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Other Commitments: </span>On September 18, 2020, the Company entered into a Standard Research Agreement with WCIC for the development of our banana genes. The agreement includes payments from the Company in the amount of $<span id="xdx_901_eus-gaap--PaymentsForRoyalties_c20200901__20200918__us-gaap--TypeOfArrangementAxis__custom--StandardResearchAgreementMember_pp0p0" title="Payments for royalties">2,159,719</span> over the <span id="xdx_906_eus-gaap--DebtInstrumentTerm_dtY_c20200901__20200918__us-gaap--TypeOfArrangementAxis__custom--StandardResearchAgreementMember_zTVpQ0mp89ad" style="display: none" title="Term">2</span> two-year expected term of the project. These costs will be reimbursed, in the form of notes payable by Dole in accordance with our DCA.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> 2378 28535 28535 262400 393600 2159719 P2Y <p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zUtKhS2wYEv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 11:<span id="xdx_825_zg1ecFW5AM42"> Related Parties and Transactions</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Steve B. Warnecke:</span> Mr. Warnecke is the Company’s Chief Executive Officer and Chairman of the Board and owns, directly or indirectly, <span id="xdx_903_ecustom--NumberOfCommonStockOutstandingOwnedByRelatedPartyShares_c20211231__us-gaap--RelatedPartyTransactionAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Number of common stock shares outstanding owned by related party">1,827,088</span> shares or <span id="xdx_902_ecustom--PercentageOfCommonStockSharesOutstandingOwnedByRelatedParty_iI_dp_c20211231__us-gaap--RelatedPartyTransactionAxis__srt--ChiefExecutiveOfficerMember_zxLOt3AbZ11" title="Percentage of common stock shares outstanding owned by related party">28.3</span>% of the Common Stock outstanding as of December 31, 2021. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 1827088 0.283 <p id="xdx_808_eus-gaap--ConcentrationRiskDisclosureTextBlock_zjMhGfDyqAa3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 12:<span> <span id="xdx_82B_zGWHsglIDJNi">Concentrations</span></span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Considerations of Credit Risk</span>: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains its cash balances at high-credit, quality financial institutions. The balances, at times, may exceed federally insured limits. The Company routinely monitors the credit quality of its customers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_802_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z854mk2J9QWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 13: <span id="xdx_825_zSSlS2Rfj2V8">Liquidity</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2021, the Company had $<span id="xdx_900_eus-gaap--CashAvailableForDistributions_iI_pp0p0_c20211231_zCU50Ilqag68" title="Operating cash">214,009</span> in operating cash and during 2021 used $<span id="xdx_903_eus-gaap--OtherCashEquivalentsAtCarryingValue_iI_pp0p0_c20211231_zKkOCnWJKuP1" title="Cash">1,583,139</span> of cash in operations. Subsequent to the year ended December 31, 2021, the Company issued an additional <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220321__us-gaap--StatementClassOfStockAxis__custom--SeriesA2PreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmtCmjZ5P05k">76,953</span> shares of Series A-2 stock at $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_c20220321__us-gaap--StatementClassOfStockAxis__custom--SeriesA2PreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGhT1nN08Hwj">5.25</span> per share and received proceeds of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220321__us-gaap--StatementClassOfStockAxis__custom--SeriesA2PreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKZUPBFuJXnj" title="Proceeds of stock issued">404,003</span>. The Company’s current projections for 2022 requires cash of $578,143. These factors raise substantial doubt as to the Company’s ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">To address these factors and in addition to the $404,000 of proceeds received subsequent to the year ended December 31, 2021 and funding from our agreement with Dole, management expects to receive additional funds from option exercises and will reduce operating expenses with employee salary deferrals to provide the necessary liquidity to meet our obligations as they come due over the next year. We expect that the funding from these sources will be sufficient to cover our obligations for the next twelve months. Additional shareholder funding could result in dilution to existing shareholders. If the funding does not arrive, the Company may not be able to meet its obligations as they become due.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 214009 1583139 76953 5.25 404003 EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( &J7=50'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !JEW54UI0<2>X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>*''8H";-I66G#08K;.QF;+4UC?]@:R1]^R5>FS*V!]C1TL^? M/H%:%83R$5^B#QC)8+H;;>^24&'-CD1! "1U1"M3.2785H ]6G24H"YK8-T\ M,9S'OH4;8(811IN^"Z@78J[^BX>6<621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M &J7=51AL,T#AP4 &\7 8 >&PO=V]R:W-H965T&UL ME9A=;]LV%(:ONU]!&,/0 G4L48ZC=(D!QZZ[K&EJQ/U -^R"EFA;B$1Z)&4G M_WZ'LBRY 7VDW=CZ.J\>'8KO.>+53JI'O>;%<=F:G@EIQ$G&A4ZD((HOKSLC M_]TD.+[&2O!X&_+QSQ-K1)P_%N* M=JI[VL#C[8/ZM'AX>)@%TWPLT^]);-;7G;!#8KYD>6H>Y.X/7CY0 1C)5!>_ M9+>_MM_OD"C71F9E,!!DB=C_LZ-&![N>]V/",5Y17&.RHP (2XP MIBE;N3#P^"5+-4D/!,GW:E/T_A?4#\[4::0&L89$^4=6[:-"XURIEU#84#;( M=;L^[08H&JW1**KU7IC$/ -9RLE]GBVX<@+A(I[G=<_[/KW$D&K?]8,V2 ]\ ME5CKA;S=L\R=IP:AK4QS.X^A+R(?N)!9$NFWY%9$9QAH[>8^[L"#'IAV \& 496.[R/6W1)]H4]D=L8\))E$K'"T9 QQB7I MH MXEX/+$".LO=_'3;LDA+&0"CRV@'M+Y@9F!)&*C&4.2870HCA77\.:4&^0.KB.?A9L,E^Q3ZD'?I40B5O9Q%9DHZ)\QW+I8 M^+C'O\0=VSU(YA>Y$TY47&[,M %7>)#1(X97UPL?M_B7>-5@SY3<)B)RIQ/7 M''_&^M:Z;%#,_) MG#,-?#&YU3H_ 8AKWDL,K:X.M%5U^ 8U2!A;@6R-5!S7#+7RSXI5'<0*V'PKQF4 ;)Y]Q %10Q#*)K,:=4'AQ!G8>A']H&T0EUM/""&_ HCQ,# M?<&IMK\A?);"-P,GO[%L\[MMM9@@L[N[,39@M:D'N!4?T&PEM"VK$Z]A$8B+ M+5?0GKN?L?(3;'>N9#&R*S8 M7',6Z_. MN;SDX>7J48!D]Y5JBKV4[K\G*Y5,F.Y51=B)(5YLF]D#G5YE9NEZJ4 MC*:54YXM,83!,J>\F*U7U6^WYWQ@MU*H/9Y3N6'%RP3CUU<$U ML%0V0KRS-Z_2JQFTB%C&$FU#4//UP&Y8EME(!L?[)NBL?:=U/+S^&/W[BKPA MLZ&*W8CL5Y[JW=4LFH&4W=-]IM^(QQ]80XC8>(G(5/4)'AM;. /)7FF1-\X& M0 MA@TO[##>:6F>B4"+C*=4L!2]H1HN$@3L;3H$%>'OW$GS[[+O54IM7 M68=ETH1]48?%$V%?LN0">&@.,,1HQ/WF?'=X[+XT!%N6N&6)JWC>%,N]E*S0 M@"IEB#D">FU KPKH3P6D:C>6E=J+5%YV!CVL,?(AC%?+AT/V8V8D\H+6[ B4 MWX+RG:!N)2LI3P%[,I-<,34&L(X0'+S91V&,>_B&5@$*23@.C[3PB N>79 N M54D3=C4S*XYB\H'-UE]_A0+X_-,^?Q::9F:23(]MS9D,V&!"(HAZI$?,PI#$ MWCCKH&4=.$OO)U$L7!"/@H9MT/#$2)MU7.H/@!9FN-_O>6E65CT'!=-C"0@' MS% 4Q%&/_]"*P#"8H!^U2",GTE>%IL66;S+6L)\$&0W3'Q"3_WYM#NV\(/ ] M?P)HW *-OT1U%B>&O^8>CW / QS#'O>AG1<;GC&->\O<,=Q.VE V$G].DG$OC!R M5](/M*I3,Z=HDL@] M>=R'9@[NG)#E?!"W_R%?>HC MI_-'Z8= 5J 4BA5J9QYRO+2MBBC&1J*K$>"F,1^ M/T.G#8\SU DRBIR3Y\Y"WXDL95)]8SL>GG#MFCR=@B*GA-K]9Y.>ZAVC_(<* MA@@V.]#!RC%BB+T XVBD?*XAS\ Q>0(C,C)?@@69[]AR$ M$9Q#6/T#M:.FB #=ZYV0_$^6S@&91Q&:1W'T\2%7RBJ%50W3)BNSW4EYL054 M ]/%L'S#9-L(54;#EJ9.#1XJ)XFB_N[GE-5Q4CIQQ<@M@FG*;=-H.[G&7T2NU>G)W*1AJ,0+WW2F" VR,&*)(DRB@]WH<1(Z MW<;N!G4@(M6$.)_#L"T=WX2.&#HWH;C;'V#W_N".20O[>H% ;[4#O[VN)OOO MKN.*3N.QNVO\NSL6% AF[ M-X[P(C019'V<6]]H458GHANAM+]S3=2SU!7LVR*PFEJ? M\?4(8Y)(FNI#B>BJ)6 MN:9.K!^_5O]BFE?-/! ![;]"D5#(UTO9(DP_]%V M%SL:6BC<",G2(ED1I#3;?9*78A"U!'PHP2T2W+X)@R)A8!K=D9FV;HDDLPEG M6\1UM*JF#\QL3+;JAF;Z:UQ*KNY2E2=GH0&^0*[CXI;T M>?]TIYENJX;+KMVR:]?4&QZHMU#/"G"N6E8##A\O4$XX8NKIEF8.SR39 ,I! M78C5"-K:W=7W37TME>>9<^4XJK7G>E==40WX00D_. W>0 I$-C)FG/Z%J UX M5].KH2BEF[\WS#T"&]C#$GMX%'O.TE3IMC9P,^8VUF&OX79%-2A')>7H!,I> MDQWM#

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end XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 134 228 1 false 24 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://evolutionarygenomicsinc.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://evolutionarygenomicsinc.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://evolutionarygenomicsinc.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Condensed and Consolidated Statement of Stockholders' Deficit Sheet http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit Condensed and Consolidated Statement of Stockholders' Deficit Statements 5 false false R6.htm 00000006 - Statement - Condensed and Consolidated Statements of Cash Flows Sheet http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows Condensed and Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - Business Activity Sheet http://evolutionarygenomicsinc.com/role/BusinessActivity Business Activity Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - New Accounting Standards Sheet http://evolutionarygenomicsinc.com/role/NewAccountingStandards New Accounting Standards Notes 9 false false R10.htm 00000010 - Disclosure - Property and Equipment Sheet http://evolutionarygenomicsinc.com/role/PropertyAndEquipment Property and Equipment Notes 10 false false R11.htm 00000011 - Disclosure - Intangible Assets Sheet http://evolutionarygenomicsinc.com/role/IntangibleAssets Intangible Assets Notes 11 false false R12.htm 00000012 - Disclosure - Income Taxes Sheet http://evolutionarygenomicsinc.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 00000013 - Disclosure - Notes Payable Notes http://evolutionarygenomicsinc.com/role/NotesPayable Notes Payable Notes 13 false false R14.htm 00000014 - Disclosure - Stockholders??? Equity Sheet http://evolutionarygenomicsinc.com/role/StockholdersEquity Stockholders??? Equity Notes 14 false false R15.htm 00000015 - Disclosure - Stock-Based Compensation Sheet http://evolutionarygenomicsinc.com/role/Stock-basedCompensation Stock-Based Compensation Notes 15 false false R16.htm 00000016 - Disclosure - Commitments and Contingencies Sheet http://evolutionarygenomicsinc.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 00000017 - Disclosure - Related Parties and Transactions Sheet http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactions Related Parties and Transactions Notes 17 false false R18.htm 00000018 - Disclosure - Concentrations Sheet http://evolutionarygenomicsinc.com/role/Concentrations Concentrations Notes 18 false false R19.htm 00000019 - Disclosure - Liquidity Sheet http://evolutionarygenomicsinc.com/role/Liquidity Liquidity Notes 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Property and Equipment (Tables) Sheet http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://evolutionarygenomicsinc.com/role/PropertyAndEquipment 21 false false R22.htm 00000022 - Disclosure - Intangible Assets (Tables) Sheet http://evolutionarygenomicsinc.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://evolutionarygenomicsinc.com/role/IntangibleAssets 22 false false R23.htm 00000023 - Disclosure - Income Taxes (Tables) Sheet http://evolutionarygenomicsinc.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://evolutionarygenomicsinc.com/role/IncomeTaxes 23 false false R24.htm 00000024 - Disclosure - Stock-Based Compensation (Tables) Sheet http://evolutionarygenomicsinc.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://evolutionarygenomicsinc.com/role/Stock-basedCompensation 24 false false R25.htm 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies 25 false false R26.htm 00000026 - Disclosure - Property and Equipment (Details) Sheet http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentTables 26 false false R27.htm 00000027 - Disclosure - Property and Equipment (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentTables 27 false false R28.htm 00000028 - Disclosure - Intangible Assets (Details) Sheet http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://evolutionarygenomicsinc.com/role/IntangibleAssetsTables 28 false false R29.htm 00000029 - Disclosure - Intangible Assets (Details 1) Sheet http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails1 Intangible Assets (Details 1) Details http://evolutionarygenomicsinc.com/role/IntangibleAssetsTables 29 false false R30.htm 00000030 - Disclosure - Intangible Assets (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://evolutionarygenomicsinc.com/role/IntangibleAssetsTables 30 false false R31.htm 00000031 - Disclosure - Income Taxes (Details) Sheet http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://evolutionarygenomicsinc.com/role/IncomeTaxesTables 31 false false R32.htm 00000032 - Disclosure - Income Taxes (Details 1) Sheet http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails1 Income Taxes (Details 1) Details http://evolutionarygenomicsinc.com/role/IncomeTaxesTables 32 false false R33.htm 00000033 - Disclosure - Income Taxes (Details 2) Sheet http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails2 Income Taxes (Details 2) Details http://evolutionarygenomicsinc.com/role/IncomeTaxesTables 33 false false R34.htm 00000034 - Disclosure - Income Taxes (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://evolutionarygenomicsinc.com/role/IncomeTaxesTables 34 false false R35.htm 00000035 - Disclosure - Notes Payable (Details Narrative) Notes http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://evolutionarygenomicsinc.com/role/NotesPayable 35 false false R36.htm 00000036 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://evolutionarygenomicsinc.com/role/StockholdersEquity 36 false false R37.htm 00000037 - Disclosure - Stock-Based Compensation (Details) Sheet http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails Stock-Based Compensation (Details) Details http://evolutionarygenomicsinc.com/role/Stock-basedCompensationTables 37 false false R38.htm 00000038 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://evolutionarygenomicsinc.com/role/Stock-basedCompensationTables 38 false false R39.htm 00000039 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://evolutionarygenomicsinc.com/role/CommitmentsAndContingencies 39 false false R40.htm 00000040 - Disclosure - Related Parties and Transactions (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactionsDetailsNarrative Related Parties and Transactions (Details Narrative) Details http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactions 40 false false R41.htm 00000041 - Disclosure - Liquidity (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative Liquidity (Details Narrative) Details http://evolutionarygenomicsinc.com/role/Liquidity 41 false false All Reports Book All Reports fnam_10k.htm fnam-20211231.xsd fnam-20211231_cal.xml fnam-20211231_def.xml fnam-20211231_lab.xml fnam-20211231_pre.xml fnam_ex31z1.htm fnam_ex31z2.htm fnam_ex32z1.htm fnam_ex32z2.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 58 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "fnam_10k.htm": { "axisCustom": 0, "axisStandard": 9, "contextCount": 134, "dts": { "calculationLink": { "local": [ "fnam-20211231_cal.xml" ] }, "definitionLink": { "local": [ "fnam-20211231_def.xml" ] }, "inline": { "local": [ "fnam_10k.htm" ] }, "labelLink": { "local": [ "fnam-20211231_lab.xml" ] }, "presentationLink": { "local": [ "fnam-20211231_pre.xml" ] }, "schema": { "local": [ "fnam-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 352, "entityCount": 1, "hidden": { "http://evolutionarygenomicsinc.com/20211231": 3, "http://fasb.org/us-gaap/2021-01-31": 102, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 109 }, "keyCustom": 30, "keyStandard": 198, "memberCustom": 10, "memberStandard": 14, "nsprefix": "fnam", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://evolutionarygenomicsinc.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Property and Equipment", "role": "http://evolutionarygenomicsinc.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Intangible Assets", "role": "http://evolutionarygenomicsinc.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Income Taxes", "role": "http://evolutionarygenomicsinc.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Notes Payable", "role": "http://evolutionarygenomicsinc.com/role/NotesPayable", "shortName": "Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Stockholders\u2019 Equity", "role": "http://evolutionarygenomicsinc.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Stock-Based Compensation", "role": "http://evolutionarygenomicsinc.com/role/Stock-basedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Commitments and Contingencies", "role": "http://evolutionarygenomicsinc.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Related Parties and Transactions", "role": "http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactions", "shortName": "Related Parties and Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Concentrations", "role": "http://evolutionarygenomicsinc.com/role/Concentrations", "shortName": "Concentrations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Liquidity", "role": "http://evolutionarygenomicsinc.com/role/Liquidity", "shortName": "Liquidity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "role": "http://evolutionarygenomicsinc.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Property and Equipment (Tables)", "role": "http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Intangible Assets (Tables)", "role": "http://evolutionarygenomicsinc.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Income Taxes (Tables)", "role": "http://evolutionarygenomicsinc.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "role": "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Property and Equipment (Details)", "role": "http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Property and Equipment (Details Narrative)", "role": "http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "Property and Equipment (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Intangible Assets (Details)", "role": "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Intangible Assets (Details 1)", "role": "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails1", "shortName": "Intangible Assets (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_PatentsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Intangible Assets (Details Narrative)", "role": "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetailsNarrative", "shortName": "Intangible Assets (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_PatentsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Income Taxes (Details)", "role": "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationDispositionOfBusiness", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Income Taxes (Details 1)", "role": "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails1", "shortName": "Income Taxes (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationDispositionOfBusiness", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Income Taxes (Details 2)", "role": "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails2", "shortName": "Income Taxes (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "fnam:FutureFederalStatutoryTaxRates", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Income Taxes (Details Narrative)", "role": "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "fnam:FutureFederalStatutoryTaxRates", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromNotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Notes Payable (Details Narrative)", "role": "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative", "shortName": "Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-02-012021-02-22_custom_SBAPaycheckProtectionProgramMember", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2015-10-19", "decimals": "INF", "first": true, "lang": null, "name": "fnam:CapitalStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "role": "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2015-10-19", "decimals": "INF", "first": true, "lang": null, "name": "fnam:CapitalStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Stock-Based Compensation (Details)", "role": "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails", "shortName": "Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2019-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Stock-Based Compensation (Details Narrative)", "role": "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetailsNarrative", "shortName": "Stock-Based Compensation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "fnam:MonthlyRentPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Commitments and Contingencies (Details Narrative)", "role": "http://evolutionarygenomicsinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "fnam:MonthlyRentPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations", "role": "http://evolutionarygenomicsinc.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31_srt_ChiefExecutiveOfficerMember", "decimals": "INF", "first": true, "lang": null, "name": "fnam:NumberOfCommonStockOutstandingOwnedByRelatedPartyShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Related Parties and Transactions (Details Narrative)", "role": "http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactionsDetailsNarrative", "shortName": "Related Parties and Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31_srt_ChiefExecutiveOfficerMember", "decimals": "INF", "first": true, "lang": null, "name": "fnam:NumberOfCommonStockOutstandingOwnedByRelatedPartyShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAvailableForDistributions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Liquidity (Details Narrative)", "role": "http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative", "shortName": "Liquidity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAvailableForDistributions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed and Consolidated Statement of Stockholders' Deficit", "role": "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit", "shortName": "Condensed and Consolidated Statement of Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed and Consolidated Statements of Cash Flows", "role": "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows", "shortName": "Condensed and Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Business Activity", "role": "http://evolutionarygenomicsinc.com/role/BusinessActivity", "shortName": "Business Activity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies", "role": "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - New Accounting Standards", "role": "http://evolutionarygenomicsinc.com/role/NewAccountingStandards", "shortName": "New Accounting Standards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fnam_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 24, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r430", "r432", "r433" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r430", "r432", "r433" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r430", "r432", "r433" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r430", "r432", "r433" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://evolutionarygenomicsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "fnam_AdditionalExpectedCostsToCompleteResearch": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Additional expected costs to complete research" } } }, "localname": "AdditionalExpectedCostsToCompleteResearch", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "fnam_CapitalLossCredits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Capital Loss credits" } } }, "localname": "CapitalLossCredits", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "fnam_CapitalStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of preferred and common stock authorized.", "label": "Capital stock, authorized shares" } } }, "localname": "CapitalStockSharesAuthorized", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "fnam_ConvertiblePreferredStockSeriesA2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Preferred Stock Series A-2 [Member]", "label": "Convertible Preferred Stock Series A 2 [Member]" } } }, "localname": "ConvertiblePreferredStockSeriesA2Member", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "fnam_DCADoleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DCA Dole [Member]", "label": "D C A Dole [Member]" } } }, "localname": "DCADoleMember", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "fnam_EIDLProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EIDL Program Member", "label": "E I D L Program [Member]" } } }, "localname": "EIDLProgramMember", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "fnam_EconomicInjuryDisasterLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Economic Injury Disaster Loan Member", "label": "Economic Injury Disaster Loan [Member]" } } }, "localname": "EconomicInjuryDisasterLoanMember", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "fnam_ExpectedFieldTrialCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Expected field trial costs", "label": "Expected field trial costs" } } }, "localname": "ExpectedFieldTrialCosts", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "fnam_ExpectedPaymentsToUnversityOfWisconsinMadisonTwoYearTerm": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Expected payments University of Wisconsin-Madison", "label": "Expected payments University of Wisconsin-Madison" } } }, "localname": "ExpectedPaymentsToUnversityOfWisconsinMadisonTwoYearTerm", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "fnam_FutureFederalStatutoryTaxRates": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Future federal statutory tax rate" } } }, "localname": "FutureFederalStatutoryTaxRates", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "fnam_IndefiniteCarryforward": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Indefinite Carry-forward" } } }, "localname": "IndefiniteCarryforward", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "fnam_LoanForgiveness": { "auth_ref": [], "calculation": { "http://evolutionarygenomicsinc.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Loan forgiveness" } } }, "localname": "LoanForgiveness", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "fnam_LongtermCapitalLossCarryforward": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Long-term capital loss carryforward" } } }, "localname": "LongtermCapitalLossCarryforward", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "fnam_MonthlyRentPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Monthly rent payment.", "label": "Monthly rent payment" } } }, "localname": "MonthlyRentPayment", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "fnam_NondeductibleExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Non-deductible expenses" } } }, "localname": "NondeductibleExpenses", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "fnam_NontaxableForgivenessOfPppAndEidlLoans": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Non-taxable forgiveness of PPP and EIDL loans" } } }, "localname": "NontaxableForgivenessOfPppAndEidlLoans", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "fnam_NotesPayableForDoleFunding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes payable for Dole funding", "label": "Notes payable for dole funding" } } }, "localname": "NotesPayableForDoleFunding", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "fnam_NumberOfCommonStockOutstandingOwnedByRelatedPartyShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common stock shares outstanding owned by related party.", "label": "Number of common stock shares outstanding owned by related party" } } }, "localname": "NumberOfCommonStockOutstandingOwnedByRelatedPartyShares", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "fnam_PaymentToCompanyByFortyEightMonthAnniversary": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment forty eight month anniversary", "label": "Payment forty eight month anniversary" } } }, "localname": "PaymentToCompanyByFortyEightMonthAnniversary", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "fnam_PaymentToCompanyByThirtySxMonthAnniversary": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment thirty six month anniversary", "label": "Payment thirty six month anniversary" } } }, "localname": "PaymentToCompanyByThirtySxMonthAnniversary", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "fnam_PaymentToCompanyByTwelveMonthAnniversary": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment twelve month anniversary", "label": "Payment twelve-month anniversary" } } }, "localname": "PaymentToCompanyByTwelveMonthAnniversary", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "fnam_PaymentToCompanyUponExecution": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment upon execution", "label": "Payment upon execution" } } }, "localname": "PaymentToCompanyUponExecution", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "fnam_PaymentUponReceipt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Payment upon receipt" } } }, "localname": "PaymentUponReceipt", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "fnam_PercentageOfCommonStockSharesOutstandingOwnedByRelatedParty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of common stock shares outstanding owned by related party.", "label": "Percentage of common stock shares outstanding owned by related party" } } }, "localname": "PercentageOfCommonStockSharesOutstandingOwnedByRelatedParty", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "fnam_PppLoanForgiveness": { "auth_ref": [], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "PppLoanForgiveness", "negatedLabel": "PPP loan forgiveness" } } }, "localname": "PppLoanForgiveness", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fnam_PreferredDividendMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Dividend [Member]" } } }, "localname": "PreferredDividendMember", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "fnam_PreferredStockDividendAccretion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Preferred stock dividend accrual" } } }, "localname": "PreferredStockDividendAccretion", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fnam_ProceedsFromEidlAndPppLoans": { "auth_ref": [], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from EIDL and PPP loans" } } }, "localname": "ProceedsFromEidlAndPppLoans", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fnam_ReimbursedCostsIncurred": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reimbursement of costs", "label": "Reimbursement of costs" } } }, "localname": "ReimbursedCostsIncurred", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "fnam_ResearchAgreementUniversityOfWisconsinMadisonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research Agreement University Of Wisconsin Madison [Member]", "label": "Research Agreement University Of Wisconsin Madison [Member]" } } }, "localname": "ResearchAgreementUniversityOfWisconsinMadisonMember", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "fnam_SBAPaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SBA Paycheck Protection Program Member", "label": "S B A Paycheck Protection Program [Member]" } } }, "localname": "SBAPaycheckProtectionProgramMember", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "fnam_SeriesA1PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A-1 Preferred Stock [Member]" } } }, "localname": "SeriesA1PreferredStockMember", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "domainItemType" }, "fnam_SeriesA2PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A-2 Preferred Stock [Member]", "label": "Series A-2 Preferred Stock [Member]" } } }, "localname": "SeriesA2PreferredStockMember", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets", "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical", "http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative", "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "fnam_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding ending, contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails" ], "xbrltype": "durationItemType" }, "fnam_StandardResearchAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Standard Research Agreement [Member]" } } }, "localname": "StandardResearchAgreementMember", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "fnam_StatedPerShareValueOfPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stated per share value of preferred stock.", "label": "Stated per share value of preferred stock" } } }, "localname": "StatedPerShareValueOfPreferredStock", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "fnam_TotalAmountOfGrantRevenueRecognizedToDate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total amount of grant revenue recognized to date.", "label": "Total amount of grant revenue recognized to date" } } }, "localname": "TotalAmountOfGrantRevenueRecognizedToDate", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "fnam_TotalDeferredIncomeTaxBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Total deferred income tax benefit" } } }, "localname": "TotalDeferredIncomeTaxBenefit", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "fnam_TotalIncomeTaxBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Total income tax benefit" } } }, "localname": "TotalIncomeTaxBenefit", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "fnam_TotalPossibleFutureRoyaltiesOwed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total possible future royalties owed.", "label": "Total possible future royalties owed" } } }, "localname": "TotalPossibleFutureRoyaltiesOwed", "nsuri": "http://evolutionarygenomicsinc.com/20211231", "presentation": [ "http://evolutionarygenomicsinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r37", "r183" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information" } } }, "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r29" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r96", "r97", "r98", "r288", "r289", "r290", "r345" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalPreferredStock": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholder in nonredeemable preferred stock-related transaction in excess of par value, value contributed to entity and value received from other stock-related transaction. Includes, but is not limited to, preferred stock redeemable solely at option of issuer. Excludes common stock.", "label": "Additional shares" } } }, "localname": "AdditionalPaidInCapitalPreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r75", "r175" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r269", "r270", "r293", "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash flows from operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r75", "r180" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset impairment charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r90", "r144", "r147", "r153", "r163", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r334", "r339", "r347", "r370", "r372", "r382", "r397" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r9", "r48", "r90", "r163", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r334", "r339", "r347", "r370", "r372" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r13", "r14", "r15", "r16", "r17", "r18", "r19", "r20", "r90", "r163", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r334", "r339", "r347", "r370" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r4", "r95", "r138" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Activity" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BusinessActivity" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r34", "r77" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r12", "r78" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAvailableForDistributions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash eligible for distribution to members or limited partners of limited liability company (LLC) or limited partnership (LP), subject to reserves to be maintained as defined in operating or partnership agreement, or in a credit facility agreement.", "label": "Operating cash" } } }, "localname": "CashAvailableForDistributions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r71", "r77", "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r71", "r351" ], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r87", "r90", "r117", "r118", "r119", "r122", "r124", "r128", "r129", "r130", "r163", "r192", "r196", "r197", "r198", "r201", "r202", "r238", "r239", "r243", "r247", "r347", "r435" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets", "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical", "http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative", "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r45", "r190", "r387", "r401" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r187", "r188", "r189", "r191", "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r96", "r97", "r345" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical", "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "verboseLabel": "Common stock, authorized shares" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical", "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r28", "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r28", "r372" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, $0.001 par value; 780,000,000 shares authorized, 5,881,898 shares issued and outstanding at December 31, 2021 and 2020" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentrations" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Concentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r83", "r336" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principals of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r238", "r239", "r243" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r91", "r313", "r323" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "U.S. Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r91", "r313", "r323", "r325" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Total current income tax benefit" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current income tax benefit:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r91", "r313", "r323" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "U.S. States" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r86", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r220", "r227", "r228", "r229", "r234" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r21", "r22", "r23", "r89", "r94", "r203", "r204", "r205", "r206", "r207", "r208", "r210", "r216", "r217", "r218", "r219", "r221", "r222", "r223", "r224", "r225", "r226", "r230", "r231", "r232", "r233", "r360", "r383", "r385", "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Forgiveness of debt" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r43", "r204" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r44", "r89", "r94", "r203", "r204", "r205", "r206", "r207", "r208", "r210", "r216", "r217", "r218", "r219", "r221", "r222", "r223", "r224", "r225", "r226", "r230", "r231", "r232", "r233", "r360" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r44", "r394" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Monthly payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r91", "r314", "r323" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "U.S. Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r75", "r91", "r314", "r323", "r324", "r325" ], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred tax benefit" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred income tax benefit:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r24", "r25", "r305", "r384", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedLabel": "Total deferred income tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Total income tax expense" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r91", "r314", "r323" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "U.S. States" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r307" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Net deferred income tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred income tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r311", "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r310", "r311", "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Research and development credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r306" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance for deferred income tax assets" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r299", "r307" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedLabel": "Net deferred income tax assets" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r311", "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedLabel": "Intangible assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred income tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r75", "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r75", "r142" ], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r10", "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends accrued" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStockStock": { "auth_ref": [ "r261", "r393" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.", "label": "Preferred stock dividends" } } }, "localname": "DividendsPreferredStockStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per common share, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Unrecognized compensation cost related to share-based compensation arrangements" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r54", "r55", "r56", "r96", "r97", "r98", "r102", "r109", "r111", "r127", "r164", "r254", "r261", "r288", "r289", "r290", "r316", "r317", "r345", "r352", "r353", "r354", "r355", "r356", "r358", "r406", "r407", "r408", "r440" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r174" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "December 31, 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "December 31, 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "December 31, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "December 31, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "December 31, 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r170", "r171", "r174", "r177", "r376", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails", "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r174", "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails", "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r170", "r173" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails", "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r174", "r376" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets, net", "verboseLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets", "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails", "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.", "label": "Income tax benefit attributable to U.S. states" } } }, "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r65", "r75", "r162" ], "calculation": { "http://evolutionarygenomicsinc.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain on investments" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r63" ], "calculation": { "http://evolutionarygenomicsinc.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r169", "r172" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "verboseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r179", "r185" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails", "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r59", "r144", "r146", "r149", "r152", "r154", "r381", "r388", "r391", "r404" ], "calculation": { "http://evolutionarygenomicsinc.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r92", "r302", "r303", "r309", "r321", "r326", "r328", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r93", "r110", "r111", "r143", "r300", "r322", "r327", "r405" ], "calculation": { "http://evolutionarygenomicsinc.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r53", "r297", "r298", "r303", "r304", "r308", "r315" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": { "auth_ref": [ "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.", "label": "Income tax benefit at statutory U.S. federal rate" } } }, "localname": "IncomeTaxReconciliationDispositionOfBusiness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r74" ], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r74" ], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r74" ], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r10", "r11", "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r64", "r141" ], "calculation": { "http://evolutionarygenomicsinc.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LaborAndRelatedExpense": { "auth_ref": [ "r62" ], "calculation": { "http://evolutionarygenomicsinc.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.", "label": "Salaries and benefits" } } }, "localname": "LaborAndRelatedExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Rent expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r40", "r90", "r148", "r163", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r335", "r339", "r340", "r347", "r370", "r371" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r33", "r90", "r163", "r347", "r372", "r386", "r399" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS'\u00a0\u00a0DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r42", "r90", "r163", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r335", "r339", "r340", "r347", "r370", "r371", "r372" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansAssumed1": { "auth_ref": [ "r79", "r80", "r81" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of loans assumed in noncash investing or financing activities.", "label": "Loans" } } }, "localname": "LoansAssumed1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Notes payable" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r71" ], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r71" ], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r71", "r73", "r76" ], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r49", "r51", "r56", "r60", "r76", "r90", "r101", "r105", "r106", "r107", "r108", "r110", "r111", "r120", "r144", "r146", "r149", "r152", "r154", "r163", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r346", "r347", "r389", "r402" ], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://evolutionarygenomicsinc.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows", "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r105", "r106", "r107", "r108", "r115", "r116", "r121", "r124", "r144", "r146", "r149", "r152", "r154" ], "calculation": { "http://evolutionarygenomicsinc.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r1", "r99", "r100", "r103", "r104", "r112", "r113", "r114", "r160", "r161", "r165", "r166", "r263", "r264", "r265", "r266", "r291", "r318", "r319", "r320", "r344", "r348", "r349", "r350", "r361", "r377", "r378", "r379", "r409", "r410", "r411", "r412", "r413", "r441" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "New Accounting Standards" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/NewAccountingStandards" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r66" ], "calculation": { "http://evolutionarygenomicsinc.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://evolutionarygenomicsinc.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r144", "r146", "r149", "r152", "r154" ], "calculation": { "http://evolutionarygenomicsinc.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating loss" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r4", "r95", "r138", "r343" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCashEquivalentsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Other Cash Equivalents, at Carrying Value", "verboseLabel": "Cash" } } }, "localname": "OtherCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r50", "r52", "r54", "r55", "r57", "r61", "r254", "r352", "r357", "r358", "r390", "r403" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails", "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRoyalties": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for royalties during the current period.", "label": "Payments for royalties" } } }, "localname": "PaymentsForRoyalties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Dividend rate" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "auth_ref": [], "calculation": { "http://evolutionarygenomicsinc.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.", "label": "Preferred Stock Dividends, Income Statement Impact", "negatedLabel": "Preferred stock dividend" } } }, "localname": "PreferredStockDividendsIncomeStatementImpact", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r87", "r243" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Preferred stock, liquidation preference, value" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockNoParValue": { "auth_ref": [ "r27", "r238" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock per share" } } }, "localname": "PreferredStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r27", "r238" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par or stated value per share", "verboseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical", "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock, authorized shares" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical", "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r27", "r238" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r27", "r372" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r6", "r8", "r167", "r168" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds of preferred stock shares" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r69" ], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from issuance of notes payable", "verboseLabel": "Proceeds" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows", "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfOtherInvestments": { "auth_ref": [ "r67" ], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the sale of investments classified as other.", "label": "Proceeds from sale of investments" } } }, "localname": "ProceedsFromSaleOfOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r49", "r51", "r56", "r70", "r90", "r101", "r110", "r111", "r144", "r146", "r149", "r152", "r154", "r163", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r333", "r337", "r338", "r341", "r342", "r346", "r347", "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r37", "r184" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r186", "r415", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r36", "r182" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r16", "r17", "r184", "r372", "r392", "r400" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets", "http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOther": { "auth_ref": [ "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Other, Gross", "negatedLabel": "Property, equipment and other" } } }, "localname": "PropertyPlantAndEquipmentOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r35", "r184", "r415", "r416" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r16", "r184" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r16", "r182" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r268", "r364", "r365", "r367" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r362", "r363", "r365", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Parties and Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet": { "auth_ref": [ "r374" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.", "label": "Research and development credits" } } }, "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r296", "r374", "r418" ], "calculation": { "http://evolutionarygenomicsinc.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r30", "r261", "r292", "r372", "r398", "r409", "r413" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r96", "r97", "r98", "r102", "r109", "r111", "r164", "r288", "r289", "r290", "r316", "r317", "r345", "r406", "r408" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r84", "r85" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r58", "r90", "r139", "r140", "r145", "r150", "r151", "r155", "r156", "r157", "r163", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r347", "r391" ], "calculation": { "http://evolutionarygenomicsinc.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Grant revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of income tax expense from continuing operations" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of income tax rate reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r170", "r173", "r376" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails", "http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r170", "r173" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r37", "r184" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r275", "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r46", "r87", "r128", "r129", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r243", "r247", "r252", "r255", "r256", "r257", "r258", "r259", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Intangible Assets Amortization" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical", "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r74" ], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation", "verboseLabel": "Compensation costs for stock options" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows", "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Number of shares reserved for issuance under 2015 Stock Incentive Plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Stock options granted during period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r277", "r287" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Balance, ending", "periodStartLabel": "Balance, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Balance, ending", "periodStartLabel": "Balance, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r271", "r274" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "verboseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Expiration period for stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r287" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Exercisable, intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable, contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding beginning, contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Number of shares vested during the period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Issuance of preferred shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r26", "r27", "r28", "r87", "r90", "r117", "r118", "r119", "r122", "r124", "r128", "r129", "r130", "r163", "r192", "r196", "r197", "r198", "r201", "r202", "r238", "r239", "r243", "r247", "r254", "r347", "r435" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets", "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical", "http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative", "http://evolutionarygenomicsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r47", "r54", "r55", "r56", "r96", "r97", "r98", "r102", "r109", "r111", "r127", "r164", "r254", "r261", "r288", "r289", "r290", "r316", "r317", "r345", "r352", "r353", "r354", "r355", "r356", "r358", "r406", "r407", "r408", "r440" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit", "http://evolutionarygenomicsinc.com/role/BalanceSheets", "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical", "http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r96", "r97", "r98", "r127", "r375" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit", "http://evolutionarygenomicsinc.com/role/BalanceSheets", "http://evolutionarygenomicsinc.com/role/BalanceSheetsParenthetical", "http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r27", "r28", "r254", "r261" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r27", "r28", "r254", "r261", "r280" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r27", "r28", "r254", "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Proceeds of stock issued" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock- based compensation" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r28", "r31", "r32", "r90", "r159", "r163", "r347", "r372" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit", "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r88", "r239", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r359", "r373" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r359", "r373" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r359", "r373" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Liquidity" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/Liquidity" ], "xbrltype": "textBlockItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "R&D credits" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r192", "r196", "r197", "r198", "r201", "r202" ], "calculation": { "http://evolutionarygenomicsinc.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Total preferred stock subject to possible redemption" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r75" ], "calculation": { "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Unrealized gain on investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r131", "r132", "r133", "r134", "r135", "r136", "r137" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r307" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Increase (decrease) in Valuation Allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average common shares outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://evolutionarygenomicsinc.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r343": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r369": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r419": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r421": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r422": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r423": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r424": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r425": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r426": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r427": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r428": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r429": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r431": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r432": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r433": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r434": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r435": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r436": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r437": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r438": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r439": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" } }, "version": "2.1" } ZIP 59 0001553350-22-000231-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001553350-22-000231-xbrl.zip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end